Section 56

EurekaMag PDF full texts Chapter 55,375


Delahaye, Ém.; Eyele-Mezui, S.ér.; Diop, M.; Leuvrey, C.éd.; Rabu, P.; Rogez, G. 2010: Rational synthesis of chiral layered magnets by functionalization of metal simple hydroxides with chiral and non-chiral Ni(II) Schiff base complexes. Dalton Transactions 39(44): 10577-10580
Wang, C.; Tian, W.; Ding, Y.; Ma, Y-Qiang.; Wang, Z.Lin.; Markovic, N.M.; Stamenkovic, V.R.; Daimon, H.; Sun, S. 2010: Rational synthesis of heterostructured nanoparticles with morphology control. Journal of the American Chemical Society 132(18): 6524-6529
Gonzato, C.; Semsarilar, M.; Jones, E.R.; Li, F.; Krooshof, G.J.P.; Wyman, P.; Mykhaylyk, O.O.; Tuinier, R.; Armes, S.P. 2014: Rational synthesis of low-polydispersity block copolymer vesicles in concentrated solution via polymerization-induced self-assembly. Journal of the American Chemical Society 136(31): 11100-11106
Chen, L.-B.; Zhang, F.; Wang, C.-C. 2009: Rational synthesis of magnetic thermosensitive microcontainers as targeting drug carriers. Small 5(5): 621-628
Wang, C.; Zhang, T.; Lin, W. 2012: Rational synthesis of noncentrosymmetric metal-organic frameworks for second-order nonlinear optics. Chemical Reviews 112(2): 1084-1104
Tadi, K.K.; Motghare, R.V. 2013: Rational synthesis of pindolol imprinted polymer by non-covalent protocol based on computational approach. Journal of Molecular Modeling 19(8): 3385-3396
Mai, L.; Xu, X.; Han, C.; Luo, Y.; Xu, L.; Wu, Y.A.; Zhao, Y. 2011: Rational synthesis of silver vanadium oxides/polyaniline triaxial nanowires with enhanced electrochemical property. Nano Letters 11(11): 4992-4996
Tanaka, S.; Yagyu, A.; Kikugawa, M.; Ohashi, M.; Yamagata, T.; Mashima, K. 2011: Rational synthesis of supramolecular assemblies based on tetraplatinum units: synthesis, characterization, and selective substitution reactions of four different Pt4 clusters. Chemistry 17(13): 3693-3709
Xu, L.; Yin, Z.; Cao, S.-W.; Fan, Z.; Zhang, X.; Zhang, H.; Xue, C. 2014: Rational synthesis of triangular Au-Ag(2)S hybrid nanoframes with effective photoresponses. Chemistry 20(10): 2742-2745
Gałeezowski, M.ł; Jaźwiński, J.ła.; Lewtak, J.P.; Gryko, D.T. 2009: Rational synthesis of tripyrranes. Journal of Organic Chemistry 74(15): 5610-5613
Zhang, G.; Kirk, B.; Jauregui, L.A.; Yang, H.; Xu, X.; Chen, Y.P.; Wu, Y. 2012: Rational synthesis of ultrathin n-type Bi2Te3 nanowires with enhanced thermoelectric properties. Nano Letters 12(1): 56-60
Morinaka, Y.; Tanabe, F.; Murata, M.; Murata, Y.; Komatsu, K. 2010: Rational synthesis, enrichment, and (13)C NMR spectra of endohedral C(60) and C(70) encapsulating a helium atom. Chemical Communications 46(25): 4532-4534
Fokwa, B.P.T.; Lueken, H.; Dronskowski, R. 2007: Rational synthetic tuning between itinerant antiferromagnetism and ferromagnetism in the complex boride series Sc2FeRu(5-n)RhnB2 (0<or=n<or=5). Chemistry 13(21): 6040-6046
Murata, H.; Cummings, C.S.; Koepsel, R.R.; Russell, A.J. 2014: Rational tailoring of substrate and inhibitor affinity via ATRP polymer-based protein engineering. Biomacromolecules 15(7): 2817-2823
Papanikolaou, N.A. 2010: Rational targeting in acute promyelocytic leukemia. In Vivo 24(1): 21-27
Miele, L. 2008: Rational targeting of Notch signaling in breast cancer. Expert Review of Anticancer Therapy 8(8): 1197-1202
Lane, J.S.; Richens, J.L.; Vere, K.-A.; O'Shea, P. 2014: Rational targeting of subclasses of intermolecular interactions: elimination of nonspecific binding for analyte sensing. Langmuir: the Acs Journal of Surfaces and Colloids 30(31): 9457-9465
Kriegbaum, M.C.; Persson, M.; Haldager, L.; Alpízar-Alpízar, W.; Jacobsen, B.; Gårdsvoll, H.; Kjær, A.; Ploug, M. 2011: Rational targeting of the urokinase receptor (uPAR): development of antagonists and non-invasive imaging probes. Current Drug Targets 12(12): 1711-1728
Serova, E.V. 1947: Rational technique in closing an open pneumothorax depending upon localization of injury. Khirurgiia 7: 63-66
Nichitaĭlo, M.E.; Skums, A.V.; Litvin, A.I.; Shkarban, V.P.; Bulik, I.I.; Tsiura, I.P. 2009: Rational technique of pancreatoduodenal resection and transplantation technology use as the basis of favourable outcome. Klinichna Khirurhiia 2009(6): 5-8
McGuire, J.T.; Kable, J.W. 2013: Rational temporal predictions can underlie apparent failures to delay gratification. Psychological Review 120(2): 395-410
Tłustochowicz, W. 2006: Rational therapeutic approach in rheumatoid arthritis. Annales Academiae Medicae Stetinensis 52(Suppl 2): 5-10
Stamelou, M.; de Silva, R.; Arias-Carrión, O.; Boura, E.; Höllerhage, M.; Oertel, W.H.; Müller, U.; Höglinger, G.ün.U. 2010: Rational therapeutic approaches to progressive supranuclear palsy. Brain: a Journal of Neurology 133(Part 6): 1578-1590
Thurn, K.T.; Thomas, S.; Moore, A.; Munster, P.N. 2011: Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer. Future Oncology 7(2): 263-283
Hoffman, R. 2011: Rational therapeutic options for patients with myeloproliferative neoplasms. Transactions of the American Clinical and Climatological Association 122: 11-26
Kohya, N.; Kitahara, K.; Miyazaki, K. 2010: Rational therapeutic strategy for T2 gallbladder carcinoma based on tumor spread. World Journal of Gastroenterology 16(28): 3567-3572
Manfredi, D.H. 1949: Rational therapeutics of intestinal obstruction in infancy. New York State Journal of Medicine 49(14): 1691
Sant'ana, J.ão.M.B.; Pepe, V.L.úc.E.; Figueiredo, T.A.ão.; Osorio-de-Castro, C.G.S.; Ventura, M. 2011: Rational therapeutics: health-related elements in lawsuits demanding medicines. Revista de Saude Publica 45(4): 714-721
Messer, J.; Drabick, J.; Kaag, M. 2013: Rational therapy for renal cell carcinoma based on its genetic targets. Advances in Experimental Medicine and Biology 779: 291-308
Patino, G.A.; Parent, J. 2014: Rational therapy from bench to bedside for a rare epilepsy. Epilepsy Currents 14(5): 286-288
Vukicević-Baudoin, D. 2009: Rational therapy in emergency states in pulmonology. Lijecnicki Vjesnik 131(Suppl 4): 31-33
Stimac, D.; Poropat, G. 2010: Rational therapy of acute pancreatitis. Digestive Diseases 28(2): 310-316
Milovanovic, D.R.; Jankovic, S.M. 2014: Rational therapy publication rate correlates with wealth of a society. Ciencia and Saude Coletiva 19(12): 4927-4928
Reynolds, N.C.; Slocum, R.B. 2011: Rational therapy: a defense against evidence-based medicine. Movement Disorders: Official Journal of the Movement Disorder Society 26(4): 567-568
Montgomery, E.B.; Turkstra, L.S. 2011: Rational therapy: if only it were so. Movement disorders: official journal of the Movement Disorder Society 26(10): 1948; author reply 1948-9
Wang, X.-S. 2010: Rational thinking about minimally invasive surgery and operative approach. Zhonghua Wai Ke Za Zhi 48(13): 961-963
Toplak, M.E.; West, R.F.; Stanovich, K.E. 2014: Rational thinking and cognitive sophistication: development, cognitive abilities, and thinking dispositions. Developmental Psychology 50(4): 1037-1048
Clark, M.K.; Flynn, P. 2011: Rational thinking in school-based practice. Language Speech and Hearing Services in Schools 42(1): 73
Millar, J.A. 2008: Rational thromboprophylaxis in medical inpatients: not quite there yet. Medical Journal of Australia 189(9): 504-506
Fletcher, J.P.; Maclellan, D.; Gibbs, H.; Matthews, G. 2009: Rational thromboprophylaxis in medical inpatients: not quite there yet. Comment. Medical journal of Australia 190(7): 398-399
Terzano, C.; Petroianni, A.; Conti, V.; Ceccarelli, D.; Graziani, E.; Sanduzzi, A.; D'Avelli, S. 2008: Rational timing of combination therapy with tiotropium and formoterol in moderate and severe COPD. Respiratory Medicine 102(12): 1701-1707
Buttelmann, D.; Carpenter, M.; Call, J.; Tomasello, M. 2008: Rational tool use and tool choice in human infants and great apes. Child Development 79(3): 609-626
Atreya, R.; Neumann, H.; Neurath, M.F. 2013: Rational treatment of Crohn's disease. MMW Fortschritte der Medizin 155(4): 61-63
Barker, W.H. 1948: Rational treatment of anemia. Southern Medical Journal 41(5): 475-479
Haynes, W.G. 1947: Rational treatment of brain abscess. Southern Surgeon 13(10): 734-744
Draper, A.J. 1947: Rational treatment of diabetic acidosis. Southern Medicine and Surgery 109(12): 397-400
Paiva, E.S.; Jones, K.D. 2010: Rational treatment of fibromyalgia for a solo practitioner. Best Practice and Research. Clinical Rheumatology 24(3): 341-352
Proksch, E.; Jensen, J.-M.; Crichton-Smith, A.; Fowler, A.; Clitherow, J. 2007: Rational treatment of first-degree burns. Der Hautarzt; Zeitschrift für Dermatologie Venerologie und verwandte Gebiete 58(7): 604-610
Atreya, R.; Neumann, H.; Neurath, M.F. 2012: Rational treatment of ulcerative colitis--local or systemic therapy? Surgery?. MMW Fortschritte der Medizin 154(13): 76-78
Lagae, L. 2009: Rational treatment options with AEDs and ketogenic diet in Landau-Kleffner syndrome: still waiting after all these years. Epilepsia 50(Suppl 7): 59-62
Rockey, W.M.; Hernandez, F.J.; Huang, S.-Y.; Cao, S.; Howell, C.A.; Thomas, G.S.; Liu, X.Y.; Lapteva, N.; Spencer, D.M.; McNamara, J.O.; Zou, X.; Chen, S.-J.; Giangrande, P.H. 2011: Rational truncation of an RNA aptamer to prostate-specific membrane antigen using computational structural modeling. Nucleic Acid Therapeutics 21(5): 299-314
Escande, A.; Guénée, L.; Nozary, H.; Bernardinelli, G.ér.; Gumy, F.éd.ér.; Aebischer, A.; Bünzli, J.-C.G.; Donnio, B.; Guillon, D.; Piguet, C. 2007: Rational tuning of melting entropies for designing luminescent lanthanide-containing thermotropic liquid crystals at room temperature. Chemistry 13(31): 8696-8713
Namuswe, F.; Kasper, G.D.; Sarjeant, A.A.N.; Hayashi, T.; Krest, C.M.; Green, M.T.; Moënne-Loccoz, P.; Goldberg, D.P. 2008: Rational tuning of the thiolate donor in model complexes of superoxide reductase: direct evidence for a trans influence in Fe(III)-OOR complexes. Journal of the American Chemical Society 130(43): 14189-14200
Ophuls, W. 1970: Rational turn to an oracle. Science 169(3949): 927-928
Kamuhabwa, A.; Ezekiel, D. 2009: Rational use and effectiveness of morphine in the palliative care of cancer patients at the Ocean Road Cancer Institute in Dar es Salaam, Tanzania. Tanzania Journal of Health Research 11(4): 170-174
Reisfield, G.M.; Salazar, E.; Bertholf, R.L. 2007: Rational use and interpretation of urine drug testing in chronic opioid therapy. Annals of Clinical and Laboratory Science 37(4): 301-314
de Menil, V.; Cohen, A. 2009: Rational use and rationale for use: psychiatric medication at an Argentine institution for intellectual disability. Transcultural Psychiatry 46(4): 651-671
Younis, M.Z.; Hamidi, S.; Forgione, D.A.; Hartmann, M. 2009: Rational use effects of implementing an essential medicines list in West Bank, Palestinian Territories. Expert Review of Pharmacoeconomics and Outcomes Research 9(3): 243-250
Brenner, R.; Altmann, D.; Ammann, P. 2014: Rational use of ambulatory ECG recordings. Therapeutische Umschau. Revue Therapeutique 71(2): 73-79
Shi, Y.; Li, P. 2012: Rational use of aminoglycoside antibiotics on the basis of pharnacokinetics and pharmacodynamics theory. Zhonghua Jie he He Hu Xi Za Zhi 35(10): 726-728
Hanberger, Håkan.; Fredriksson, M.; Ternhag, A.; Giske, C.G. 2013: Rational use of aminoglycosides - author response. Scandinavian Journal of Infectious Diseases 45(8): 655-656
Hanberger, Håkan.; Edlund, C.; Furebring, M.; G Giske, C.; Melhus, A.; Nilsson, L.E.; Petersson, J.; Sjölin, J.; Ternhag, A.; Werner, M.; Eliasson, E. 2013: Rational use of aminoglycosides--review and recommendations by the Swedish Reference Group for Antibiotics (SRGA). Scandinavian Journal of Infectious Diseases 45(3): 161-175
Kinshoku, M.R.ér.; Rodriguez, C.A.L.; Fidalgo, R.d.S.; Duran, C.C.G.; Leme, P.L.S.; Duarte, I.d.S. 2012: Rational use of animal models for research and microsurgery training. Revista do Colegio Brasileiro de Cirurgioes 39(5): 414-417
Zumla, A.; Blasi, F.; Raviglione, M. 2012: Rational use of anti-tuberculosis drugs in the EU: better patient care and less drug resistance. European Respiratory Journal 39(4): 802-804
Anonymous 2011: Rational use of anti-ulcer drugs to prevent serious gastroduodenal adverse effects associated with NSAIDS. Prescrire International 20(119): 219
Arora, N.K.; Awasthi, S.; Gupta, P.; Kabra, S.K.; Mathew, J.L.; Nedunchelian, K.; Niswade, A.K.; Patel, A.; Rewal, S.; Sethi, G.R.; Shah, D.; Singh, V.; Shah, D.; Gupta, P.; Arora, N.K. 2010: Rational use of antibiotics for pneumonia. Indian Pediatrics 47(1): 11-18
Chiappini, E.; Mazzantini, R.; Bruzzese, E.; Capuano, A.; Colombo, M.; Cricelli, C.; Di Mauro, G.; Esposito, S.; Festini, F.; Guarino, A.; Miniello, V.Leonardo.; Principi, N.; Marchisio, P.; Rafaniello, C.; Rossi, F.; Sportiello, L.; Tancredi, F.; Venturini, E.; Galli, L.; de Martino, M. 2014: Rational use of antibiotics for the management of children's respiratory tract infections in the ambulatory setting: an evidence-based consensus by the Italian Society of Preventive and Social Pediatrics. Paediatric respiratory reviews 15(3): 231-236
Berild, D.; Haug, J.B. 2008: Rational use of antibiotics in hospitals. Tidsskrift for den Norske Laegeforening: Tidsskrift for Praktisk Medicin Ny Raekke 128(20): 2335-2339
Shi, G.-f.; Huang, C. 2012: Rational use of antibiotics in patients with hepatic dysfunction. Zhonghua Gan Zang Bing Za Zhi 20(3): 182-184
Pawa, A.; Wight, J.; Onwochei, D.N.; Vargulescu, R.; Reed, I.; Chrisman, L.; Pushpanathan, E.; Kothari, A.; El-Boghdadly, K. 2018: Combined thoracic paravertebral and pectoral nerve blocks for breast surgery under sedation: a prospective observational case series. Anaesthesia 73(4): 438-443
Kollef, M.H.; Micek, S.T. 2014: Rational use of antibiotics in the ICU: balancing stewardship and clinical outcomes. JAMA 312(14): 1403-1404
Nausheen, S.; Hammad, R.; Khan, A. 2013: Rational use of antibiotics--a quality improvement initiative in hospital setting. Jpma. Journal of the Pakistan Medical Association 63(1): 60-64
Schetgen, M. 2007: Rational use of antibiotics. Reality on the ground of the general medicine. Revue Medicale de Bruxelles 28(4): 391-395
Dandolini, B.Werner.; Batista, L.de.Bem.; Souza, Lúcia.Helena.Fernandes.de.; Galato, D.; Piovezan, A.Paula. 2012: Rational use of antibiotics: an experiment for the health education of schoolchildren. Ciencia and Saude Coletiva 17(5): 1323-1331
Lopes, L.C.; Barberato-Filho, S.; Costa, A.C.; Osorio-de-Castro, C.G.S. 2010: Rational use of anticancer drugs and patient lawsuits in the state of São Paulo, Southeastern Brazil. Revista de Saude Publica 44(4): 620-628
Fava, G.A. 2014: Rational use of antidepressant drugs. PsychoTherapy and Psychosomatics 83(4): 197-204
Ferguson, M.A.; Flynn, J.T. 2014: Rational use of antihypertensive medications in children. Pediatric Nephrology 29(6): 979-988
Lodi, K.B.; Carvalho, L.F.d.C.e.S.d.; Koga-Ito, C.Y.; Carvalho, V.ér.A.P.; Rocha, R.F.d. 2009: Rational use of antimicrobials in dentistry during pregnancy. Medicina Oral Patologia Oral y Cirugia Bucal 14(1): E15-E19
De Waele, J.J. 2011: Rational use of antimicrobials in patients with severe acute pancreatitis. Seminars in Respiratory and Critical Care Medicine 32(2): 174-180
Elliott, J.H.; Lynen, L.; Calmy, A.; De Luca, A.; Shafer, R.W.; Zolfo, M.; Clotet, B.; Huffam, S.; Boucher, C.A.B.; Cooper, D.A.; Schapiro, J.M. 2008: Rational use of antiretroviral therapy in low-income and middle-income countries: optimizing regimen sequencing and switching. Aids 22(16): 2053-2067
Arora, D.; Kumar, M. 2002: Rational use of ayurvedic literaature for drug development. Ancient Science of Life 21(3): 182-187
Ferreira-Junior, M.; Lichtenstein, A.; Sales, M.M.; Taniguchi, L.U.; Aguiar, F.J.é B.d.; Fonseca, L.A.M.; Sumita, N.M.; Duarte, A.J.é d.S. 2014: Rational use of blood calcium determinations. Sao Paulo Medical Journal 132(4): 243-248
Wade, M.; Sharma, R.; Manglani, M. 2009: Rational use of blood components - an audit. Indian Journal of Hematology and Blood Transfusion: An Official Journal of Indian Society of Hematology and Blood Transfusion 25(2): 66-69
Siva, C.; Larson, E.C.; Barnett, M. 2012: Rational use of blood tests in the evaluation of rheumatic diseases. Missouri Medicine 109(1): 59-63
Vachhani, J.H.; Joshi, J.R.; Bhanvadia, V.M. 2008: Rational use of blood: a study report on single unit transfusion. Indian Journal of Hematology and Blood Transfusion: An Official Journal of Indian Society of Hematology and Blood Transfusion 24(2): 69-71
Moraes-Souza, H. 2013: Rational use of blood: how to do it?. Revista Brasileira de Hematologia e Hemoterapia 35(4): 237-239
Aggarwal, C.; Borghaei, H. 2009: Rational use of cetuximab in the treatment of advanced non-small cell lung cancer. Oncotargets and Therapy 2: 251-260
Li, Y. 2008: Rational use of clinical detection of serum tumor markers in diagnosis of colorectal cancer. Zhonghua Yi Xue Za Zhi 88(29): 2023-2024
Weiss, J.P. 2011: Rational use of desmopressin in adults. Journal of Urology 185(1): 12-13
Goebel, J.A.; Van Bakel, A.B. 2008: Rational use of diuretics in acute decompensated heart failure. Current Heart Failure Reports 5(3): 153-162
Remmel, M.; Hartmann, F.; Harland, L.C.; Schunkert, H.; Radke, P.W. 2007: Rational use of drug-eluting stents: a comparison of different policies. Critical Pathways in Cardiology 6(2): 85-89
Eggleston, E.M.; Klompas, M. 2014: Rational use of electronic health records for diabetes population management. Current Diabetes Reports 14(4): 479
Bhansali, A.; Dutta, P.; Bhat, M.H.; Mukherjee, K.K.; Rajput, R.; Bhadada, S. 2008: Rational use of glucocorticoid during pituitary surgery--a pilot study. Indian Journal of Medical Research 128(3): 294-299
Gu, J.; Xiao, H.-p. 2013: Rational use of hepato-protectants in the prophylaxis and treatment of anti-tuberculosis drug-induced hepatotoxicity. Zhonghua Jie he He Hu Xi Za Zhi 36(10): 767-769
Amicosante, M.; Ciccozzi, M.; Markova, R. 2010: Rational use of immunodiagnostic tools for tuberculosis infection: guidelines and cost effectiveness studies. New Microbiologica 33(2): 93-107
Waits, J.B. 2010: Rational use of laboratory testing in the initial evaluation of soft tissue and joint complaints. Primary Care 37(4): 673-689 V
Llinares-Tello, F. 2013: Rational use of laboratory tests: albuminuria. Clinical Chemistry and Laboratory Medicine 51(4): E55-E56
Califf, R.M. 2009: Rational use of medications: if Canada can't do it .. Cmaj: Canadian Medical Association Journal 181(1-2): 15-16
Kelishadi, R.; Mousavinasab, F. 2012: Rational use of medicine in the pediatric age group: A summary on the role of clinical pharmacists. Journal of Research in Pharmacy Practice 1(1): 10-13
Chambers, P. 2011: Rational use of medicines. Veterinary Record 169(9): 226-227
Mendes, L.V.P.; Luiza, V.L.; Campos, M.ôn.R. 2014: Rational use of medicines by individuals with diabetes mellitus and arterial hypertension in the municipality of Rio de Janeiro, Brazil. Ciencia and Saude Coletiva 19(6): 1673-1684
Thawani, V. 2010: Rational use of medicines: Achievements and challenges. Indian Journal of Pharmacology 42(2): 63-64
Sharma, S.; Mathur, A.G.; Pradhan, S.; Singh, D.B. 2010: Rational use of medicines: How the armed forces do it. Indian Journal of Pharmacology 42(6): 421
Oyeyemi, A.S.; Ogunleye, O.A. 2013: Rational use of medicines: assessing progress using primary health centres in Shomolu local government area of Lagos, Nigeria. West African Journal of Medicine 32(2): 121-125
Bergsten-Mendes, G. 2008: Rational use of medicines: the pivotal role of the pharmacist. Ciencia and Saude Coletiva 13 Suppl: 569-571; Discussion: 575-577
Rockstroh, J.K.; Wasmuth, J.C. 2008: Rational use of modern substances for the treatment of HIV-infection. Der Internist 49(12): 1463-1464; 1466-1469
Cox, H.; Ford, N.; Keshavjee, S.; McDermid, C.; von Schoen-Angerer, T.; Mitnick, C.; Goemaere, E. 2011: Rational use of moxifloxacin for tuberculosis treatment. Lancet. Infectious Diseases 11(4): 259-260
Preskorn, S.H.; Khan, A.Y. 2013: Rational use of multiple medications in medicine and psychiatry: a dimensional perspective. Journal of Psychiatric Practice 19(1): 54-61
Berland, D.; Rodgers, P. 2012: Rational use of opioids for management of chronic nonterminal pain. American Family Physician 86(3): 252-258
Meier, J.; Habler, O. 2011: Rational use of oxygen in anesthesiology and intensive care medicine. Der Anaesthesist 60(4): 292-302
Meyhoff, C.S.; Staehr, A.K.; Rasmussen, L.S. 2012: Rational use of oxygen in medical disease and anesthesia. Current Opinion in Anaesthesiology 25(3): 363-370
Liu, X.; Wright, M.; Hop, C.E.C.A. 2014: Rational use of plasma protein and tissue binding data in drug design. Journal of Medicinal Chemistry 57(20): 8238-8248
Tandon, R.; Kalra, H. 2002: Rational use of psychotropic drugs by general practitioners. Indian Journal of Psychiatry 44(2): 192
Alvarez, R.J. 1954: Rational use of root canal therapy instruments. Revista Odontologica 42(8): 319-324
Oita, I.; Halewyck, H.; Pieters, S.; Dejaegher, B.; Thys, B.; Rombaut, B.; Vander Heyden, Y. 2011: Rational use of stacking principles for signal enhancement in capillary electrophoretic separations of poliovirus samples. Journal of Pharmaceutical and Biomedical Analysis 55(1): 135-145
Reisfield, G.M.; Wilson, G.R. 2007: Rational use of sublingual opioids in palliative medicine. Journal of Palliative Medicine 10(2): 465-475
Yeh, J.; Kravitz, D.; Francis, B. 2008: Rational use of the fixed combination of dorzolamide - timolol in the management of raised intraocular pressure and glaucoma. Clinical Ophthalmology 2(2): 389-399
Goel, S.; Chirgwin, J.; Francis, P.; Stuart-Harris, R.; Dewar, J.; Mileshkin, L.; Snyder, R.; Michael, M.; Koczwara, B. 2011: Rational use of trastuzumab in metastatic and locally advanced breast cancer: implications of recent research. Breast 20(2): 101-110
Wu, H.; Xu, Z.; Qin, K.; Joji, A. 2007: Rational utilization of a silicone tube flow chamber system. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi 24(5): 1061-1064
Klykov, M.A. 1949: Rational utilization of phantom perceptions for prosthetes. Khirurgiia 58(1): 60-65
Denison, S.; Bonawitz, E.; Gopnik, A.; Griffiths, T.L. 2013: Rational variability in children's causal inferences: the Sampling Hypothesis. Cognition 126(2): 285-300
Kopriva, I.; Hadžija, M.; Popović Hadžija, M.; Korolija, M.; Cichocki, A. 2011: Rational variety mapping for contrast-enhanced nonlinear unsupervised segmentation of multispectral images of unstained specimen. American Journal of Pathology 179(2): 547-554
Backliwal, G.; Hildinger, M.; Chenuet, S.; Wulhfard, S.; De Jesus, M.; Wurm, F.M. 2008: Rational vector design and multi-pathway modulation of HEK 293E cells yield recombinant antibody titers exceeding 1 g/l by transient transfection under serum-free conditions. Nucleic Acids Research 36(15): E96
Rubinelli, S. 2013: Rational versus unreasonable persuasion in doctor-patient communication: a normative account. Patient Education and Counseling 92(3): 296-301
Santos, C.N.S.; Xiao, W.; Stephanopoulos, G. 2012: Rational, combinatorial, and genomic approaches for engineering L-tyrosine production in Escherichia coli. Proceedings of the National Academy of Sciences of the United States of America 109(34): 13538-13543
Sobti, M.; Mabbutt, B.C. 2013: Rational-based protein engineering: tips and tools. Methods in Molecular Biology 996: 233-250
Li, A.; Staunton, R.; Tjahjadi, T. 2013: Rational-operator-based depth-from-defocus approach to scene reconstruction. Journal of the Optical Society of America. a Optics Image Science and Vision 30(9): 1787-1795
Nagano, J.; Morita, T.; Taneichi, K.; Nagaoka, S.; Katsube, S.; Asai, T.; Yukioka, M.; Takasugi, K.; Kondo, M.; Nishibayashi, Y. 2014: Rational/antiemotional behaviors in interpersonal relationships and the functional prognosis of patients with rheumatoid arthritis: a Japanese multicenter, longitudinal study. Biopsychosocial Medicine 8(1): 8
Prewitt, P.V.; Easton, E.R. 1938: Rationale of Bone Drilling in Delayed and Ununited Fractures. Annals of Surgery 107(2): 303-310
Gańczak, M.; Szych, Z. 2009: Rationale against preoperative screening for HIV in Polish hospitals: a prevalence study of anti-HIV in contrast to anti-hepatitis C virus and hepatitis B surface antigen. Infection Control and Hospital Epidemiology 30(12): 1227-1229
Zhou, Y.; McArdle, J.J. 2015: Rationale and Applications of Survival Tree and Survival Ensemble Methods. Psychometrika 80(3): 811-833
Fürnkranz, A.; Brugada, J.; Albenque, J.-P.; Tondo, C.; Bestehorn, K.; Wegscheider, K.; Ouyang, F.; Kuck, K.-H. 2014: Rationale and Design of Fire and Ice: a Multicenter Randomized Trial Comparing Efficacy and Safety of Pulmonary Vein Isolation using a Cryoballoon versus Radiofrequency Ablation with 3d-Reconstruction. Journal of Cardiovascular Electrophysiology 25(12): 1314-1320
Morton, L.M.; Sampson, J.N.; Cerhan, J.R.; Turner, J.J.; Vajdic, C.M.; Wang, S.S.; Smedby, K.E.; de Sanjosé, S.; Monnereau, A.; Benavente, Y.; Bracci, P.M.; Chiu, B.C.H.; Skibola, C.F.; Zhang, Y.; Mbulaiteye, S.M.; Spriggs, M.; Robinson, D.; Norman, A.D.; Kane, E.V.; Spinelli, J.J.; Kelly, J.L.; La Vecchia, C.; Dal Maso, L.; Maynadié, M.; Kadin, M.E.; Cocco, P.; Costantini, A.Seniori.; Clarke, C.A.; Roman, E.; Miligi, L.; Colt, J.S.; Berndt, S.I.; Mannetje, A.; de Roos, A.J.; Kricker, A.; Nieters, A.; Franceschi, S.; Melbye, M.; Boffetta, P.; Cla 2014: Rationale and Design of the International Lymphoma Epidemiology Consortium (InterLymph) Non-Hodgkin Lymphoma Subtypes Project. Journal of the National Cancer Institute. Monographs 2014(48): 1-14
Uno, K.; Bayturan, O.; Lavoie, A.; Nicholls, S.J. 2010: Rationale and approach to evaluation of the impact of medical therapies on progression of atherosclerosis with arterial wall imaging. Current Medical Research and Opinion 26(3): 737-744
De Flora, S.; Izzotti, A.; D'Agostini, F.; La Maestra, S.; Micale, R.T.; Ceccaroli, C.; Steele, V.E.; Balansky, R. 2014: Rationale and approaches to the prevention of smoking-related diseases: overview of recent studies on chemoprevention of smoking-induced tumors in rodent models. Journal of Environmental Science and Health. Part C Environmental Carcinogenesis and Ecotoxicology Reviews 32(2): 105-120
Bechdolf, A.; Müller, H.; Stützer, H.; Wagner, M.; Maier, W.; Lautenschlager, M.; Heinz, A.; de Millas, W.; Janssen, B.; Gaebel, W.; Michel, T.Maria.; Schneider, F.; Lambert, M.; Naber, D.; Brüne, M.; Krüger-Özgürdal, S.; Wobrock, T.; Riedel, M.; Klosterkötter, J.; Klosterkötter, J.; Bechdolf, A.; Pützfeld, V.; Müller, H.; Konkol, C.; Wiessmann, T.; Schönborn, T.; Biesenbach, Jörn.; Kadow, I.; Ackermann, V.; Maier, W.; Wagner, M.; Hurlemann, Ré.; Moessner, R.; Kayser, S.; Striepens, N.; Schulze-Rauschenbach, S.; Berning, J.; Drees, J.;, 2011: Rationale and baseline characteristics of PREVENT: a second-generation intervention trial in subjects at-risk (prodromal) of developing first-episode psychosis evaluating cognitive behavior therapy, aripiprazole, and placebo for the prevention of psychosis. Schizophrenia Bulletin 37 Suppl. 2: S111-S121
Goodwin, J.J. 2006: Rationale and benefit of using high throughput solubility screens in drug discovery. Drug Discovery Today. Technologies 3(1): 67-71
Lococo, F.; Cesario, A.; Sterzi, S.; Magrone, G.; Dall'armi, V.; Mattei, F.; Varone, F.; Porziella, V.; Margaritora, S.; Granone, P. 2012: Rationale and clinical benefits of an intensive long-term pulmonary rehabilitation program after oesophagectomy: preliminary report. Multidisciplinary respiratory medicine 7(1): 21
Engelborghs, S.; Gilles, C.; Ivanoiu, A.; Vandewoude, M. 2014: Rationale and clinical data supporting nutritional intervention in Alzheimer's disease. Acta Clinica Belgica 69(1): 17-24
Mani, L.-Y.; Vogt, B.; Burnier, M.; Golshayan, D.él. 2011: Rationale and clinical evidence for the use of rituximab in glomerular diseases. Revue Medicale Suisse 7(290): 819-824
Moriyama-Gonda, N.; Shiina, H.; Terashima, M.; Satoh, K.; Igawa, M. 2008: Rationale and clinical implication of combined chemotherapy with cisplatin and oestrogen in prostate cancer: primary evidence based on methylation analysis of oestrogen receptor-alpha. Bju International 101(4): 485-491
Martinez-Ramirez, D.; Okun, M.S. 2014: Rationale and clinical pearls for primary care doctors referring patients for deep brain stimulation. Gerontology 60(1): 38-48
Torrado, J.J.é; Blanco, M.ía.; Farré, M.í; Roset, P.; García-Arieta, A. 2010: Rationale and conditions for the requirement of chiral bioanalytical methods in bioequivalence studies. European Journal of Clinical Pharmacology 66(6): 599-604
Allen, P.J.; Batra, P.; Geiger, B.M.; Wommack, T.; Gilhooly, C.; Pothos, E.N. 2012: Rationale and consequences of reclassifying obesity as an addictive disorder: neurobiology, food environment and social policy perspectives. Physiology and Behavior 107(1): 126-137
Danger, R.; Giral, M.; Soulillou, J.-P.; Brouard, S. 2008: Rationale and criteria of eligibility for calcineurin inhibitor interruption following kidney transplantation. Current Opinion in Organ Transplantation 13(6): 609-613
Agyemang, C.; Beune, E.; Meeks, K.; Owusu-Dabo, E.; Agyei-Baffour, P.; Aikins, A.de-Graft.; Dodoo, F.; Smeeth, L.; Addo, J.; Mockenhaupt, F.P.; Amoah, S.K.; Schulze, M.B.; Danquah, I.; Spranger, J.; Nicolaou, M.; Klipstein-Grobusch, K.; Burr, T.; Henneman, P.; Mannens, M.M.; van Straalen, J.P.; Bahendeka, S.; Zwinderman, A.H.; Kunst, A.E.; Stronks, K. 2014: Rationale and cross-sectional study design of the Research on Obesity and type 2 Diabetes among African Migrants: the RODAM study. Bmj Open 4(3): E004877
Blay, J-Yves.; Koscielny, S.; Trédaniel, J.; Asselain, B.; Goldwasser, Fçois.; Misset, J-Louis.; de Labareyre, Cécile.; Hagège, C.; Bismut, Hé.; Marty, M. 2007: Rationale and delineation of a composite index of relative antitumoural efficacy (In-RATE). Critical reviews in oncology/hematology 64(2): 106-114
Traverse, J.H.; Henry, T.D.; Vaughan, D.E.; Vaughn, D.E.; Ellis, S.G.; Pepine, C.J.; Willerson, J.T.; Zhao, D.X.M.; Piller, L.B.; Penn, M.S.; Byrne, B.J.; Perin, E.C.; Gee, A.P.; Hatzopoulos, A.K.; McKenna, D.H.; Forder, J.R.; Taylor, D.A.; Cogle, C.R.; Olson, R.E.; Jorgenson, B.C.; Sayre, S.L.; Vojvodic, R.W.; Gordon, D.J.; Skarlatos, S.I.; Moye', L.A.; Simari, R.D. 2009: Rationale and design for TIME: a phase II, randomized, double-blind, placebo-controlled pilot trial evaluating the safety and effect of timing of administration of bone marrow mononuclear cells after acute myocardial infarction. American Heart Journal 158(3): 356-363
Brunetti, N.Daniele.; De Gennaro, L.; Dellegrottaglie, G.; Straziota, E.; Novielli, V.; Antonelli, G.; Di Biase, M. 2011: Rationale and design for a cardiovascular screening and prevention study with tele-cardiology in Mediterranean Italy: the CAPITAL study (CArdiovascular Prevention wIth Telecardiology in ApuLia). International Journal of Cardiology 149(1): 130-133
Saeed, M.; Razavi, M.; Neason, C.G.; Petrutiu, S. 2011: Rationale and design for programming implantable cardioverter-defibrillators in patients with primary prevention indication to prolong time to first shock (PROVIDE) study. Europace: European Pacing Arrhythmias and Cardiac Electrophysiology: Journal of the Working Groups on Cardiac Pacing Arrhythmias and Cardiac Cellular Electrophysiology of the European Society of Cardiology 13(11): 1648-1652
Kadish, A.H.; Bello, D.; Finn, J.Paul.; Bonow, R.O.; Schaechter, A.; Subacius, H.; Albert, C.; Daubert, J.P.; Fonseca, C.G.; Goldberger, J.J. 2009: Rationale and design for the Defibrillators to Reduce Risk by Magnetic Resonance Imaging Evaluation (DETERMINE) trial. Journal of Cardiovascular Electrophysiology 20(9): 982-987
Lemos, P.A.; Moulin, B.; Perin, M.A.; Oliveira, L.A.R.R.; Arruda, J.A.; Lima, V.C.; Lima, A.A.G.; Caramori, P.R.A.; Medeiros, C.R.; Barbosa, M.R.; Brito, F.S.; Ribeiro, E.E.; Martinez, E.óg.E. 2009: Rationale and design for the PAINT randomized trial. Arquivos Brasileiros de Cardiologia 93(6): 547
Keren, R.; Carpenter, M.A.; Hoberman, A.; Shaikh, N.; Matoo, T.K.; Chesney, R.W.; Matthews, R.; Gerson, A.C.; Greenfield, S.P.; Fivush, B.; McLurie, G.A.; Rushton, H.G.; Canning, D.; Nelson, C.P.; Greenbaum, L.; Bukowski, T.; Primack, W.; Sutherland, R.; Hosking, J.; Stewart, D.; Elder, J.; Moxey-Mims, M.; Nyberg, L. 2008: Rationale and design issues of the Randomized Intervention for Children with Vesicoureteral Reflux (RIVUR) study. Pediatrics 122(Suppl 5): S240-S250
Eikelboom, J.W.; O'Donnell, M.; Yusuf, S.; Diaz, R.; Flaker, G.; Hart, R.; Hohnloser, S.; Joyner, C.; Lawrence, J.; Pais, P.; Pogue, J.; Synhorst, D.; Connolly, S.J. 2010: Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. American Heart Journal 159(3): 348-353.E1
Hak, E.; Grobbee, D.E.; Sanders, E.A.M.; Verheij, T.J.M.; Bolkenbaas, M.; Huijts, S.M.; Gruber, W.C.; Tansey, S.; McDonough, A.; Thoma, B.; Patterson, S.; van Alphen, A.J.; Bonten, M.J.M. 2008: Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults. Netherlands Journal of Medicine 66(9): 378-383
Zhao, S.-p.; Peng, D.-q.; Yu, B.-l.; Huo, Y.; Zhao, S.; Peng, Q.; Yu, B.; Gai, L.; Wang, Z.; Yang, X.; Fang, W.; Xu, Y.; Dai, J.; Gao, W.; Niu, J.; He, G.; Jing, T.; Hou, Y.; Zhou, Z.; Wang, Y.; Hua, Q.; Wang, W.; Li, Q.; Xu, Y.; Yu, X.; Yang, T.; Yu, G.; Yang, X.; Yang, Z.; Yang, Y.; Xu, H.; Zeng, Q.; Li, S.; Zhang, S.; Jiang, J.; Sun, B.; Qi, G.; Huo, H.; Guo, X.; Zhou, W.; Chen, J.; Huang, W.; Du, Z.; Mai, W.; Wang, X.; Li, W.; Han, W. 2009: Rationale and design of China intensive lipid lowering with statins in acute coronary syndrome: the CHILLAS study. American Heart Journal 158(4): 509-512.E1
Van der Schaaf, R.é J.; Claessen, B.E.; Hoebers, L.P.; Verouden, N.J.; Koolen, J.J.; Suttorp, M.J.; Barbato, E.; Bax, M.; Strauss, B.H.; Olivecrona, G.ör.K.; Tuseth, V.; Glogar, D.; Råmunddal, T.; Tijssen, J.G.; Piek, J.J.; Henriques, J.é P.S. 2010: Rationale and design of EXPLORE: a randomized, prospective, multicenter trial investigating the impact of recanalization of a chronic total occlusion on left ventricular function in patients after primary percutaneous coronary intervention for acute ST-elevation myocardial infarction. Trials 11: 89
Taljaard, M.; Ward, M.R.; Kutryk, M.J.B.; Courtman, D.W.; Camack, N.J.; Goodman, S.G.; Parker, T.G.; Dick, A.J.; Galipeau, J.; Stewart, D.J. 2010: Rationale and design of Enhanced Angiogenic Cell Therapy in Acute Myocardial Infarction (ENACT-AMI): the first randomized placebo-controlled trial of enhanced progenitor cell therapy for acute myocardial infarction. American Heart Journal 159(3): 354-360
Lancaster, K.J.; Schoenthaler, A.M.; Midberry, S.A.; Watts, S.O.; Nulty, M.R.; Cole, H.V.; Ige, E.; Chaplin, W.; Ogedegbe, G. 2014: Rationale and design of Faith-based Approaches in the Treatment of Hypertension (FAITH), a lifestyle intervention targeting blood pressure control among black church members. American Heart Journal 167(3): 301-307
Anker, S.D.; Colet, J.Comin.; Filippatos, G.; Willenheimer, R.; Dickstein, K.; Drexler, H.; Lüscher, T.F.; Mori, C.; von Eisenhart Rothe, B.; Pocock, S.; Poole-Wilson, P.A.; Ponikowski, P. 2009: Rationale and design of Ferinject assessment in patients with IRon deficiency and chronic Heart Failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia. European Journal of Heart Failure 11(11): 1084-1091
Cannon, C.P.; Giugliano, R.P.; Blazing, M.A.; Harrington, R.A.; Peterson, J.L.; Sisk, C.McCrary.; Strony, J.; Musliner, T.A.; McCabe, C.H.; Veltri, E.; Braunwald, E.; Califf, R.M.; Braunwald, E.; Cannon, C.P.; Giugliano, R.; McCabe, C.; McCagg, A.; Califf, R.M.; Harrington, R.A.; Blazing, M.A.; Petersen, J.L.; Reist, C.; White, J.; Ezkenazi, L.; Martz, C.; Grundy, S.; Bertrand, M.; DeMets, D.; Kjekshus, J.; Gersh, B.; Davidson, M.; Waters, D.; Wiviott, S.D.; Gurfinkel, E.; Aylward, P.; Maurer, G.; Van de Werf, F.; Nicolau, J.C.; Theroux, P.; Corba 2008: Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. American Heart Journal 156(5): 826-832
O'Donnell, M.; Xavier, D.; Diener, C.; Sacco, R.; Lisheng, L.; Zhang, H.; Pias, P.; Truelsen, T.; Chin, S.L.; Rangarajan, S.; Devilliers, L.; Damasceno, A.; Mondo, C.; Lanas, F.; Avezum, A.; Diaz, R.; Varigos, J.; Hankey, G.; Teal, P.; Kapral, M.; Ryglewicz, D.; Czlonkowska, A.; Skowronska, M.; Lopez-Jaramillo, P.; Dans, T.; Langhorne, P.; Yusuf, S. 2010: Rationale and design of INTERSTROKE: a global case-control study of risk factors for stroke. Neuroepidemiology 35(1): 36-44
Nanasato, M.; Nakajima, K.; Fujita, H.; Zen, K.; Kohsaka, S.; Hashimoto, A.; Moroi, M.; Fukuzawa, S.; Chikamori, T.; Nishimura, S.; Yamashina, A.; Kusuoka, H.; Hirayama, A.; Nishimura, T. 2014: Rationale and design of J-ACCESS 4: prognostic impact of reducing myocardial ischemia identified using ECG-gated myocardial perfusion SPECT in Japanese patients with coronary artery disease. Journal of cardiology 63(2): 159-164
Robinson, J.G.; Rogers, W.J.; Nedergaard, B.S.; Fialkow, J.; Neutel, J.M.; Ramstad, D.; Somaratne, R.; Legg, J.C.; Nelson, P.; Scott, R.; Wasserman, S.M.; Weiss, R. 2014: Rationale and design of LAPLACE-2: a phase 3, randomized, double-blind, placebo- and ezetimibe-controlled trial evaluating the efficacy and safety of evolocumab in subjects with hypercholesterolemia on background statin therapy. Clinical Cardiology 37(4): 195-203
Machiels, J.-P.H.; Licitra, L.F.; Haddad, R.I.; Tahara, M.; Cohen, E.E. 2014: Rationale and design of LUX-Head and Neck 1: a randomised, Phase IIi trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy. Bmc Cancer 14: 473
Scagliotti, G.V.; Novello, S.; Schiller, J.H.; Hirsh, V.; Sequist, L.V.; Soria, J.-C.; von Pawel, J.; Schwartz, B.; Von Roemeling, R.; Sandler, A.B. 2012: Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer. Clinical Lung Cancer 13(5): 391-395
Gridelli, C.; Rossi, A.; Di Maio, M.; Leo, S.; Filipazzi, V.; Favaretto, A.G.; Burgio, M.A.; Cinieri, S.; Bianco, R.; Ciardiello, F.; Cavanna, L.; Bordonaro, R.; Costanzo, R.; Sandomenico, C.; Gallo, C.; Perrone, F.; Morabito, A. 2014: Rationale and design of MILES-3 and MILES-4 studies: two randomized phase 3 trials comparing single-agent chemotherapy versus cisplatin-based doublets in elderly patients with advanced non--small-cell lung cancer. Clinical Lung Cancer 15(2): 166-170
Beck-Peccoz, P.; Minuto, F.; Leal-Cerro, A.; Zabransky, M.; Stalla, Günter. 2012: Rationale and design of PATRO Adults, a multicentre, noninterventional study of the long-term efficacy and safety of Omnitrope(®) for the treatment of adult patients with growth hormone deficiency. Therapeutic Advances in Endocrinology and Metabolism 3(3): 85-91
Gámez-López, A.L.; Bonilla-Palomas, J.L.; Anguita-Sánchez, M.; Moreno-Conde, M.; López-Ibáñez, C.; Alhambra-Expósito, R.; Castillo-Domínguez, J.C.; Villar-Ráez, A.; Suárez de Lezo, Jé. 2014: Rationale and design of PICNIC study: nutritional intervention program in hospitalized patients with heart failure who are malnourished. Revista Espanola de Cardiologia 67(4): 277-282
Stienen, S.; Salah, K.; Moons, A.H.M.; Bakx, A.L.M.; van Pol, P.E.; Schroeder-Tanka, J.M.; Voogel, A.J.; Keijer, J.T.; Kortz, R.A.M.; Dickhoff, C.; Meregalli, P.G.; Tijssen, J.G.; Pinto, Y.M.; Kok, W.E. 2014: Rationale and design of PRIMA II: a multicenter, randomized clinical trial to study the impact of in-hospital guidance for acute decompensated heart failure treatment by a predefined NT-PRoBNP target on the reduction of readm Ission and Mortality rAtes. American Heart Journal 168(1): 30-36
Riess, H.; Pelzer, U.; Hilbig, A.; Stieler, J.; Opitz, B.; Scholten, T.; Kauschat-Brüning, D.ör.; Bramlage, P.; Dörken, B.; Oettle, H. 2008: Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy). Bmc Cancer 8: 361
Ezekowitz, M.D.; Connolly, S.; Parekh, A.; Reilly, P.A.; Varrone, J.; Wang, S.; Oldgren, J.; Themeles, E.; Wallentin, L.; Yusuf, S. 2009: Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. American Heart Journal 157(5): 805
Smith, K.S.; Hocking, J.S.; Chen, M.; Fairley, C.K.; McNulty, A.; Read, P.; Bradshaw, C.S.; Tabrizi, S.N.; Wand, H.; Saville, M.; Rawlinson, W.; Garland, S.M.; Donovan, B.; Kaldor, J.M.; Guy, R. 2014: Rationale and design of REACT: a randomised controlled trial assessing the effectiveness of home-collection to increase chlamydia retesting and detect repeat positive tests. Bmc Infectious Diseases 14: 223
Reiffel, J.; Verma, A.; Halperin, J.L.; Gersh, B.; Tombul, S.; Carrithers, J.; Sherfesee, L.; Kowey, P. 2014: Rationale and design of REVEAL AF: a prospective study of previously undiagnosed atrial fibrillation as documented by an insertable cardiac monitor in high-risk patients. American Heart Journal 167(1): 22-27
Nock, N.L.; Dimitropoulos, A.; Rao, S.M.; Flask, C.A.; Schluchter, M.; Zanotti, K.M.; Rose, P.G.; Kirwan, J.P.; Alberts, J. 2014: Rationale and design of REWARD (revving-up exercise for sustained weight loss by altering neurological reward and drive): a randomized trial in obese endometrial cancer survivors. Contemporary Clinical Trials 39(2): 236-245
Park, W.Jung.; Jo, S-Ho.; Kim, S-Ai.; Kim, H-Sook.; Han, S-Jin.; Choi, Y.Jin.; Rhim, C-Yun. 2011: Rationale and design of STOP DVT study: rosuvastatin for the prevention of deep vein thrombosis in patients undergoing total knee replacement arthroplasty--a prospective randomized open-label controlled trial. Contemporary Clinical Trials 32(5): 779-782
Fiedler, K.A.; Byrne, R.A.; Schulz, S.; Sibbing, D.; Mehilli, J.; Ibrahim, T.; Maeng, M.; Laugwitz, K.-L.; Kastrati, A.; Sarafoff, N. 2014: Rationale and design of the Intracoronary Stenting and Antithrombotic Regimen-Testing of a six-week versus a six-month clopidogrel treatment Regimen in Patients with concomitant aspirin and oraL anticoagulant therapy following drug-Eluting stenting (ISAR-TRIPLE) study. American Heart Journal 167(4): 459-465.E1
Hong, K.-S.; Choi, Y.J.; Kwon, S.U. 2015: Rationale and design of Triple AXEL: trial for early anticoagulation in acute ischemic stroke patients with nonvalvular atrial fibrillation. International Journal of Stroke: Official Journal of the International Stroke Society 10(1): 128-133
Naccarelli, G.V.; Cappato, R.; Hohnloser, S.H.; Marchlinski, F.E.; Wilber, D.J.; Xiang, J.; Ma, C.; Hess, S.; Davies, D.W.; Fields, L.E.; Natale, A. 2014: Rationale and design of VENTURE-AF: a randomized, open-label, active-controlled multicenter study to evaluate the safety of rivaroxaban and vitamin K antagonists in subjects undergoing catheter ablation for atrial fibrillation. Journal of Interventional Cardiac Electrophysiology: An International Journal of Arrhythmias and Pacing 41(2): 107-116
Pedersen, S.S.; Spek, V.; Theuns, D.A.M.J.; Alings, M.; van der Voort, P.; Jordaens, L.; Cuijpers, P.; Denollet, J.; van den Broek, K.C. 2009: Rationale and design of WEBCARE: a randomized, controlled, web-based behavioral intervention trial in cardioverter-defibrillator patients to reduce anxiety and device concerns and enhance quality of life. Trials 10: 120
Turpie, A.G.G.; Schmidt, A.é C.; Kreutz, R.; Lassen, M.R.; Jamal, W.; Mantovani, L.; Haas, S. 2012: Rationale and design of XAMOS: noninterventional study of rivaroxaban for prophylaxis of venous thromboembolism after major hip and knee surgery. Vascular Health and Risk Management 8: 363-370
Karthikeyan, G.; Zühlke, L.; Engel, M.; Rangarajan, S.; Yusuf, S.; Teo, K.; Mayosi, B.M. 2012: Rationale and design of a Global Rheumatic Heart Disease Registry: the REMEDY study. American Heart Journal 163(4): 535
Ciccolo, J.T.; Lo, A.C.; Jennings, E.G.; Motl, R.W. 2012: Rationale and design of a clinical trial investigating resistance training as an aid to smoking cessation in persons with multiple sclerosis. Contemporary Clinical Trials 33(4): 848-852
Jones, M.R.; Mudaliar, S.; Hernandez-Triana, E.; Unnikrishnan, A.G.; Lai, Y.-L.; Abby, S.L.; Misir, S.; Jin, X.; Nagendran, S. 2009: Rationale and design of a clinical trial to evaluate metformin and colesevelam HCl as first-line therapy in type 2 diabetes and colesevelam HCl in prediabetes. Current Medical Research and Opinion 25(9): 2239-2249
Böhm, M.; Mahfoud, F.; Ukena, C.; Bauer, A.; Fleck, E.; Hoppe, U.C.; Kintscher, U.; Narkiewicz, K.; Negoita, M.; Ruilope, L.; Rump, L.C.; Schlaich, M.; Schmieder, R.; Sievert, H.; Weil, J.; Williams, B.; Zeymer, U.; Mancia, G. 2013: Rationale and design of a large registry on renal denervation: the Global SYMPLICITY registry. Eurointervention: Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 9(4): 484-492
Odudu, A.; Eldehni, M.Tarek.; Fakis, A.; McIntyre, C.William. 2012: Rationale and design of a multi-centre randomised controlled trial of individualised cooled dialysate to prevent left ventricular systolic dysfunction in haemodialysis patients. Bmc Nephrology 13: 45
Shah, A.M.; Cheng, S.; Skali, H.; Wu, J.; Mangion, J.R.; Kitzman, D.; Matsushita, K.; Konety, S.; Butler, K.R.; Fox, E.R.; Cook, N.; Ni, H.; Coresh, J.; Mosley, T.H.; Heiss, G.; Folsom, A.R.; Solomon, S.D. 2014: Rationale and design of a multicenter echocardiographic study to assess the relationship between cardiac structure and function and heart failure risk in a biracial cohort of community-dwelling elderly persons: the Atherosclerosis Risk in Communities study. CIRCULATION. Cardiovascular Imaging 7(1): 173-181
Orlando, G.; Tanzi, E.; Chatenoud, L.; Gramegna, M.; Rizzardini, G.; Antonacci, M.C.; Arcidiacono, I.; Bertuccio, P.; Bianchi, S.; Boero, V.; Cambiè, G.; Esposito, S.; Falchetti, M.; Fasolo, M.M.; Galli, C.; Bertazzoli, E.; Lunghi, G.; Matteelli, A.; Tisi, G.; Zanchetta, N.; Zuccotti, G. 2012: Rationale and design of a multicenter prospective cohort study for the eVALuation and monitoring of HPV infections and rel ATEd cervical diseases in high-risk women (VALHIDATE study). Bmc Cancer 12: 204
Brown, C.S.; Foster, D.C.; Wan, J.Y.; Rawlinson, L.A.; Bachmann, G.A. 2013: Rationale and design of a multicenter randomized clinical trial of extended release gabapentin in provoked vestibulodynia and biological correlates of response. Contemporary Clinical Trials 36(1): 154-165
Pickering, G.èl.; Pereira, B.; Morel, V.ér.; Tiberghien, F.; Martin, E.; Marcaillou, F.; Picard, P.; Delage, N.ém.; de Montgazon, G.ér.; Sorel, M.; Roux, D.; Dubray, C. 2014: Rationale and design of a multicenter randomized clinical trial with memantine and dextromethorphan in ketamine-responder patients. Contemporary Clinical Trials 38(2): 314-320
Liang, J.; Li, F.; Wei, C.; Song, H.; Wu, L.; Tang, Y.; Jia, J. 2014: Rationale and design of a multicenter, phase 2 clinical trial to investigate the efficacy of traditional Chinese medicine SaiLuoTong in vascular dementia. Journal of Stroke and Cerebrovascular Diseases: the Official Journal of National Stroke Association 23(10): 2626-2634
Borg, J.ör.; Ward, A.B.; Wissel, J.ör.; Kulkarni, J.; Sakel, M.; Ertzgaard, P.; Åkerlund, P.; Reuter, I.; Herrmann, C.; Satkunam, L.; Wein, T.; Girod, I.; Wright, N.; Åkerlund, P.; Aung, T.; Biörklund, J.; Borg, J.ör.; Ceballos-Baumann, A.; Dohle, C.; Edblom, M.; Ertzgaard, P.; Haboubi, N.; Häggström, A.; Herrmann, C.; Hesse, S.; Kulkarni, J.; Kullander, K.; Landham, L.; Lindgren, K.; Mehnert, S.; Müller, F.; Phillips, M.; Platz, T.; Prempeh, R.; Reuter, I.; Roy, C.; Sakel, M.; Säterö, P.; Satkunam, L.; Schupp, W.; Seigel, K.; Sharma, S.; van der Ven, C.; Walsh, M.; Ward, A.; Wein, T.; Wissel, J.ör. 2011: Rationale and design of a multicentre, double-blind, prospective, randomized, European and Canadian study: evaluating patient outcomes and costs of managing adults with post-stroke focal spasticity. Journal of Rehabilitation Medicine 43(1): 15-22
Kawut, S.M.; Bagiella, E.; Shimbo, D.; Lederer, D.J.; Al-Naamani, N.; Roberts, K.E.; Barr, R.G.; Post, W.; Horn, E.M.; Tracy, R.; Hassoun, P.; Girgis, R.; Moore, T.; Gail, D.; Kiley, J.; Kawut, S.; Girgis, R.; Bagiella, E.; Singh, V.; Marathe, S.; Chang, H.; Schlesinger, M.; Lederer, D.; Kawut, S.; Horn, E.; Rosenzweig, E.; Girgis, R.; Hassoun, P.; Zaiman, A.; Post, W.; Kawut, S.; Palevsky, H.; Taichman, D.; Halpern, S.; Forfia, P.; Archer-Chicko, C.; Roberts, K.; Preston, I.; Hill, N.; Kuvin, J.; Karas, R.; Shimbo, D.; Homma, S.; Zhang, M.; Sashida, Y.; Tracy, R.; Cornell, E.; Boyle, R.; MacArthur, R.; Altincatal, A.; Johnson, J.; Horwitz, P.; Fisher, M.; Mathier, M.; Farber, H.; Mandel, J.; Halperin, J.; Heitjen, D.; Mauger, D. 2011: Rationale and design of a phase Ii clinical trial of aspirin and simvastatin for the treatment of pulmonary arterial hypertension: ASA-STAT. Contemporary Clinical Trials 32(2): 280-287
Visser, M.; Davids, M.; Verberne, H.J.; Kok, W.E.M.; Niessen, H.W.M.; van Venrooij, L.M.W.; Cocchieri, R.; Wisselink, W.; de Mol, B.A.J.M.; van Leeuwen, P.A.M. 2011: Rationale and design of a proof-of-concept trial investigating the effect of uninterrupted perioperative (par)enteral nutrition on amino acid profile, cardiomyocytes structure, and cardiac perfusion and metabolism of patients undergoing coronary artery bypass grafting. Journal of Cardiothoracic Surgery 6: 36
Bays, H.E.; Cohen, D.E. 2007: Rationale and design of a prospective clinical trial program to evaluate the glucose-lowering effects of colesevelam HCl in patients with type 2 diabetes mellitus. Current Medical Research and Opinion 23(7): 1673-1684
Cowie, M.R.; Conraads, V.; Tavazzi, L.; Yu, C.M.; Conraads, V.; Boland, J.; Yu, C.M.; Kautzner, J.; Taborsky, M.; Hassager, C.; Defaye, P.; Kacet, S.; Pousset, F.; Leclercq, C.; Lascault, G.; Chauvin, M.; Anselme, F.; Schauerte, P.; Lamp, B.; Keweloh, B.; Meyer zu Vilsendorf, D.; Bauer, A.; Dörnberger, V.; Hoffmann, E.; Schmieder, S.; Maounis, T.; Vardas, P.; Vassilikos, V.; Strasberg, B.; Glikson, M.; Ferrari, R.; Padeletti, L.; Raviele, A.; Oliva, F.; Frigerio, M.; Landolina, M.; Santini, M.; Sinagra, G.; Ponikowski, P.; Hatala, R.; Sedlak, J.; Stancak, B.; Lozano, I.; Beiras Torrado, J.; Cowie, M.; Elliott, P.; Paul, V. 2009: Rationale and design of a prospective trial to assess the sensitivity and positive predictive value of implantable intrathoracic impedance monitoring in the prediction of heart failure hospitalizations: the SENSE-HF study. Journal of Cardiac Failure 15(5): 394-400
Xhepa, E.; Byrne, R.A.; Schulz, S.; Helde, S.; Gewalt, S.; Cassese, S.; Linhardt, M.; Ibrahim, T.; Mehilli, J.; Hoppe, K.; Grupp, K.; Kufner, S.; Böttiger, C.; Hoppmann, P.; Burgdorf, C.; Fusaro, M.; Ott, I.; Schneider, S.; Hengstenberg, C.; Schunkert, H.; Laugwitz, K.-L.; Kastrati, A.; Kastrati, A.; Linhardt, M.; Ibrahim, T.; Mehilli, J.; Schulz, S.; Goedel, J.; Koppara, T.; Grupp, K.; Hoppe, K.; Bruskina, O.; Stein, A.; Ndrepepa, G.; Böttiger, C.; Groha, P.; Kufner, S. 2014: Rationale and design of a randomised clinical trial comparing vascular closure device and manual compression to achieve haemostasis after diagnostic coronary angiography: the Instrumental Sealing of ARterial puncture site - CLOSURE device versus manual compression (ISAR-CLOSURE) trial. Eurointervention: Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 10(2): 198-203
Zuazagoitia, A.; Grandes, G.; Torcal, Jús.; Lekuona, Iñaki.; Echevarria, P.; Gómez, M.A.; Domingo, M.; de la Torre, M.M.; Ramírez, J.I.; Montoya, I.; Oyanguren, J.; Pinilla, R.Ortega-Sánchez.; Zuazagoitia, A.; Grandes, G.; Torcal, Jús.; Oyanguren, J.; Montoya, I.; Latorre, K.; Torcal, Jús.; Chirapozu, J.Manuel.; Arce, Vónica.; Oyanguren, J.; Oses, M.; Alarcon, J.Antonio.; Echevarria, P.; Palomar, S.; Arietaleanizbeaskoa, M.Soledad.; Otxandategi, A.; Pascual, A.; Marcos, M.Angel.Gómez.; Ortiz, L.García.; Santos, I.; Diego, M.; Cruz, I.; Moreiras, J.; Rodríguez, Jé.I.Recio.; Pavón, 2010: Rationale and design of a randomised controlled trial evaluating the effectiveness of an exercise program to improve the quality of life of patients with heart failure in primary care: The EFICAR study protocol. Bmc Public Health 10: 33
Angermann, C.E.; Gelbrich, G.öt.; Störk, S.; Fallgatter, A.; Deckert, J.ür.; Faller, H.; Ertl, G. 2007: Rationale and design of a randomised, controlled, multicenter trial investigating the effects of selective serotonin re-uptake inhibition on morbidity, mortality and mood in depressed heart failure patients (MOOD-HF). European Journal of Heart Failure 9(12): 1212-1222
Jensen, L.O.; Thayssen, P.; Tilsted, H.H.; Ravkilde, J.; Junker, A.; Hansen, H.S.; Hansen, K.N.ør.; Pedersen, K.E.; Sørensen, H.T.; Thuesen, L.; Lassen, J.F.; Thayssen, P.; Jensen, L.O.; Thygesen, K.; Terkelsen, C.J.; Madsen, M.; Johnsen, S.ør.P.; Toft Sørensen, H.; Thayssen, P.; Jensen, L.O.; Tilsted, H.H.; Ravkilde, J.; Lassen, J.F.; Thuesen, L. 2010: Rationale and design of a randomized clinical comparison of everolimus-eluting (Xience v/Promus) and sirolimus-eluting (cypher select+) coronary stents in unselected patients with coronary heart disease. Cardiology 116(2): 73-78
Hiro, T.; Hirayama, A.; Ueda, Y.; Komatsu, S.; Matsuoka, H.; Takayama, T.; Ishihara, M.; Hayashi, T.; Saito, S.; Kodama, K. 2014: Rationale and design of a randomized clinical study to investigate the effect of ezetimibe, a cholesterol absorption inhibitor, on the regression of intracoronary plaque evaluated by non-obstructive angioscopy and ultrasound: the ZIPANGU study. Journal of Cardiology 64(6): 501-507
Detaint, D.; Aegerter, P.; Tubach, F.; Hoffman, I.; Plauchu, H.; Dulac, Y.; Faivre, L.O.; Delrue, M.-A.; Collignon, P.; Odent, S.; Tchitchinadze, M.; Bouffard, C.; Arnoult, F.; Gautier, M.; Boileau, C.; Jondeau, G. 2010: Rationale and design of a randomized clinical trial (Marfan Sartan) of angiotensin Ii receptor blocker therapy versus placebo in individuals with Marfan syndrome. Archives of Cardiovascular Diseases 103(5): 317-325
Donahue, R.G.; Lampert, R.; Dornelas, E.; Clemow, L.; Burg, M.M.; Burg, M.M.; Lampert, R.; Donahue, R.G.; Donovan, T.; Ginter, S.; McGloin, J.; Dornelas, E.; Kluger, J.; Barbagalo, J.; Clemow, L.; Schwartz, J.; Wang, W.; Hickey, K.T. 2010: Rationale and design of a randomized clinical trial comparing stress reduction treatment to usual cardiac care: the Reducing Vulnerability to Implantable Cardioverter Defibrillator Shock-Treated Ventricular Arrhythmias (RISTA) trial. Psychosomatic Medicine 72(2): 172-177
Abraham, W.T.; Gras, D.; Yu, C.M.; Guzzo, L.; Gupta, M.S.; Abraham, W.; Bonometti, C.; Clyne, C.; Gradaus, R.; Gras, D.; Green, U.B.; Hasan, A.; Herre, J.; Maounis, T.; Meine, M.; Morgan, J.; Mortensen, P.; Sheppard, R.; Wijetunga, M.; Yu, C.M. 2010: Rationale and design of a randomized clinical trial to assess the safety and efficacy of frequent optimization of cardiac resynchronization therapy: the Frequent Optimization Study Using the QuickOpt Method (FREEDOM) trial. American Heart Journal 159(6): 944-948.E1
Levsky, J.M.; Travin, M.I.; Spevack, D.M.; Menegus, M.A.; Huang, P.W.; Goldberg, Y.; Clark, E.T.; Banoth, P.; Freeman, K.D.; Tobin, J.N.; Haramati, L.B. 2009: Rationale and design of a randomized controlled trial comparing stress myocardial perfusion imaging with coronary CT angiography as the initial imaging study for intermediate-risk patients admitted with chest pain. Journal of Cardiovascular Computed Tomography 3(4): 264-271
Litwin, A.H.; Berg, K.M.; Li, X.; Hidalgo, J.; Arnsten, J.H. 2011: Rationale and design of a randomized controlled trial of directly observed hepatitis C treatment delivered in methadone clinics. Bmc Infectious Diseases 11: 315
Nahvi, S.; Segal, K.S.; Litwin, A.H.; Arnsten, J.H. 2014: Rationale and design of a randomized controlled trial of varenicline directly observed therapy delivered in methadone clinics. Addiction Science and Clinical Practice 9: 9
Sharman, J.E.; Marwick, T.H.; Abhayaratna, W.P.; Stowasser, M. 2012: Rationale and design of a randomized study to determine the value of central Blood Pressure for GUIDing manag Ement of hypertension: the BP GUIDE study. American Heart Journal 163(5): 761-767
Levsky, J.M.; Haramati, L.B.; Taub, C.C.; Spevack, D.M.; Menegus, M.A.; Travin, M.I.; Vega, S.; Lerer, R.; Brown-Manhertz, D.; Hirschhorn, E.; Tobin, J.N.; Garcia, M.J. 2014: Rationale and design of a randomized trial comparing initial stress echocardiography versus coronary CT angiography in low-to-intermediate risk emergency department patients with chest pain. Echocardiography 31(6): 744-750
Lechtzin, N.; West, N.; Allgood, S.; Wilhelm, E.; Khan, U.; Mayer-Hamblett, N.; Aitken, M.L.; Ramsey, B.W.; Boyle, M.P.; Mogayzel, P.J.; Goss, C.H. 2013: Rationale and design of a randomized trial of home electronic symptom and lung function monitoring to detect cystic fibrosis pulmonary exacerbations: the early intervention in cystic fibrosis exacerbation (eICE) trial. Contemporary Clinical Trials 36(2): 460-469
Conraads, V.M.; Van Craenenbroeck, E.M.; Pattyn, N.; Cornelissen, V.ér.A.; Beckers, P.J.; Coeckelberghs, E.; De Maeyer, C.; Denollet, J.; Frederix, G.; Goetschalckx, K.; Hoymans, V.Y.; Possemiers, N.; Schepers, D.; Shivalkar, B.; Vanhees, L. 2013: Rationale and design of a randomized trial on the effectiveness of aerobic interval training in patients with coronary artery disease: the SAINTEX-CAD study. International Journal of Cardiology 168(4): 3532-3536
Leung, M.; Wong, V.W.; Heritier, S.; Mihailidou, A.S.; Leung, D.Y. 2013: Rationale and design of a randomized trial on the impact of aldosterone antagonism on cardiac structure and function in diabetic cardiomyopathy. Cardiovascular Diabetology 12: 139
Shrank, W.H.; Parker, R.; Davis, T.; Pandit, A.U.; Knox, J.P.; Moraras, P.; Rademaker, A.; Wolf, M.S. 2010: Rationale and design of a randomized trial to evaluate an evidence-based prescription drug label on actual medication use. Contemporary Clinical Trials 31(6): 564-571
Wang, Y.; Johnston, S.Claiborne.; Wang, Y.; Johnston, S.Claiborne.; Nguyen-Huynh, M.N.; Cui, L.; Jia, J.; Wu, J.; Dong, Q.; Zeng, J.; Zhao, Z.; Zhao, X.; Wang, C.; Li, H.; Wang, Y.; Zhou, Y.; Li, Y.; Xu, A.; Gao, P.; Gao, P.; Wong, K.S.Lawrence.; Zhang, S.; Zhang, W.; Wang, Z. 2010: Rationale and design of a randomized, double-blind trial comparing the effects of a 3-month clopidogrel-aspirin regimen versus aspirin alone for the treatment of high-risk patients with acute nondisabling cerebrovascular event. American Heart Journal 160(3): 380-386.E1
Bousser, M.G.; Amarenco, P.; Chamorro, A.; Fisher, M.; Ford, I.; Fox, K.; Hennerici, M.G.; Mattle, H.P.; Rothwell, P.M.; Bousser, M.G.; Amarenco, P.; Chamorro, A.; Fisher, M.; Ford, I.; Fox, K.; Hennerici, M.G.; Rothwell, P.; Julian, D.; Fieschi, G.; Fieschi, C.; Boysen, G.; Pocock, S.; Conard, J.; Orgogozo, J.M.; Inzitari, D.; Erkinjuntti, T.; Pasquier, F.; O'Brien, J.T.; Mas, J.L.; Gueret, P.; Lenzi, G.L.; Leys, D.; Lopez-Sendon, J.L.; Norrving, B.; Ferro, J.; Thygesen, K.; Orgogozo, J.M.; Inzitari, D.; Erkinjuntti, T.; Pasquier, F.; O'Brien, J.T.; Cowpply-Bonny, P.; Ameriso, S.; Donnan, D.; Lang, W.; Thijs, V.; Fernandes, J.G.; Stamenova, P.; Teal, P.; Lavados, P.; Lu, C.; Poljakovic, Z.; Kalita, Z.; Kaste, M.; Moulin, T.; Vemm 2009: Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study. Cerebrovascular Diseases 27(5): 509-518
Swedberg, K.; Komajda, M.; Böhm, M.; Borer, J.S.; Ford, I.; Tavazzi, L. 2010: Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT). European Journal of Heart Failure 12(1): 75-81
Byrne, R.A.; Schulz, S.; Mehilli, J.; Iijima, R.; Massberg, S.; Neumann, F.-J.; ten Berg, J.ën.M.; Schömig, A.; Kastrati, A.; Kastrati, A.; Mehilli, J.; M ten Berg, J.ën.; Schulz, S.; Mann, J.; Hauschke, D.; Hoffmann, F.; Schmitt, C.; Poci, D.; Barthel, P.; Pinieck, S.; Byrne, R.A.; Birkmeier, A. 2009: Rationale and design of a randomized, double-blind, placebo-controlled trial of 6 versus 12 months clopidogrel therapy after implantation of a drug-eluting stent: the Intracoronary Stenting and Antithrombotic Regimen: Safety and EFficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) study. American Heart Journal 157(4): 620
Mizuma, H.; Inoue, T.; Takano, H.; Shindo, S.; Oka, T.; Fujimatsu, D.; Kuwabara, Y.; Node, K.; Komuro, I.; Kira, Y.; Morita, H.; Hashimoto, Y.; Yamashina, A.; Yamazaki, T.; Ishizuka, N.; Komuro, I.; Kuwabara, Y.; Takano, H.; Node, K.; Inoue, T.; Ito, H.; Himi, T.; Tomaru, T.; Kanda, J.; Kobayashi, S.; Shimizu, M.; Miyazaki, A.; Inoue, T.; Aouda, A.; Nakamura, F.; Kanoh, T.; Katoh, Y.; Seino, Y.; Hiroe, M.; Yamazaki, J.; Mizuno, K.; Murohara, T.; Kitakaze, M.; Kawajiri, K.; Saito, Y.; Kusano, K.; Kohno, M.; Saku, K.; Yano, K.; Oku, K.; Ogawa, H.; Saika, T. 2012: Rationale and design of a study to evaluate effects of pitavastatin on Japanese patients with chronic heart failure: the pitavastatin heart failure study (PEARL study). International Journal of Cardiology 156(2): 144-147
Oyama, J.-I.; Ishizu, T.; Sato, Y.; Kodama, K.; Bando, Y.K.; Murohara, T.; Node, K. 2014: Rationale and design of a study to evaluate the effects of sitagliptin on atherosclerosis in patients with diabetes mellitus: PROLOGUE study. International Journal of Cardiology 174(2): 383-384
Nagai, R.; Izumi, T.; Kurabayashi, M.; Daida, H.; Tojo, T.; Hasegawa, A.; Miyauchi, K.; Hayashi, D.; Kohro, T.; Okada, Y.; Yamazaki, T.; Nagai, R.; Yamazaki, T.; Kurabayashi, M.; Izumi, T.; Daida, H.; Hasegawa, A.; Tojo, T.; Miyauchi, K.; Yamazaki, T.; Hayashi, D.; Kohro, T.; Okada, Y.; Yamazaki, T.; Ohtsu, H.; Suzuki, S.; Hayashi, D.; Kohro, T.; Okada, Y.; Imai, Y.; Ishiwata, S.; Tanahashi, N.; Nonogi, H.; Kawana, M.; Mitamura, H.; Takayama, M.; Nakano, A.; Kanesawa, N.; Sasaki, T.; Ohshima, S.; Hoshizaki, H.; To 2008: Rationale and design of a study to examine lower targets for low-density lipoprotein-cholesterol and blood pressure in coronary artery disease patients. Circulation Journal: Official Journal of the Japanese Circulation Society 72(4): 515-520
Gambarin, F.I.; Favalli, V.; Serio, A.; Regazzi, M.; Pasotti, M.; Klersy, C.; Dore, R.; Mannarino, S.; Viganò, M.; Odero, A.; Amato, S.; Tavazzi, L.; Arbustini, E. 2009: Rationale and design of a trial evaluating the effects of losartan vs. nebivolol vs. the association of both on the progression of aortic root dilation in Marfan syndrome with FBN1 gene mutations. Journal of Cardiovascular Medicine 10(4): 354-362
Hsu, D.T.; Mital, S.; Ravishankar, C.; Margossian, R.; Li, J.S.; Sleeper, L.A.; Williams, R.V.; Levine, J.C.; McCrindle, B.W.; Atz, A.M.; Servedio, D.; Mahony, L.; Pearson, G.; Pemberton, V.; Stylianou, M.; Mathis, M.; Mahony, L.; Sleeper, L.; Colan, S.; Kalish, L.; Connell, P.; Virzi, L.; Wruck, L.; Zak, V.; Teitel, D.F.; Newburger, J.; Breitbart, R.; Levine, J.; McGrath, E.; Dunbar-Masterson, C.; Hsu, D.; Mital, S.; Prakash, A.; Servedio, D.; Vetter, V.L.; Tabbutt, S.; Nolan, M.; Piacentino, S.; Benson, D.W.; Dent, C.; Bogenschutz, L.; Barnard, T.; Schwartz, S.; Nelson, D.; Anderson, P.A.W.; Covitz, W.; Crawford, K.; Hines, M.; Jaggers, J.; Koutlas, T.; Li, J.; Sang, C.; Sutton, L.J.; Xu, M.; Saul, J. P.; Atz, A.; Shirali, G.; Atz, T.; Mi 2009: Rationale and design of a trial of angiotensin-converting enzyme inhibition in infants with single ventricle. American Heart Journal 157(1): 37-45
Van der Bom, T.; Winter, M.M.; Bouma, B.J.; Groenink, M.; Vliegen, H.W.; Pieper, P.G.; van Dijk, A.P.J.; Sieswerda, G.T.; Roos-Hesslink, J.W.; Zwinderman, A.H.; Mulder, B.J.M. 2010: Rationale and design of a trial on the effect of angiotensin Ii receptor blockers on the function of the systemic right ventricle. American Heart Journal 160(5): 812-818
Rubin, D.A.; Wilson, K.S.; Wiersma, L.D.; Weiss, J.W.; Rose, D.J. 2014: Rationale and design of active play @ home: a parent-led physical activity program for children with and without disability. Bmc Pediatrics 14: 41
Nosè, M.; Accordini, S.; Artioli, P.; Barale, F.; Barbui, C.; Beneduce, R.; Berardi, D.; Bertolazzi, G.; Biancosino, B.; Bisogno, A.; Bivi, R.; Bogetto, F.; Boso, M.; Bozzani, A.; Bucolo, P.; Casale, M.; Cascone, L.; Ciammella, L.; Cicolini, A.; Cipresso, G.; Cipriani, A.; Colombo, P.; Dal Santo, B.; De Francesco, M.; Di Lorenzo, G.; Di Munzio, W.; Ducci, G.; Erlicher, A.; Esposito, E.; Ferrannini, L.; Ferrato, F.; Ferro, A.; Fragomeno, N.; Parise, V.F.; Frova, M.; Gardellin, F.; Garzotto, N.; Giambartolomei, A.; Giupponi, G.; Grassi, L.; Grazian, N.; Grecu, L.; Guerrini, G.; Laddomada, F.; Lazzarin, E.; Lintas, C.; Malchiodi, F.; Malvini, L.; Marchiaro, L.; Marsilio, A.; Mauri, M.C.; Mautone, A.; Menchetti, M.; Migliorini, G.; Mollica, M. 2009: Rationale and design of an independent randomised controlled trial evaluating the effectiveness of aripiprazole or haloperidol in combination with clozapine for treatment-resistant schizophrenia. Trials 10: 31
Rangan, G.K.; Harris, D.C. 2013: Rationale and design of an observational study to determine the effects of cholecalciferol on hypertension, proteinuria and urinary MCP-1 in ADPKD. Current Hypertension Reviews 9(2): 115-120
Kashima, Y.; Izawa, A.; Aizawa, K.; Koshikawa, M.; Kasai, H.; Tomita, T.; Kumazaki, S.; Tsutsui, H.; Koyama, J.; Ikeda, U. 2009: Rationale and design of assessment of lipophilic vs. hydrophilic statin therapy in acute myocardial infarction (the ALPS-AMI) study. Journal of Cardiology 54(1): 76-79
Kastelein, J.J.P.; Duivenvoorden, R.ël.; Deanfield, J.; de Groot, E.; Jukema, J.W.; Kaski, J.-C.; Münzel, T.; Taddei, S.; Lehnert, V.; Burgess, T.; Kallend, D.; Lüscher, T.F. 2011: Rationale and design of dal-VESSEL: a study to assess the safety and efficacy of dalcetrapib on endothelial function using brachial artery flow-mediated vasodilatation. Current Medical Research and Opinion 27(1): 141-150
Brose, M.S.; Nutting, C.M.; Sherman, S.I.; Shong, Y.K.; Smit, J.W.A.; Reike, G.; Chung, J.; Kalmus, J.; Kappeler, C.; Schlumberger, M. 2011: Rationale and design of decision: a double-blind, randomized, placebo-controlled phase IIi trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer. Bmc Cancer 11: 349
Setacci, C.; de Donato, G.; Chisci, E.; Setacci, F. 2008: Rationale and design of emergent/urgent carotid artery stenting (EUCAS) registry. Journal of Cardiovascular Surgery 49(6): 737-742
Atar, D.; Abitbol, J.-L.; Arheden, H.; Berdeaux, A.; Bonnet, J.-L.; Carlsson, M.; Clemmensen, P.; Cuvier, V.ér.; Danchin, N.; Dubois-Randé, J.-L.; Engblom, H.; Erlinge, D.; Firat, H.üs.; Eggert Jensen, S.; Halvorsen, S.; Hansen, H.S.; Heiberg, E.; Larsen, A.-I.; Le Corvoisier, P.; Longlade, P.; Nordrehaug, J.E.; Perez, C.; Pruss, R.; Sonou, G.; Schaller, S.; Tuseth, V.; Vicaut, E. 2012: Rationale and design of the 'MITOCARE' Study: a phase II, multicenter, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of TRO40303 for the reduction of reperfusion injury in patients undergoing percutaneous coronary intervention for acute myocardial infarction. Cardiology 123(4): 201-207
Edelmann, F.; Schmidt, A.G.; Gelbrich, G.öt.; Binder, L.; Herrmann-Lingen, C.; Halle, M.; Hasenfuss, G.; Wachter, R.; Pieske, B. 2010: Rationale and design of the 'aldosterone receptor blockade in diastolic heart failure' trial: a double-blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure (Aldo-DHF). European Journal of Heart Failure 12(8): 874-882
Webb, D.R.; Khunti, K.; Srinivasan, B.; Gray, L.J.; Taub, N.; Campbell, S.; Barnett, J.; Henson, J.; Hiles, S.; Farooqi, A.; Griffin, S.J.; Wareham, N.J.; Davies, M.J. 2010: Rationale and design of the ADDITION-Leicester study, a systematic screening programme and randomised controlled trial of multi-factorial cardiovascular risk intervention in people with type 2 diabetes mellitus detected by screening. Trials 11: 16
Hernandez, A.F.; O'Connor, C.M.; Starling, R.C.; Reist, C.J.; Armstrong, P.W.; Dickstein, K.; Lorenz, T.J.; Gibler, W.B.; Hasselblad, V.; Komajda, M.; Massie, B.; McMurray, J.J.V.; Nieminen, M.; Rouleau, J.L.; Swedberg, K.; Califf, R.M. 2009: Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF). American Heart Journal 157(2): 271-277
Chaturvedi, N.; Bilous, R.; Sjolie, A.Katrin.; Klein, R. 2007: Rationale and design of the AdRem study: evaluating the effects of blood pressure lowering and intensive glucose control on vascular retinal disorders in patients with type 2 diabetes mellitus. Contemporary Clinical Trials 28(6): 780
Gibson, M.C.; Krucoff, M.; Fischell, D.; Fischell, T.A.; Keenan, D.; Abueg, C.; Patel, C.; Holmes, D. 2014: Rationale and design of the AngeLmed for Early Recognition and Treatment of STEMi trial: a randomized, prospective clinical investigation. American Heart Journal 168(2): 168-174
Gibson, C.Michael.; Mega, J.L.; Burton, P.; Goto, S.; Verheugt, F.; Bode, C.; Plotnikov, A.; Sun, X.; Cook-Bruns, N.; Braunwald, E. 2011: Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome. American Heart Journal 161(5): 815-821.E6
Vila-Corcoles, A.; Hospital-Guardiola, I.; Ochoa-Gondar, O.; de Diego, C.; Salsench, E.; Raga, X.; Fuentes-Bellido, C.M. 2010: Rationale and design of the CAPAMIS study: effectiveness of pneumococcal vaccination against community-acquired pneumonia, acute myocardial infarction and stroke. Bmc Public Health 10: 25
Hendrix, A.; van der Werf, C.; Bots, M.L.; Birnie, E.; van der Smagt, J.J.; Borleffs, C.J.W.; Vink, A.; van Weert, H.C.; Doevendans, P.A.F.M.; Wilde, A.A.M.; Mosterd, A.; van Langen, I.M. 2010: Rationale and design of the CAREFUL study : the yield of CARdiogenetic scr Eening in first degree relatives of sudden cardiac and UnexpLained death victims <45 years. Netherlands Heart Journal: Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation 18(6): 286-290
Min, J.K.; Dunning, A.; Lin, F.Y.; Achenbach, S.; Al-Mallah, M.H.; Berman, D.S.; Budoff, M.J.; Cademartiri, F.; Callister, T.Q.; Chang, H-Jae.; Cheng, V.; Chinnaiyan, K.M.; Chow, B.; Delago, A.; Hadamitzky, M.; Hausleiter, J.; Karlsberg, R.P.; Kaufmann, P.; Maffei, E.; Nasir, K.; Pencina, M.J.; Raff, G.L.; Shaw, L.J.; Villines, T.C. 2011: Rationale and design of the CONFIRM (COronary CT Angiography EvaluatioN For Clinical Outcomes: An InteRnational Multicenter) Registry. Journal of Cardiovascular Computed Tomography 5(2): 84-92
Imazio, M.; Cecchi, E.; Demichelis, B.; Chinaglia, A.; Coda, L.; Ghisio, A.; Demarie, D.; Ierna, S.; Trinchero, R. 2007: Rationale and design of the COPPS trial: a randomised, placebo-controlled, multicentre study on the use of colchicine for the primary prevention of postpericardiotomy syndrome. Journal of Cardiovascular Medicine 8(12): 1044-1048
Imazio, M.; Belli, R.; Brucato, A.; Ferrazzi, P.; Patrini, D.; Martinelli, L.; Polizzi, V.; Cemin, R.; Leggieri, A.; Caforio, A.L.P.; Finkelstein, Y.; Hoit, B.; Maisch, B.; Mayosi, B.M.; Oh, J.K.; Ristic, A.D.; Seferovic, P.; Spodick, D.H.; Adler, Y. 2013: Rationale and design of the COlchicine for Prevention of the Post-pericardiotomy Syndrome and Post-operative Atrial Fibrillation (COPPS-2 trial): a randomized, placebo-controlled, multicenter study on the use of colchicine for the primary prevention of the postpericardiotomy syndrome, postoperative effusions, and postoperative atrial fibrillation. American Heart Journal 166(1): 13-19
Wald, R.M.; Altaha, M.A.; Alvarez, N.; Caldarone, C.A.; Cavallé-Garrido, T.; Dallaire, F.éd.ér.; Drolet, C.; Grewal, J.; Hancock Friesen, C.L.; Human, D.G.; Hickey, E.; Kayedpour, C.; Khairy, P.; Kovacs, A.H.; Lebovic, G.; McCrindle, B.W.; Nadeem, S.N.; Patton, D.J.; Redington, A.N.; Silversides, C.K.; Tham, E.B.; Therrien, J.; Warren, A.E.; Wintersperger, B.J.; Vonder Muhll, I.F.; Farkouh, M.E. 2014: Rationale and design of the Canadian Outcomes Registry Late After Tetralogy of Fallot Repair: the CORRELATE study. Canadian Journal of Cardiology 30(11): 1436-1443
Leonardi, S.; Mahaffey, K.W.; White, H.D.; Gibson, C.M.; Stone, G.W.; Steg, G.W.; Hamm, C.W.; Price, M.J.; Todd, M.; Dietrich, M.; Gallup, D.; Liu, T.; Skerjanec, S.; Harrington, R.A.; Bhatt, D.L. 2012: Rationale and design of the Cangrelor versus standard therapy to ac Hieve optimal Management of Platelet InhibitiON PHOENIX trial. American Heart Journal 163(5): 768-776.E2
Everett, B.M.; Pradhan, A.D.; Solomon, D.H.; Paynter, N.; Macfadyen, J.; Zaharris, E.; Gupta, M.; Clearfield, M.; Libby, P.; Hasan, A.A.K.; Glynn, R.J.; Ridker, P.M. 2013: Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. American Heart Journal 166(2): 199-207.E15
Meijer, E.; Drenth, J.P.H.; d'Agnolo, H.; Casteleijn, N.F.; de Fijter, J.W.; Gevers, T.J.; Kappert, P.; Peters, D.J.M.; Salih, M.; Soonawala, D.; Spithoven, E.M.; Torres, V.E.; Visser, F.W.; Wetzels, J.F.M.; Zietse, R.; Gansevoort, R.T.; d'Agnolo, H.; Casteleijn, N.F.; Dekker, H.; Drenth, J.; de Fijter, J.W.; Gansevoort, R.T.; Gevers, T.J.; Happé, H.; Horst, G.t.; Kappert, P.; Meijer, E.; Peters, D.J.M.; Renken, R.; Pieterman, H.; Salih, M.; Soonawala, D.; Spithoven, E.M.; Torres, V.E.; Wasser, M.; Wetzels, J.F.M.; Zietse, R.; Drenth, J.; de Fijter, J.W.; Gansevoort, R.T.; Meijer, E.; Peters, D.J.M.; Torres, V.E.; Wetzels, J.F.M.; Zietse, R.; Gaillard, C.; van Buren, M.; Veeger, N.; Vervloet, M. 2014: Rationale and design of the DIPAK 1 study: a randomized controlled clinical trial assessing the efficacy of lanreotide to Halt disease progression in autosomal dominant polycystic kidney disease. American Journal of Kidney Diseases: the Official Journal of the National Kidney Foundation 63(3): 446-455
Koontz, J.I.; Haithcock, D.; Cumbea, V.; Waldron, A.; Stricker, K.; Hughes, A.; Nilsson, K.; Sun, A.; Piccini, J.P.; Kraus, W.E.; Pitt, G.S.; Shah, S.H.; Hranitzky, P. 2009: Rationale and design of the Duke Electrophysiology Genetic and Genomic Studies (EPGEN) biorepository. American Heart Journal 158(5): 719-725
Stokmans, R.A.; Broos, P.P. H.L.; Cuypers, P.W.M.; Forbes, T.L.; Vahl, A.C.; Swartbol, P.; Van Sambeek, M.R.H.M.; Teijink, J.A.W. 2014: Rationale and design of the EAGLE Registry: EVAR with Endurant® in challenging anatomy. Journal of Cardiovascular Surgery 55(5): 699-704
Chakrabarti, A.K.; Feeney, K.; Abueg, C.; Brown, D.A.; Czyz, E.; Tendera, M.; Janosi, A.; Giugliano, R.P.; Kloner, R.A.; Weaver, W.D.; Bode, C.; Godlewski, J.; Merkely, B.; Gibson, C.M. 2013: Rationale and design of the EMBRACE STEMi study: a phase 2a, randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability and efficacy of intravenous Bendavia on reperfusion injury in patients treated with standard therapy including primary percutaneous coronary intervention and stenting for ST-segment elevation myocardial infarction. American Heart Journal 165(4): 509-514.E7
Ueno, Y.; Yamashiro, K.; Tanaka, Y.; Watanabe, M.; Shimada, Y.; Kuroki, T.; Miyamoto, N.; Daimon, M.; Tanaka, R.; Miyauchi, K.; Daida, H.; Hattori, N.; Urabe, T. 2014: Rationale and design of the EPISTEME trial: efficacy of post-stroke intensive rosuvastatin treatment for aortogenic embolic stroke. Cardiovascular Drugs and Therapy 28(1): 79-85
Li, J.-P.; Liu, Q.; Huo, Y. 2012: Rationale and design of the ETN-STEP (Early administration of Tirofiban in mid to high risk patients with non-ST elevation acute coronary syndrome referred for percutaneous coronary intervention) project: a multi-center, randomized, controlled clinic trial in Chinese patients. Journal of Geriatric Cardiology: Jgc 9(4): 375-378
Sabaté, M.; Cequier, A.; Iñiguez, A.és.; Serra, A.; Hernández-Antolín, R.; Mainar, V.; Valgimigli, M.; Tespili, M.; den Heijer, P.; Bethencourt, A.; Vázquez, N.ás.; Brugaletta, S.; Backx, B.; Serruys, P. 2011: Rationale and design of the EXAMINATION trial: a randomised comparison between everolimus-eluting stents and cobalt-chromium bare-metal stents in ST-elevation myocardial infarction. Eurointervention: Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 7(8): 977-984
Böckler, D.; Fitridge, R.; Wolf, Y.; Hayes, P.; Silveira, P.G.; Numan, F.; Riambau, V.; Bosiers, M.; Dai-Do, D.; Schmidli, J.; Forbes, T.; Goktay, Y.; Gomez Palons, F.; Hill, A.; Hoffman, G.; Kiskinis, D.; Mwipatayi, P.; Novotny, J.; Oguzkurt, L.; Papazoglou, K.; Peeters, P.; Ziekenhuis, I.; Puerta, C.Vaquero.; Punt, C.Leendert.; Rand, T.; Ros, E.; Staszkiewicz, W.; Teijink, J.; Torsello, G.; Van Marle, J.; van Sterkenburg, S.; Zorggroep, A.; Vasudevan, T.; Vermassen, F.; Welten, R. 2010: Rationale and design of the Endurant Stent Graft Natural Selection Global Postmarket Registry (ENGAGE): interim analysis at 30 days of the first 180 patients enrolled. Journal of Cardiovascular Surgery 51(4): 481-491
Zannad, F.; McMurray, J.J.V.; Drexler, H.; Krum, H.; van Veldhuisen, D.J.; Swedberg, K.; Shi, H.; Vincent, J.; Pitt, B. 2010: Rationale and design of the Eplerenone in Mild Patients Hospitalization and SurvIval Study in Heart Failure (EMPHASIS-HF). European Journal of Heart Failure 12(6): 617-622
Jones, L.W.; Douglas, P.S.; Eves, N.D.; Marcom, P.K.; Kraus, W.E.; Herndon, J.E.; Inman, B.A.; Allen, J.D.; Peppercorn, J. 2010: Rationale and design of the Exercise Intensity Trial (EXCITE): a randomized trial comparing the effects of moderate versus moderate to high-intensity aerobic training in women with operable breast cancer. Bmc Cancer 10: 531
Luik, A.; Merkel, M.; Hoeren, D.; Riexinger, T.; Kieser, M.; Schmitt, C. 2010: Rationale and design of the FreezeAF trial: a randomized controlled noninferiority trial comparing isolation of the pulmonary veins with the cryoballoon catheter versus open irrigated radiofrequency ablation in patients with paroxysmal atrial fibrillation. American Heart Journal 159(4): 555-560.E1
Felker, G.M.; Ahmad, T.; Anstrom, K.J.; Adams, K.F.; Cooper, L.S.; Ezekowitz, J.A.; Fiuzat, M.; Houston-Miller, N.; Januzzi, J.L.; Leifer, E.S.; Mark, D.B.; Desvigne-Nickens, P.; Paynter, G.; Piña, I.L.; Whellan, D.J.; O'Connor, C.M. 2014: Rationale and design of the GUIDE-IT study: Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure. JACC. Heart Failure 2(5): 457-465
Broom, J.K.; O'Shea, S.; Govindarajulu, S.; Playford, E.Geoffrey.; Hawley, C.M.; Isbel, N.M.; Campbell, S.B.; Mudge, D.W.; Carpenter, S.; Johnson, B.C.; Underwood, N.P.; Johnson, D.W. 2009: Rationale and design of the HEALTHY-CATH trial: a randomised controlled trial of Heparin versus EthAnol Lock THerapY for the prevention of Catheter Associated infec Tion in Haemodialysis patients. Bmc Nephrology 10: 23
Gaur, S.; Achenbach, S.; Leipsic, J.; Mauri, L.; Bezerra, H.G.; Jensen, J.M.øl.; Bøtker, H.E.; Lassen, J.F.; Nørgaard, B.L. 2013: Rationale and design of the HeartFlowNXT (HeartFlow analysis of coronary blood flow using CT angiography: NeXt sTeps) study. Journal of Cardiovascular Computed Tomography 7(5): 279-288
Al-Mallah, M.H.; Keteyian, S.J.; Brawner, C.A.; Whelton, S.; Blaha, M.J. 2014: Rationale and design of the Henry Ford Exercise Testing Project (the FIT project). Clinical Cardiology 37(8): 456-461
Rossignol, P.; Dorval, M.; Fay, R.; Ros, J.Fort.; Loughraieb, N.; Moureau, Fédérique.; Laville, M. 2013: Rationale and design of the HepZero study: a prospective, multicenter, international, open, randomized, controlled clinical study with parallel groups comparing heparin-free dialysis with heparin-coated dialysis membrane (Evodial) versus standard care: study protocol for a randomized controlled trial. Trials 14: 163
Gibson, C.M.; Maehara, A.; Lansky, A.J.; Wohrle, J.; Stuckey, T.; Dave, R.; Cox, D.; Grines, C.; Dudek, D.; Steg, G.; Parise, H.; Wolff, S.D.; Cristea, E.; Stone, G.W. 2011: Rationale and design of the INFUSE-AMi study: a 2 × 2 factorial, randomized, multicenter, single-blind evaluation of intracoronary abciximab infusion and aspiration thrombectomy in patients undergoing percutaneous coronary intervention for anterior ST-segment elevation myocardial infarction. American Heart Journal 161(3): 478-486.E7
Huybregts, J.G.J.; Jacobs, W.C.H.; Peul, W.C.; Vleggeert-Lankamp, C.L.A. 2014: Rationale and design of the INNOVATE Trial: an international cooperative study on surgical versus conservative treatment for odontoid fractures in the elderly. Bmc Musculoskeletal Disorders 15: 7
Jin, Y.; Jacobs, L.; Baelen, M.; Thijs, L.; Renkin, J.; Hammer, F.; Kefer, J.; Petit, T.; Verhamme, P.; Janssens, S.; Sinnaeve, P.; Lengelé, J.-P.; Persu, A.; Staessen, J.A.; De Sutter, J.; Cornelis, K.; Muyldermans, L.; Thoeng, J.; Henry, M.; Maimone, A.; Lalaoui, A.; Leroy, P.; Migali, G.; De Wispelaere, J.-F.ço.; Pochet, J.-M.; Tintillier, M.; Hanet, C.; Guedes, A.; Dangoisse, V.; Gabriel, L.; Brasseur, A.; Blouard, P.; Timmermans, P.; Pochet, J.-M.; Tintillier, M.; Cuvelier, C.; Lengelé, J.-P.; Carlier, M.; Jourdan, A.; Vinck, W.; Scharpé, J.; Vrolix, M.; Dujardin, K.; Janssens, L.; Ector, B.; Ziekenhuis, J.; Timmermans, P.; Goethals, M.; Persu, A.; Lengelé, J.-P.; Renkin, J.; le Polain de Waroux, J.-B.; Scavée, C.; Pasquet, A.ès 2014: Rationale and design of the Investigator-Steered Project on Intravascular Renal Denervation for Management of Drug-Resistant Hypertension (INSPiRED) trial. Blood Pressure 23(3): 138-146
Sprengers, R.W.; Moll, F.L.; Teraa, M.; Verhaar, M.C.; Sprengers, R.W.; Teraa, M.; Verhaar, M.C.; Moll, F.L.; Schutgens, R.E.G.; Slaper-Cortenbach, I.C.M.; van der Graaf, Y.; Doevendans, P.A.; Mali, W.P.T.M. 2010: Rationale and design of the JUVENTAS trial for repeated intra-arterial infusion of autologous bone marrow-derived mononuclear cells in patients with critical limb ischemia. Journal of Vascular Surgery 51(6): 1564-1568
Liu, H.; Patel, A.; Brown, A.; Eades, S.; Hayman, N.; Jan, S.; Ring, I.; Stewart, G.; Tonkin, A.; Weeramanthri, T.; Wade, V.; Rodgers, A.; Usherwood, T.; Neal, B.; Peiris, D.; Burke, H.; Reid, C.; Cass, A.; Kanyini GAP Study Team; Patel, A.; Cass, A.; Brown, A.; Peiris, D.; Reid, C.; Jan, S.; Hayman, N.; Thomas, S.; Burke, H.; Rodgers, A.; Tonkin, A.; Usherwood, T.; Henry, D.; Groenestein, P.; Rafter, N.; Neal, B.; Hillis, G.; Molanus, B.; Liu, H.; Patel, B.; Simes, J.; Harris, M.; Walsh, W.; Chapman, N.; Gupta, A.; Chow, C.; McGrady, M.; H 2010: Rationale and design of the Kanyini guidelines adherence with the polypill (Kanyini-GAP) study: a randomised controlled trial of a polypill-based strategy amongst indigenous and non indigenous people at high cardiovascular risk. Bmc Public Health 10: 458
Donal, E.; Lund, L.H.; Linde, C.; Edner, M.; Lafitte, S.ép.; Persson, H.; Bauer, F.; Ohrvik, J.; Ennezat, P.-V.; Hage, C.; Löfman, I.; Juilliere, Y.; Logeart, D.; Derumeaux, G.èv.; Gueret, P.; Daubert, J.-C. 2009: Rationale and design of the Karolinska-Rennes (KaRen) prospective study of dyssynchrony in heart failure with preserved ejection fraction. European Journal of Heart Failure 11(2): 198-204
Whitlock, R.; Healey, J.; Vincent, J.; Brady, K.; Teoh, K.; Royse, A.; Shah, P.; Guo, Y.; Alings, M.; Folkeringa, R.J.; Paparella, D.; Colli, A.; Meyer, S.R.; Legare, J.-F.ço.; Lamontagne, F.ço.; Reents, W.; Böning, A.; Connolly, S. 2014: Rationale and design of the Left Atrial Appendage Occlusion Study (LAAOS) IIi. Annals of Cardiothoracic Surgery 3(1): 45-54
Beutner, F.; Teupser, D.; Gielen, S.; Holdt, L.M.; Scholz, M.; Boudriot, E.; Schuler, G.; Thiery, J. 2011: Rationale and design of the Leipzig (LIFE) Heart Study: phenotyping and cardiovascular characteristics of patients with coronary artery disease. Plos one 6(12): E29070
Zabel, M.; Müller-Riemenschneider, F.; Geller, J.C.; Brachmann, J.; Kühlkamp, V.; Dissmann, R.üd.; Reinhold, T.; Roll, S.; Lüthje, L.; Bode, F.; Eckardt, L.; Willich, S.N. 2014: Rationale and design of the MONITOR-ICD study: a randomized comparison of economic and clinical effects of automatic remote MONITORing versus control in patients with Implantable Cardioverter Defibrillators. American Heart Journal 168(4): 430-437
Braber, T.L.; Mosterd, A.; Prakken, N.H.J.; Doevendans, P.A.F.M.; Mali, W.P.Th.M.; Backx, F.J.G.; Grobbee, D.E.; Rienks, R.; Nathoe, H.M.; Bots, M.L.; Velthuis, B.K. 2015: Rationale and design of the Measuring Athlete's Risk of Cardiovascular events (MARC) study : The role of coronary CT in the cardiovascular evaluation of middle-aged sportsmen. Netherlands Heart Journal: Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation 23(2): 133-138
Carrasquillo, O.; Patberg, E.; Alonzo, Y.; Li, H.; Kenya, S. 2014: Rationale and design of the Miami Healthy Heart Initiative: a randomized controlled study of a community health worker intervention among Latino patients with poorly controlled diabetes. International Journal of General Medicine 7: 115-126
Hammer, F.; Krane, V.; Störk, S.; Röser, C.; Hofmann, K.; Pollak, N.; Allolio, B.; Wanner, C. 2014: Rationale and design of the Mineralocorticoid Receptor Antagonists in End-Stage Renal Disease Study (MiREnDa). Nephrology Dialysis Transplantation: Official Publication of the European Dialysis and Transplant Association - European Renal Association 29(2): 400-405
Pituskin, E.; Haykowsky, M.; Mackey, J.R.; Thompson, R.B.; Ezekowitz, J.; Koshman, S.; Oudit, G.; Chow, K.; Pagano, J.J.; Paterson, I. 2011: Rationale and design of the Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research Trial (MANTICORE 101--Breast): a randomized, placebo-controlled trial to determine if conventional heart failure pharmacotherapy can prevent trastuzumab-mediated left ventricular remodeling among patients with HER2+ early breast cancer using cardiac MRI. Bmc Cancer 11: 318
Dunlop, J.L.; Vandal, A.C.; de Zoysa, J.R.; Gabriel, R.S.; Gerber, L.M.; Haloob, I.A.; Hood, C.J.; Irvine, J.H.; Matheson, P.J.; McGregor, D.O.R.; Rabindranath, K.S.; Schollum, J.B.W.; Semple, D.J.; Marshall, M.R. 2014: Rationale and design of the Myocardial Microinjury and Cardiac Remodeling Extension Study in the Sodium Lowering in Dialysate trial (Mac-SoLID study). Bmc Nephrology 15: 120
Matsushita, K.; Muramatsu, T.; Kondo, T.; Maeda, K.; Shintani, S.; Murohara, T.; Murohara, T.; Kondo, T.; Shintani, S.; Maeda, K.; Matsushita, K.; Muramatsu, T.; Watarai, M.; Marui, N.; Takanaka, C.; Ohno, M.; Obayashi, T.; Kondo, T.; Takada, Y.; Iwama, Y.; Akahoshi, M.; Iida, M.; Hirayama, H.; Sone, S.; Ohno, O.; Kaneko, S.; Ichimiya, S.; Matsubara, T.; Komori, K.; Doyu, M.; Toyoshima, H.; Oiso, Y.; Hirai, M.; Murohara, T.; Kondo, T.; Shintani, S.; Maeda, K.; Matsushita, K.; Muramatsu, T.; Sasaki, K.; Watanabe, E.; Inoue, Y.; Shirahashi, N. 2010: Rationale and design of the NAGOYA HEART Study: comparison between valsartan and amlodipine regarding morbidity and mortality in patients with hypertension and glucose intolerance. Journal of Cardiology 56(1): 111-117
Eagle, K.A.; Eagle, K.A.; LeMaire, S.A.; Volguina, I.; Basson, C.T.; Devereux, R.; Weinsaft, J.W.; McDermott, D.; Holmes, K.W.; Dietz, H.; Ravekes, W.; Lurman, K.; Maslen, C.L.; Song, H.K.; Menashe, V.; Kushner, J.D.; Pyeritz, R.E.; Bavaria, J.E.; Morales, M.; Milewicz, D.M.; Baysinger-Morin, K.; Noll, C.; Tolunay, H.Eser.; Desvigne-Nickens, P.; Mitchell, M.; Stylianou, M.P.; Lapham, C.; Kroner, B.L.; Brambilla, D.; Hendershot, T.; Ringer, D.; Cunningham, M.; Wills, T.; Kindem, M. 2009: Rationale and design of the National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions (GenTAC). American Heart Journal 157(2): 319-326
Odili, A.N.; Richart, T.; Thijs, L.; Kingue, S.; Boombhi, H.J.; Lemogoum, D.; Kaptue, J.; Kamdem, M.K.; Mipinda, J.-B.; Omotoso, B.A.; Kolo, P.M.; Aderibigbe, A.; Ulasi, I.I.; Anisiuba, B.C.; Ijoma, C.K.; Ba, S.A.; Ndiaye, M.B.; Staessen, J.A.; M'buyamba-Kabangu, J.-R.é 2011: Rationale and design of the Newer Versus Older Antihypertensive Agents in African Hypertensive Patients (NOAAH) trial. Blood Pressure 20(5): 256-266
Kolb, C.; Tzeis, S.; Sturmer, M.; Babuty, D.; Schwab, J.ör.O.; Mantovani, G.; Janko, S.; Aimé, E.; Ocklenburg, R.; Sick, P. 2010: Rationale and design of the OPTION study: optimal antitachycardia therapy in ICD patients without pacing indications. Pacing and Clinical Electrophysiology: Pace 33(9): 1141-1148
Kim, M.; Chow, W.; Benson, C. 2013: Rationale and design of the Oxycodone Users Registry: a prospective, multicenter registry of patients with nonmalignant pain. Journal of Opioid Management 9(3): 189-204
Limalanathan, S.; Andersen, G.Øy.; Hoffmann, P.; Kløw, N.-E.; Abdelnoor, M.; Eritsland, J. 2010: Rationale and design of the POSTEMi (postconditioning in ST-elevation myocardial infarction) study. Cardiology 116(2): 103-109
Olde Nordkamp, L.R.A.; Knops, R.E.; Bardy, G.H.; Blaauw, Y.; Boersma, L.V.A.; Bos, J.S.; Delnoy, P.P.H.M.; van Dessel, P.F.H.M.; Driessen, A.H.G.; de Groot, J.R.; Herrman, J.P.R.; Jordaens, L.J.L.M.; Kooiman, K.M.; Maass, A.H.; Meine, M.; Mizusawa, Y.; Molhoek, S.G.; van Opstal, J.; Tijssen, J.G.P.; Wilde, A.A.M. 2012: Rationale and design of the PRAETORIAN trial: a Prospective, RAndomizEd comparison of subcuTaneOus and tRansvenous ImplANtable cardioverter-defibrillator therapy. American Heart Journal 163(5): 753-760.E2
Yamamoto, H.; Awai, K.; Kuribayashi, S.; Kihara, Y.; Ohashi, N.; Utsunomiya, H.; Miyazaki, S.; Kobuke, K.; Kawasaki, T.; Daida, H.; Matsunaga, E.; Kinoshita, R.; Fujii, T.; Tomohiro, Y.; Kunita, E.; Sato, A.; Hayashi, Y.; Okimoto, T.; Himeno, H.; Yano, H.; Kondo, T.; Fujimoto, S.; Yamashina, A.; Hirano, M.; Yokoi, Y.; Yamaji, K.; Inoue, N.; Dote, K.; Kato, M.; Sasaki, S.; Kawamura, M.; Yoshino, H.; Ishiguro, H.; Ikeda, S.; Hirayama, A.; Fujii, N.; Doi, O.; Fukuda, S.; Shimada, K.; Miura, T.; Nawa, T.; Tanabe, K.; Mochizuki, T.; Kurata, A.; Morishita, H.; Matsumoto, N.; Sato, Y.; Ohta, H. 2014: Rationale and design of the PREDICT (Plaque Registration and Evaluation Detected in Computed Tomography) registry. Journal of Cardiovascular Computed Tomography 8(2): 90-96
Frame, J.N.; Rice, L.; Bartholomew, J.R.; Whelton, A. 2010: Rationale and design of the PREVENT-HIT study: a randomized, open-label pilot study to compare desirudin and argatroban in patients with suspected heparin-induced thrombocytopenia with or without thrombosis. Clinical Therapeutics 32(4): 626-636
Chang, A.T.; Haines, T.; Jackson, C.; Yang, I.; Nitz, J.; Low Choy, N.; Vicenzino, B. 2008: Rationale and design of the PRSM study: pulmonary rehabilitation or self management for chronic obstructive pulmonary disease (COPD), what is the best approach?. Contemporary Clinical Trials 29(5): 796-800
Singh, A.; Ford, I.; Greenwood, J.P.; Khan, J.N.; Uddin, A.; Berry, C.; Neubauer, S.; Prendergast, B.; Jerosch-Herold, M.; Williams, B.; Samani, N.J.; McCann, G.P. 2013: Rationale and design of the PRognostic Importance of MIcrovascular Dysfunction in asymptomatic patients with Aortic Stenosis (PRIMID-AS): a multicentre observational study with blinded investigations. Bmj Open 3(12): E004348
Keefe, D.M.K.; Chan, A.; Kim, H.-K.; Hsieh, R.K.; Yu, S.; Wang, Y.; Nicholls, R.J.; Burke, T.A. 2015: Rationale and design of the Pan Australasian chemotherapy-induced emesis burden of illness study. Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer 23(1): 253-261
Bonny, A.é; Ngantcha, M.; Amougou, S.N.; Kane, A.; Marrakchi, S.; Okello, E.; Taty, G.; Gehani, A.; Diakite, M.; Talle, M. A.; Lambiase, P. D.; Houenassi, M.; Chin, A.; Otieno, H.; Temu, G.; Owusu, I.K.; Karaye, K.M.; Awad, A.A.M.; Winkel, B.G.; Priori, S.G. 2014: Rationale and design of the Pan-African Sudden Cardiac Death survey: the Pan-African SCD study. Cardiovascular Journal of Africa 25(4): 176-184
Camenzind, E.; Wijns, W.; Mauri, L.; Boersma, E.; Parikh, K.; Kurowski, V.; Gao, R.; Bode, C.; Greenwood, J.P.; Gershlick, A.; O'Neill, W.; Serruys, P.W.; Jorissen, B.; Steg, P.Gabriel.; Camenzind, E.; Mauri, L.; O'Neill, W.; Serruys, P.W.; Steg, P.Gabriel.; Wijns, W.; Verheugt, F.W.A.; Bertrand, M.E.; Califf, R.; DeMets, D.; Wallentin, L.; Bosmans, J.; Hanet, C.; Herrman, J-P.R.; Kelbaek, H.; Mc Fadden, E.; Radke, P.W.; RutschC, W.; Tilsted, H.H.; Boersma, E.; Alvarez, C.; Rodriguez, A.; Meredith, I.; Muller, D.; Whitbourn, R.; Worthley, S.; Whelan, A.; Walters, D.; Shetty, S.; New, G.; Cox, S.; Batra, R.; van Gaal, W.; Bellamy, G 2009: Rationale and design of the Patient Related OuTcomes with Endeavor versus Cypher stenting Trial (PROTECT): randomized controlled trial comparing the incidence of stent thrombosis and clinical events after sirolimus or zotarolimus drug-eluting stent implantation. American Heart Journal 158(6): 902-909.E5
Mushtaq, M.; DiFede, D.L.; Golpanian, S.; Khan, A.; Gomes, S.A.; Mendizabal, A.; Heldman, A.W.; Hare, J.M. 2014: Rationale and design of the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis in Dilated Cardiomyopathy (the POSEIDON-DCM study): a phase I/II, randomized pilot study of the comparative safety and efficacy of transendocardial injection of autologous mesenchymal stem cell vs. allogeneic mesenchymal stem cells in patients with non-ischemic dilated cardiomyopathy. Journal of Cardiovascular Translational Research 7(9): 769-780
Devereaux, P.J. 2014: Rationale and design of the PeriOperative ISchemic Evaluation-2 (POISE-2) trial: an international 2 × 2 factorial randomized controlled trial of acetyl-salicylic acid vs. placebo and clonidine vs. placebo in patients undergoing noncardiac surgery. American Heart Journal 167(6): 804-9.E4
Schnipper, J.L.; Roumie, C.L.; Cawthon, C.; Businger, A.; Dalal, A.K.; Mugalla, I.; Eden, S.; Jacobson, T.A.; Rask, K.J.; Vaccarino, V.; Gandhi, T.K.; Bates, D.W.; Johnson, D.C.; Labonville, S.; Gregory, D.; Kripalani, S.; Kripalani, S.; Schnipper, J.L.; Roumie, C.L.; Dalal, A.K.; Jacobson, T.A.; Rask, K.J.; Vaccarino, V.; Gandhi, T.K.; Bates, D.W.; Eden, S.K.; Dupont, C.; Cawthon, C.; Businger, A.; Mugalla, I.; Niesner, K.J.; Stufflebam, A.; Higgins, M.M.; Swain, E.; Kemnitz, J.; Reyes, H.; Pietras, A.C.; Cordon, A.; Liang, C.; Johnson, D.; Bedard, E.; Labonville, S.; Cheng, J.; Dell'Orfano, H.; Levinson, R.; Filkins, B.A.; Bamarni, P.; Guadalupe, E.; Helmke, J.; Gregory, D.; Marvanova, M.; Cunningham, K.E.; Harris, L.J.; Theobald, C. 2010: Rationale and design of the Pharmacist Intervention for Low Literacy in Cardiovascular Disease (PILL-CVD) study. CIRCULATION. Cardiovascular Quality and Outcomes 3(2): 212-219
Hennerici, M.G. 2009: Rationale and design of the Prevention of Cerebrovascular and Cardiovascular Events of Ischemic Origin with Terutroban in Patients with a History of Ischemic Stroke or Transient Ischemic Attack (PERFORM) Study. Cerebrovascular Diseases 27 Suppl. 3: 28-32
Gevers, T.J.G.; Chrispijn, M.; Wetzels, J.F.M.; Drenth, J.P.H. 2012: Rationale and design of the RESOLVE trial: lanreotide as a volume reducing treatment for polycystic livers in patients with autosomal dominant polycystic kidney disease. Bmc Nephrology 13: 17
Schiffer, L.; Schiffer, M.; Merkel, S.; Schwarz, A.; Mengel, M.; Jürgens, C.; Schroeder, C.; Zoerner, A.A.; Püllmann, K.; Bröcker, V.; Becker, J.U.; Dämmrich, M.E.; Träder, J.; Grosshennig, A.; Biertz, F.; Haller, H.; Koch, A.; Gwinner, W. 2013: Rationale and design of the RIACT-study: a multi-center placebo controlled double blind study to test the efficacy of RItuximab in Acute Cellular tubulointerstitial rejection with B-cell infiltrates in renal Transplant patients: study protocol for a randomized controlled trial. Trials 13: 199
Alfonso, F.; Pérez-Vizcayno, M.ía.J.é; Cárdenas, A.; García Del Blanco, B.; García-Touchard, A.; López-Minguéz, J.é R.ón.; Rivero, F.; Masotti, M.ón.; Zueco, J.; Cequier, A.; Morís, C.; Fernández-Ortíz, A.; Escaned, J.; Jiménez-Quevedo, P.; Gonzalo, N.; Fernández, C.; Macaya, C.; Alfonso, F.; Zueco, J.; Cequier, A.; Morís, C.; Macaya, C.; Hernández, R.; Sabaté, M.; Cárdenas, A.; Pérez-Vizcayno, M.J.; Pérez-Vizcayno, M.J.; Fernández-Pérez, C.; Gonzalo, N.; Alfonso, F.; Jiménez-Quevedo, P.; Gonzalo, N.; Escaned, J.; Fernández-Ortiz, A.; Macaya, C.; García del Blanco, B.; Alfonso, F.; Benedicto, A.; Rivero, F.; Iñiguez, A.; Gómez-Recio, M.; Masotti, M.; Velázquez, T.; Sanchís, J.; García-Touchard, A.; Zueco, J.; 2015: Rationale and design of the RIBS IV randomised clinical trial (drug-eluting balloons versus everolimus-eluting stents for patients with drug-eluting stent restenosis). Eurointervention: Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 11(3): 336-342
Peker, Yüksel.; Glantz, H.; Thunström, E.; Kallryd, A.; Herlitz, J.; Ejdebäck, J. 2009: Rationale and design of the Randomized Intervention with CPAP in Coronary Artery Disease and Sleep Apnoea--RICCADSA trial. Scandinavian Cardiovascular Journal: Scj 43(1): 24-31
Tomai, F.; Petrolini, A.; De Luca, L.; Nudi, F.; Lanza, G.; Vassanelli, C.; Ribichini, F. 2010: Rationale and design of the Randomized comparison of XiEnce V and Multilink VisioN coronary stents in the sAme mu Ltivessel patient with chronic kiDnEy disease (RENAL-DES) study. Journal of Cardiovascular Medicine 11(4): 310-317
Chow, C.K.; Joshi, R.; Gottumukkala, A.K.; Raju, K.; Raju, R.; Reddy, S.; Macmahon, S.; Neal, B. 2009: Rationale and design of the Rural Andhra Pradesh Cardiovascular Prevention Study (RAPCAPS): a factorial, cluster-randomized trial of 2 practical cardiovascular disease prevention strategies developed for rural Andhra Pradesh, India. American Heart Journal 158(3): 349-355
Meijs, M.F.L.; Bots, M.L.; Vonken, E.-J.A.; Cramer, M.-J.M.; Melman, P.G.; Velthuis, B.K.; van der Graaf, Y.; Mali, W.P.T.M.; Doevendans, P.A. 2007: Rationale and design of the SMART Heart study: a prediction model for left ventricular hypertrophy in hypertension. Netherlands Heart Journal: Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation 15(9): 295-298
Pieske, B.; Butler, J.; Filippatos, G.; Lam, C.; Maggioni, A.P.; Ponikowski, P.; Shah, S.; Solomon, S.; Kraigher-Krainer, E.; Samano, E.T.; Scalise, A.V.; Müller, K.; Roessig, L.; Gheorghiade, M.; Filippatos, G.; Ponikowski, P.; Fonarow, G.; Atherton, J.; Dwyer, N.; Kaye, D.; Keogh, A.; Pieske, B.; Stefenelli, T.; Hoppe, U.; Mörtl, D.; Bonderman, D.; Kinova, E.; Vitlianova, K.; Shalganov, C.; Mincheva, V.; Kamburov, I.; Pouleur, A.-C.; Vervoort, G.; Striekwold, H.; Vrints, C.; De Ceuninck, M.; Leroy, J.; Vandekerckhove, Y.; Vandekerckhove, H.; Delforge, M.; Lepage, S.; Moe, G.; Bergeron, S.; Roth, S.; Gupta, M.; Knot, J.; Krcova, E.; Belohlavek, J.; Stancik, R.; Vojacek, J.; Melenovsky, V.; Trestik, P.; Refsgaard, J.; Bruun, N.; Johansen, 2014: Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES). European Journal of Heart Failure 16(9): 1026-1038
Shrank, W.H.; Choudhry, N.K.; Solomon, D.H.; Snedden, T.M.; Lee, T.H.; Glynn, R.J.; Brown, T.V.; Jolda, C.; Spetman, M.; Brookhart, M.A.; Schneeweiss, S.; Avorn, J. 2009: Rationale and design of the Study Assessing the Effect of Cardiovascular Medications Provided as Low-cost, Evidence-based Generic Samples (SAMPLES) trial. American Heart Journal 157(4): 613-619
Garratt, K.N.; Lee, D.P.; Rose, E.M.; Windle, K.J.; Liao, H.; Nwachuku, C.E.; Winters, K.J.; Bowman, T.S.; Dawkins, K.D. 2012: Rationale and design of the TAXUS Libertē Post-Approval Study: examination of patients receiving the TAXUS Liberté stent with concomitant prasugrel therapy in routine interventional cardiology practice. American Heart Journal 163(2): 142-8.E6
Torres, V.E.; Meijer, E.; Bae, K.T.; Chapman, A.B.; Devuyst, O.; Gansevoort, R.T.; Grantham, J.J.; Higashihara, E.; Perrone, R.D.; Krasa, H.B.; Ouyang, J.J.; Czerwiec, F.S. 2011: Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study. American Journal of Kidney Diseases: the Official Journal of the National Kidney Foundation 57(5): 692-699
Moreira, D.M.; Lueneberg, M.E.; da Silva, R.L.; Fattah, T.; Mascia Gottschall, C.A. 2013: Rationale and design of the TETHYS trial: the effects of methotrexate therapy on myocardial infarction with ST-segment elevation. Cardiology 126(3): 167-170
Trachtenberg, B.; Velazquez, D.L.; Williams, A.R.; McNiece, I.; Fishman, J.; Nguyen, K.; Rouy, D.; Altman, P.; Schwarz, R.; Mendizabal, A.; Oskouei, B.; Byrnes, J.; Soto, V.; Tracy, M.; Zambrano, J.P.; Heldman, A.W.; Hare, J.M. 2011: Rationale and design of the Transendocardial Injection of Autologous Human Cells (bone marrow or mesenchymal) in Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction (TAC-HFT) trial: a randomized, double-blind, placebo-controlled study of safety and efficacy. American Heart Journal 161(3): 487-493
Cantor, W.J.; Fitchett, D.; Borgundvaag, B.; Heffernan, M.; Cohen, E.A.; Morrison, L.J.; Ducas, J.; Langer, A.; Mehta, S.; Lazzam, C.; Schwartz, B.; Dzavik, V.; Goodman, S.G. 2008: Rationale and design of the Trial of Routine ANgioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI). American Heart Journal 155(1): 19-25
Min, J.K.; Arsanjani, R.; Kurabayashi, S.; Andreini, D.; Pontone, G.; Choi, B-Wook.; Chang, H-Jae.; Lu, B.; Narula, J.; Karimi, A.; Roobottom, C.; Gomez, M.; Berman, D.S.; Cury, R.C.; Villines, T.; Kang, J.; Leipsic, J. 2013: Rationale and design of the ViCTORY (Validation of an Intracycle CT Motion CORrection Algorithm for Diagnostic AccuracY) trial. Journal of Cardiovascular Computed Tomography 7(3): 200-206
Pittas, A.G.; Dawson-Hughes, B.; Sheehan, P.R.; Rosen, C.J.; Ware, J.H.; Knowler, W.C.; Staten, M.A.; Tracy, R.; Lewis, M.R.; Phillips, L.; Foreyt, J.; Chatterjee, R.; Pratley, R.; Chadha, C.; Robbins, D.; Peters, A.; Brodsky, I.; Aroda, V.; Desouza, C.; Poretsky, L.; Neff, L.; Bray, G.A.; Curtis, J.; Nelson, R.; Weil, J.; O'Neil, P.; Kim, S.; Johnson, K.; Fonseca, V.; Raskin, P.; LeBlanc, E.; Kashyap, S. 2014: Rationale and design of the Vitamin D and Type 2 Diabetes (D2d) study: a diabetes prevention trial. Diabetes Care 37(12): 3227-3234
Johnson, D.W.; Clarke, M.; Wilson, V.; Woods, F.; Brown, F.G. 2010: Rationale and design of the balANZ trial: a randomised controlled trial of low GDP, neutral pH versus standard peritoneal dialysis solution for the preservation of residual renal function. Bmc Nephrology 11: 25
Zhou, J.; Shi, H.; Zhang, J.; Lu, Y.; Fu, M.; Ge, J.; Ge, J.; Zhu, J.; Zhang, J.; Lu, Y.; Fu, M.; Jin, X.; Jiang, H.; Zou, Y.; Zhou, J.; Cai, N.; Li, Y.; Zhang, F.; Dou, K.; Liao, Y.; Ge, Z.; Shi, H.; Wei, M.; Zhang, Y.; Chen, L.; Ma, C.; Yang, X.; Zhu, J.; Zhao, M.; Li, Y.; Lu, G.; He, B.; Fu, G.; Du, Z. 2010: Rationale and design of the beta-blocker in heart failure with normal left ventricular ejection fraction (beta-PRESERVE) study. European Journal of Heart Failure 12(2): 181-185
Miyauchi, K.; Takaya, N.; Hirose, T.; Ikeda, F.; Kawamori, R.; Ohishi, H.; Yoshida, K.; Yamamoto, M.; Arai, H.; Urabe, T.; Hattori, N.; Suzuki, M.; Maehara, T.; Sase, K.; Hatsukami, T.S.; Yuan, C.; Daida, H. 2009: Rationale and design of the carotid plaque in human for all evaluations with aggressive rosuvastatin therapy (CHALLENGER trial): evaluation by magnetic resonance imaging. Circulation Journal: Official Journal of the Japanese Circulation Society 73(1): 111-115
Mauri, L.; Leon, M.B.; Yeung, A.C.; Negoita, M.; Keyes, M.J.; Massaro, J.M. 2011: Rationale and design of the clinical evaluation of the Resolute Zotarolimus-Eluting Coronary Stent System in the treatment of de novo lesions in native coronary arteries (the RESOLUTE US clinical trial). American Heart Journal 161(5): 807-814
Mangen, M.-J.ée.J.; Bonten, M.J.M.; de Wit, G.A. 2013: Rationale and design of the costs, health status and outcomes in community-acquired pneumonia (CHO-CAP) study in elderly persons hospitalized with CAP. Bmc Infectious Diseases 13: 597
Schwartz, G.G.; Olsson, A.G.; Ballantyne, C.M.; Barter, P.J.; Holme, I.M.; Kallend, D.; Leiter, L.A.; Leitersdorf, E.; McMurray, J.J.V.; Shah, P.K.; Tardif, J.-C.; Chaitman, B.R.; Duttlinger-Maddux, R.; Mathieson, J.; Alvarez, C.; Alvarez, M.; Berli, M.; Bono, J.; Botto, F.; Labarta, G.B.; Caccavo, A.; Caime, G.; Cartasegna, L.; Caruso, O.; Chekherdemian, S.; Covelli, G.; Cuneo, C.; Dran, R.; Fernandez, A.A.; Fuselli, J.; Gadaleta, F.; Garrido, M.; Giacomi, G.; Hasbani, E.; Hominal, M.; Iglesias, R.M.; Litvak, B.M.; Llanos, J.; Luciardi, H.; Macin, S.; Mackinnon, I.; Manuale, O.; Muntaner, J.; Pelagagge, J.M.; Piskorz, D.; Pomposiello, J.C.; Porcile, R.; Sanchez, A.S.; Santos, D.; Schygiel, P.O.; Stisman, D.J.; Vico, M.L.; Amerena, J.; Ardi 2009: Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. American Heart Journal 158(6): 896-901.E3
Mauri, L.; Kereiakes, D.J.; Normand, S.-L.T.; Wiviott, S.D.; Cohen, D.J.; Holmes, D.R.; Bangalore, S.; Cutlip, D.E.; Pencina, M.; Massaro, J.M. 2010: Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions. American Heart Journal 160(6): 1035-1041; 1041.E1
Ezekowitz, M.D.; Cappato, R.; Klein, A.L.; Camm, A.John.; Ma, C-Sheng.; Le Heuzey, J-Yves.; Talajic, M.; Scanavacca, Mício.I.; Vardas, P.E.; Kirchhof, P.; Hohnloser, S.H.; Hemmrich, M.; Lanius, V.; Meng, I.Ling.; Wildgoose, P.; van Eickels, M. 2014: Rationale and design of the eXplore the efficacy and safety of once-daily oral ri Varoxaban for the pr Evention of ca Rdiovascular events in patients with nonvalvular aTrial fibrillation scheduled for cardioversion trial: A comparison of oral rivaroxaban once daily with dose-adjusted vitamin K antagonists in patients with nonvalvular atrial fibrillation undergoing elective cardioversion. American Heart Journal 167(5): 646-652
O'Brien, E.C.; Roe, M.T.; Fraulo, E.S.; Peterson, E.D.; Ballantyne, C.M.; Genest, J.; Gidding, S.S.; Hammond, E.; Hemphill, L.C.; Hudgins, L.C.; Kindt, I.; Moriarty, P.M.; Ross, J.; Underberg, J.A.; Watson, K.; Pickhardt, D.; Rader, D.J.; Wilemon, K.; Knowles, J.W. 2014: Rationale and design of the familial hypercholesterolemia foundation CAscade SCreening for Awareness and DEtection of Familial Hypercholesterolemia registry. American Heart Journal 167(3): 342-349.E17
Blair, J.E.A.; Macarie, C.; Ruzyllo, W.; Bacchieri, A.; Valentini, G.; Bianchetti, M.; Pang, P.S.; Harinstein, M.E.; Sabbah, H.N.; Filippatos, G.S.; Gheorghiade, M.; Gheorghiade, M.; Ruzyllo, W.; Macarie, C.; Filippatos, G.; Sabbah, H.; Tavazzi, L.; Ardia, A.; Ferrari, R.; Mebazaa, A.; Tubaro, M.; Gheorghiade, M.; Sabbah, H.; Filippatos, G.; Blair, J.; Valentini, G.; Taralek-Urbaniec, K.; Dumitrescu, L.; Emmanouil, P.; Ruzyllo, W.; Grzybowski, J.; Korewicki, J.; Drodz, J.; Ponikowski, P.; Macarie, C.; Chioncel, O.; Bubenek-Turconi, S.-I.; Miclea, I.; Dorobantu, M.; Kremastinos, D.; Parissis, J.; Nanas, J. 2008: Rationale and design of the hemodynamic, echocardiographic and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure (HORIZON-HF) trial. American Journal of Therapeutics 15(3): 231-240
Sultana, F.; English, D.R.; Simpson, J.A.; Brotherton, J.M.L.; Drennan, K.; Mullins, R.; Heley, S.; Wrede, C.D.; Saville, M.; Gertig, D.M. 2014: Rationale and design of the iPap trial: a randomized controlled trial of home-based HPV self-sampling for improving participation in cervical screening by never- and under-screened women in Australia. Bmc Cancer 14: 207
Altenberger, J.; Parissis, J.T.; Ulmer, H.; Poelzl, G.; Poelzl, G.; Frick, M.; Trieb, T.; Steinacher, R.; Berger, R.; Mayr, H.; Stefenelli, T.; Dimopoulos, L.; Ebner, C.; Nesser, H.J.; Mori, M.; Hoellinger, K.; Akh, L.; Sihorsch, K.; Kammler, J.; Weber, T.; Eber, B.; Parissis, J.T.; Avgeropoulo, E.; Karavida, A.; Altenberger, J.; Hergan, K.; Siebert, U.; Hintringer, F.; Schuler, J.; Pfeiffer, K.P.; Ulmer, H. 2010: Rationale and design of the multicentre randomized trial investigating the efficacy and safety of pulsed infusions of levosimendan in outpatients with advanced heart failure (LevoRep study). European Journal of Heart Failure 12(2): 186-192
Gheorghiade, M.; Albaghdadi, M.; Zannad, F.; Fonarow, G.C.; Böhm, M.; Gimpelewicz, C.; Botha, J.; Moores, S.; Lewis, E.F.; Rattunde, H.; Maggioni, A.; Gheorghiade, M.; Maggioni, A.; Fonarow, G.C.; Böhm, M.; Zannad, F.; Solomon, S.; Lewis, E.; Finn, P.; Hartley, H.; Weinrach, L.; Barkoudah, E.; Duong, C.; Rogers, A.; Swedberg, K.; Pocock, S.; Pitt, B.; Borer, J.S.; Rouleau, J.; Wibberg, M. 2011: Rationale and design of the multicentre, randomized, double-blind, placebo-controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT). European Journal of Heart Failure 13(1): 100-106
Barraclough, K.A.; Noble, E.; Leary, D.; Brown, F.; Hawley, C.M.; Campbell, S.B.; Isbel, N.M.; Mudge, D.W.; van Eps, C.L.; Sturtevant, J.M.; Johnson, D.W. 2009: Rationale and design of the oral HEMe iron polypeptide Against Treatment with Oral Controlled Release Iron Tablets trial for the correction of anaemia in peritoneal dialysis patients (HEMATOCRIT trial). Bmc Nephrology 10: 20
Knorr, U.; Vinberg, M.; Klose, M.; Feldt-Rasmussen, U.; Hilsted, L.; Gade, A.; Haastrup, E.; Paulson, O.; Wetterslev, Jørn.; Gluud, C.; Gether, U.; Kessing, L. 2009: Rationale and design of the participant, investigator, observer, and data-analyst-blinded randomized AGENDA trial on associations between gene-polymorphisms, endophenotypes for depression and antidepressive intervention: the effect of escitalopram versus placebo on the combined dexamethasone-corticotrophine releasing hormone test and other potential endophenotypes in healthy first-degree relatives of persons with depression. Trials 10: 66
Carcillo, J.; Holubkov, R.; Dean, J.Michael.; Berger, J.; Meert, K.L.; Anand, K.J.S.; Zimmerman, J.; Newth, C.J.L.; Harrison, R.; Willson, D.F.; Nicholson, C.; Carcillo, J.; Bell, M.; Abraham, A.; Dean, J.Michael.; Burr, J.; Donaldson, A.; Holubkov, R.; Hellem, T.; Morrison, B.; Enriquez, R.; Yearley, J.; Berger, J.; Ratney, A.; Reardon, J.; Meert, K.L.; Heidemann, S.; Frey, M.; Anand, K.J.S.; Prodhan, P.; Hefley, G.; Zimmerman, J.; Jardine, D.; Barker, R.; Newth, C.J.L.; Fajardo, J.Francisco.; Harrison, R.; Willson, D.F.; Nicholson, C.; Jenkins, T. 2009: Rationale and design of the pediatric critical illness stress-induced immune suppression (CRISIS) prevention trial. Jpen. Journal of Parenteral and Enteral Nutrition 33(4): 368-374
Heck, S.Lagethon.; Gulati, G.; Ree, A.Hansen.; Schulz-Menger, J.; Gravdehaug, B.; Røsjø, H.; Steine, K.; Bratland, A.; Hoffmann, P.; Geisler, Jürgen.; Omland, Tørn. 2012: Rationale and design of the prevention of cardiac dysfunction during an Adjuvant Breast Cancer Therapy (PRADA) Trial. Cardiology 123(4): 240-247
Grill, E.; Klein, A.-M.; Howell, K.; Arndt, M.; Bodrozic, L.; Herzog, J.ür.; Jox, R.; Koenig, E.; Mansmann, U.; Müller, F.; Müller, T.; Nowak, D.; Schaupp, M.; Straube, A.; Bender, A. 2013: Rationale and design of the prospective German registry of outcome in patients with severe disorders of consciousness after acute brain injury. Archives of Physical Medicine and Rehabilitation 94(10): 1870-1876
Tadić, A.é; Gorbulev, S.; Dahmen, N.; Hiemke, C.; Braus, D.F.; Röschke, J.; van Calker, D.; Wachtlin, D.; Kronfeld, K.; Gorbauch, T.; Seibert-Grafe, M.; Lieb, K.; Lieb, K.; Tadić, A.é; Hiemke, C.; Dreimüller, N.; Baskaya, O.ür.; Krannich, D.; Lorenz, S.; Bernius, A.; Weichert, T.; Lorscheider, M.; Wagner, S.; Helmreich, I.; Grüllich, K.; Ostad Haji, E.; Lober, Y.; Weichert, D.; Schlicht, K.; Gorbulev, S.; Wachtlin, D.; Kronfeld, K.; Friedrich-Mai, P.; Ehrlich, A.; Powaska, A.; Gorbauch, T.; Seibert-Grafe, M.; Tubic-Grozdanis, M.; Jekle, C.; Krämer, I.; Dahmen, N.; Gerbaulet, M.; Sachsenheimer, D.; Rutschinski, A.; Engel, A.; Schwarz, K.; Gehrmann, U.; Bader, S.; Schneider-Pohl, B.; Justi, M.; Thierolf, H.-C.; Röschke, J.; Gabriel, 2010: Rationale and design of the randomised clinical trial comparing early medication change (EMC) strategy with treatment as usual (TAU) in patients with major depressive disorder--the EMC trial. Trials 11: 21
Leonardi, S.; Rao, S.V.; Harrington, R.A.; Bhatt, D.L.; Gibson, C.M.; Roe, M.T.; Kochman, J.; Huber, K.; Zeymer, U.; Madan, M.; Gretler, D.D.; McClure, M.W.; Paynter, G.E.; Thompson, V.; Welsh, R.C. 2010: Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI). American Heart Journal 160(1): 65-72
Cortese, B.; Danzi, G.B.; Pitì, A.; Severi, S.; Limbruno, U. 2011: Rationale and design of the randomized, multicenter EREMUS trial, a study that investigates how to achieve low restenosis and early reendothelialization after percutaneous coronary interventions. Catheterization and Cardiovascular Interventions: Official Journal of the Society for Cardiac Angiography and Interventions 78(1): 32-37
Carrasquillo, O.; McCann, S.; Amofah, A.; Pierre, L.; Rodriguez, B.; Alonzo, Y.; Ilangovan, K.; Gonzalez, M.; Trevil, D.; Byrne, M.M.; Koru-Sengul, T.; Kobetz, E. 2014: Rationale and design of the research project of the South Florida Center for the Reduction of Cancer Health Disparities (SUCCESS): study protocol for a randomized controlled trial. Trials 15: 299
Whitlock, R.; Teoh, K.; Vincent, J.; Devereaux, P.J.; Lamy, A.; Paparella, D.; Zuo, Y.; Sessler, D.I.; Shah, P.; Villar, J.-C.; Karthikeyan, G.; Urrútia, G.; Alvezum, A.; Zhang, X.; Abbasi, S.H.; Zheng, H.; Quantz, M.; Yared, J.-P.; Yu, H.; Noiseux, N.; Yusuf, S. 2014: Rationale and design of the steroids in cardiac surgery trial. American Heart Journal 167(5): 660-665
Abraham, W.T.; Aranda, J.M.; Boehmer, J.P.; Elkayam, U.; Gilbert, E.M.; Gottlieb, S.S.; Hasenfuss, G.; Kukin, M.; Lowes, B.D.; O'Connell, J.B.; Tavazzi, L.; Feldman, A.M.; Ticho, B.; Orlandi, C. 2010: Rationale and design of the treatment of hyponatremia based on lixivaptan in NYHA class III/IV cardiac patient evaluation (THE BALANCE) study. Clinical and Translational Science 3(5): 249-253
Bergmann, J.F.; Slavenburg, S.; Roomer, R.; de Knegt, R.J.; Drenth, J.P.H. 2008: Rationale and design of the virological response and ribavirin dosage (VIRID) study in hepatitis. Netherlands Journal of Medicine 66(1): 44-45
Rohde, L.E.P.; Danzmann, L.C.; Canesin, M.F.; Hoffmann Filho, C.R.; Fragata Filho, A.A.; Baruzzi, A.; Pereira-Barretto, A.C.; Matsubara, B.B.; Mady, C.; Albuquerque, D.C.d.; Bocchi, E.A.; Gouvea, E.P.; Santos, E.S.d.; Figueiredo, E.ão.L.; Pena, F.M.; Neuenschwander, F.C.; Almeida, G.L.G.d.; Villacorta, H.; Sampaio, J.; Dantas, J.ão.M.d.M.; Bittencourt, M.I.; Garcia, M.I.; Hernandes, M.E.; Simões, M.V.íc.; Oliveira Filho, M.T.d.; Gebara, O.áv.; Nogueira, P.R.; Alves, R.J.; Lopes, R.D.; Gusmão, R.; Rocha, R.M.; Pavanello, R.; Freitas Júnior, A.; Moreira, M.d.C.ção.V.; Marino, R.L.; Rassi, S.; Nascimento, C.V.; José, S.A.új.S.ão.; Rabelo, A.; Sousa, A.C.S.; Darzé, E.; Silveira, F.S.; Feitosa, G.S.; Villas-Boas, F.; Souza Neto, J. 2013: Rationale and design: BREATHE registry--i Brazilian Registry of Heart Failure. Arquivos Brasileiros de Cardiologia 100(5): 390-394
Egede, L.E.; Strom, J.L.; Durkalski, V.L.; Mauldin, P.D.; Moran, W.P. 2010: Rationale and design: telephone-delivered behavioral skills interventions for Blacks with Type 2 diabetes. Trials 11: 35
Egede, L.E.; Frueh, C.B.; Richardson, L.K.; Acierno, R.; Mauldin, P.D.; Knapp, R.G.; Lejuez, C. 2009: Rationale and design: telepsychology service delivery for depressed elderly veterans. Trials 10: 22
Aicken, C.R.; Cassell, J.A.; Estcourt, C.S.; Keane, F.; Brook, G.; Rait, G.; White, P.J.; Mercer, C.H. 2011: Rationale and development of a survey tool for describing and auditing the composition of, and flows between, specialist and community clinical services for sexually transmitted infections. Bmc Health Services Research 11: 30
Bucchi, L.; Cristiani, P.; Costa, S.; Schincaglia, P.; Garutti, P.; Sassoli de Bianchi, P.; Naldoni, C.; Olea, O.; Sideri, M. 2013: Rationale and development of an on-line quality assurance programme for colposcopy in a population-based cervical screening setting in Italy. Bmc Health Services Research 13: 237
Gu, J.; Ghayur, T. 2010: Rationale and development of multispecific antibody drugs. Expert Review of Clinical Pharmacology 3(4): 491-508
Moore, J.B.; Schneider, L.; Lazorick, S.; Shores, K.A.; Beighle, A.; Jilcott, S.B.; Newkirk, J. 2010: Rationale and development of the Move more North Carolina: Recommended Standards for After-School Physical Activity. Journal of Public Health Management and Practice: Jphmp 16(4): 359-366
Nwe, S.M.; Champlain, A.H.; Gordon, K.B. 2013: Rationale and early clinical data on IL-17 blockade in psoriasis. Expert Review of Clinical Immunology 9(7): 677-682
Vezzoli, P.; Berti, E.; Marzano, A.V. 2008: Rationale and efficacy for the use of rituximab in paraneoplastic pemphigus. Expert Review of Clinical Immunology 4(3): 351-363
Cochereau, D.; Georgin-Lavialle, S.; Maisonobe, T.; Dubourg, O.; Melboucy-Belkhir, S.; Hermine, O.; Aouba, A. 2014: Rationale and efficacy of CD52 targeting in HTLV-1-associated myositis. Joint Bone Spine 81(4): 362-365
Aouba, A.; Georgin-Lavialle, S.; Pagnoux, C.; Martin Silva, N.; Renand, A.éd.ée.; Galateau-Salle, F.ço.; Le Toquin, S.; Bensadoun, H.; Larousserie, F.; Silvera, S.ép.; Provost, N.; Candon, S.; Seror, R.èl.; de Menthon, M.; Hermine, O.; Guillevin, L.ïc.; Bienvenu, B. 2010: Rationale and efficacy of interleukin-1 targeting in Erdheim-Chester disease. Blood 116(20): 4070-4076
Kaufman, S.E.; Donnell, R.W.; Hickey, W.S. 2011: Rationale and evidence for extended infusion of piperacillin-tazobactam. American Journal of Health-System Pharmacy: Ajhp: Official Journal of the American Society of Health-System Pharmacists 68(16): 1521-1526
Hoffmann, C.J.; Gallant, J.E. 2014: Rationale and evidence for human immunodeficiency virus treatment as prevention at the individual and population levels. Infectious Disease Clinics of North America 28(4): 549-561
Roberto, C.A.; Schwartz, M.B.; Brownell, K.D. 2009: Rationale and evidence for menu-labeling legislation. American Journal of Preventive Medicine 37(6): 546-551
Joshua, A.M.; Ezzat, S.; Asa, S.L.; Evans, A.; Broom, R.; Freeman, M.; Knox, J.J. 2009: Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma. Journal of Clinical Endocrinology and Metabolism 94(1): 5-9
Adegbola, R.A.; Levine, O.S. 2011: Rationale and expectations of the Pneumonia Etiology Research for Child Health (PERCH) study. Expert Review of Respiratory Medicine 5(6): 731-733
Burton, C.C. 1947: Rationale and factors for consideration in Cooper's ligament hernioplasty. Surgery Gynecology and Obstetrics 85(1): 1-8
Ryder, H.W.; Kehoe, R.A. 1948: Rationale and hazards of pressure breathing and oxygen therapy. Anesthesiology 9(1): 21-31
Bien, D.P. 2011: Rationale and implementation of anterior cruciate ligament injury prevention warm-up programs in female athletes. Journal of Strength and Conditioning Research 25(1): 271-285
Shah, S.I. 2008: Rationale and implementation policy for use of oral, live, reassortant rotavirus vaccine in the neonatal intensive care unit. Advances in Neonatal Care: Official Journal of the National Association of Neonatal Nurses 8(3): 148-149
Meissner, M.H. 2012: Rationale and indications for aggressive early thrombus removal. Phlebology 27(Suppl 1): 78-84
Juliano, E.F.G.ãe.d.A.; Feuerwerker, L.C.M.; Coutinho, S.M.V.; Malheiros, T.F.íc. 2012: Rationale and knowledge for the universal implementation of sanitation in areas of social vulnerability. Ciencia and Saude Coletiva 17(11): 3037-3046
Chen, J.; Cesario, T.C.; Rentzepis, P.M. 2014: Rationale and mechanism for the low photoinactivation rate of bacteria in plasma. Proceedings of the National Academy of Sciences of the United States of America 111(1): 33-38
McDade, T.W.; Hayward, M.D. 2009: Rationale and methodological options for assessing infectious disease and related measures in social science surveys. Biodemography and Social Biology 55(2): 159-177
Kline, J.A.; Hernandez, J.; Hogg, M.M.; Jones, A.E.; Courtney, D.M.; Kabrhel, C.; Nordenholz, K.E.; Diercks, D.B.; Rondina, M.T.; Klinger, J.R. 2013: Rationale and methodology for a multicentre randomised trial of fibrinolysis for pulmonary embolism that includes quality of life outcomes. Emergency Medicine Australasia: Ema 25(6): 515-526
Foong, A.W.P.; Saw, S-Mei.; Loo, J-Liang.; Shen, S.; Loon, S-Chee.; Rosman, M.; Aung, T.; Tan, D.T.H.; Tai, E.Shyong.; Wong, T.Y. 2007: Rationale and methodology for a population-based study of eye diseases in Malay people: The Singapore Malay eye study (SiMES). Ophthalmic Epidemiology 14(1): 25-35
Barrett, B.; Rakel, D.; Chewning, B.; Marchand, L.; Rabago, D.; Brown, R.; Scheder, J.; Schmidt, R.; Gern, J.E.; Bone, K.; Thomas, G.; Barlow, S.; Bobula, J. 2007: Rationale and methods for a trial assessing placebo, echinacea, and doctor-patient interaction in the common cold. Explore 3(6): 561-572
Negus, S.S.; Bilsky, E.J.; Do Carmo, G.P.; Stevenson, G.W. 2010: Rationale and methods for assessment of pain-depressed behavior in preclinical assays of pain and analgesia. Methods in Molecular Biology 617: 79-91
Della Corte, A.; Buonocore, M.; Del Viscovo, L. 2012: Rationale and methods for quantifying ascending aortic flow eccentricity: back to the underlying mechanism?. Journal of magnetic resonance imaging: JMRI 36(2): 505-6; author reply 507
Rattan, S.I.S. 2012: Rationale and methods of discovering hormetins as drugs for healthy ageing. Expert Opinion on Drug Discovery 7(5): 439-448
Rodríguez-Artalejo, F.; Guallar, E.; Borghi, C.; Dallongeville, J.; De Backer, G.; Halcox, J.P.; Hernández-Vecino, Rón.; Jiménez, F.Javier.; Massó-González, E.L.; Perk, J.; Steg, P.Gabriel.; Banegas, Jé.R. 2010: Rationale and methods of the European Study on Cardiovascular Risk Prevention and Management in Daily Practice (EURIKA). Bmc Public Health 10: 382
Larson, M.Jo.; Adams, R.Sayko.; Mohr, B.A.; Harris, A.H.S.; Merrick, E.L.; Funk, W.; Hofmann, K.; Wooten, N.R.; Jeffery, D.D.; Williams, T.V. 2013: Rationale and methods of the Substance Use and Psychological Injury Combat Study (SUPIC): a longitudinal study of Army service members returning from deployment in FY2008-2011. Substance use and Misuse 48(10): 863-879
Gil-Guillen, V.; Orozco-Beltran, D.; Redon, J.; Pita-Fernandez, S.; Navarro-Pérez, J.; Pallares, V.; Valls, F.; Fluixa, C.; Fernandez, A.; Martin-Moreno, J.M.; Pascual-de-la-Torre, M.; Trillo, J.L.; Durazo-Arvizu, R.; Cooper, R.; Hermenegildo, M.; Rosado, L. 2010: Rationale and methods of the cardiometabolic Valencian study (Escarval-Risk) for validation of risk scales in Mediterranean patients with hypertension, diabetes or dyslipidemia. Bmc Public Health 10: 717
Pascual, C.Rodríguez.; Galán, E.Paredes.; Guerrero, J.Luis.Gonzalez.; Colino, R.Menendez.; Soler, P.Abizanda.; Calvo, M.Hornillos.; Jaurieta, J.Jose.Solano.; Arambarri, J.Manzarbeitia.; Casado, J.Manuel.Ribera.; Rodríguez-Artalejo, F. 2011: Rationale and methods of the multicenter randomised trial of a heart failure management programme among geriatric patients (HF-Geriatrics). Bmc Public Health 11: 627
Rodríguez-Artalejo, F.; Graciani, A.; Guallar-Castillón, P.; León-Muñoz, L.M.; Zuluaga, M.C.; López-García, E.; Gutiérrez-Fisac, J.L.; Taboada, J.é M.; Aguilera, M.T.; Regidor, E.; Villar-Álvarez, F.; Banegas, J.é R. 2011: Rationale and methods of the study on nutrition and cardiovascular risk in Spain (ENRICA). Revista Espanola de Cardiologia 64(10): 876-882
Saul, J.P.; Schwartz, P.J.; Ackerman, M.J.; Triedman, J.K. 2014: Rationale and objectives for ECG screening in infancy. Heart Rhythm 11(12): 2316-2321
Koshy, S.K.G.; Govindarajan, G. 2012: Rationale and pitfalls of noninvasive coronary flow reserve estimation in assessment of microvascular disease. Echocardiography 29(6): 631-633
Yu, P.; Nguyen, B.T.; Tao, M.; Campagna, C.; Ozaki, C.K. 2010: Rationale and practical techniques for mouse models of early vein graft adaptations. Journal of Vascular Surgery 52(2): 444-452
Fu, M.; Maresh, E.L.; Helguera, G.F.; Kiyohara, M.; Qin, Y.; Ashki, N.; Daniels-Wells, T.R.; Aziz, N.; Gordon, L.K.; Braun, J.; Elshimali, Y.; Soslow, R.A.; Penichet, M.L.; Goodglick, L.; Wadehra, M. 2014: Rationale and preclinical efficacy of a novel anti-EMP2 antibody for the treatment of invasive breast cancer. Molecular Cancer Therapeutics 13(4): 902-915
Arant, B.S. 2008: Rationale and procedures. Journal of Urology 179(5): 1662-1663
Schatz, E. 2012: Rationale and procedures for nesting semi-structured interviews in surveys or censuses. Population Studies 66(2): 183-195
Obermajer, N.ša.; Popp, F.C.; Johnson, C.L.; Benseler, V.; Dahlke, M.H. 2014: Rationale and prospects of mesenchymal stem cell therapy for liver transplantation. Current Opinion in Organ Transplantation 19(1): 60-64
Taylor, P.; Hutton, P.; Dudley, R. 2014: Rationale and protocol for a systematic review and meta-analysis on reduced data gathering in people with delusions. Systematic Reviews 3: 44
Procopio, G.; Verzoni, E.; Biondani, P.; Grassi, P.; Testa, I.; Garanzini, E.; de Braud, F. 2014: Rationale and protocol of RESORT, a randomized, open-label, multicenter phase II study to evaluate the efficacy of sorafenib in patients with advanced renal cell carcinoma after radical resection of the metastases. Tumori 100(1): E28-E30
Dainiak, N. 2010: Rationale and recommendations for treatment of radiation injury with cytokines. Health Physics 98(6): 838-842
Grant, O.; Lich, R. 1947: Rationale and results in retropubic prostatectomy. Transactions of the Southern Surgical Association. Southern Surgical Association 59: 174-185
Scacciatella, P.; D'Amico, M.; Meynet, I.; Pennone, M.; Conrotto, F.; Amato, G.; Frisenda, V.; Pelloni, E.; Marra, S. 2011: Rationale and results of percutaneous coronary revascularization with endothelial progenitor cell capture stent in high-risk patients requiring undeferrable non-cardiac surgery. Minerva Cardioangiologica 59(5): 411-418
Miller, D.C. 2015: Rationale and results of the Stanford modification of the David V reimplantation technique for valve-sparing aortic root replacement. Journal of Thoracic and Cardiovascular Surgery 149(1): 112-114
Chemtob, D.; Levy, A. 2009: Rationale and staff evaluation of using a "therapeutic milieu" for substance users within a tuberculosis ward. Substance use and Misuse 44(5): 672-683
Radbill, B.; Murphy, B.; LeRoith, D. 2008: Rationale and strategies for early detection and management of diabetic kidney disease. Mayo Clinic Proceedings 83(12): 1373-1381
Wilmot, E.G.; Davies, M.J.; Edwardson, C.L.; Gorely, T.; Khunti, K.; Nimmo, M.; Yates, T.; Biddle, S.J.H. 2011: Rationale and study design for a randomised controlled trial to reduce sedentary time in adults at risk of type 2 diabetes mellitus: project stand (Sedentary time ANd diabetes). Bmc Public Health 11: 908
Kiss, T.; Güldner, A.; Bluth, T.; Uhlig, C.; Spieth, P.Markus.; Markstaller, K.; Ullrich, R.; Jaber, S.; Santos, J.Alberto.; Mancebo, J.; Camporota, L.; Beale, R.; Schettino, G.; Saddy, F.; Vallverdú, I.; Wiedemann, Bärbel.; Koch, T.; Schultz, M.Josephus.; Pelosi, P.; de Abreu, M.Gama. 2013: Rationale and study design of ViPS - variable pressure support for weaning from mechanical ventilation: study protocol for an international multicenter randomized controlled open trial. Trials 14: 363
Gill, P.S.; Davis, R.; Davies, M.; Freemantle, N.; Lip, G.Yh. 2009: Rationale and study design of a cross sectional study documenting the prevalence of Heart Failure amongst the minority ethnic communities in the UK: the E-ECHOES Study (Ethnic--Echocardiographic Heart of England Screening Study). Bmc Cardiovascular Disorders 9: 47
Waldron-Lynch, F.; Kareclas, P.; Irons, K.; Walker, N.M.; Mander, A.; Wicker, L.S.; Todd, J.A.; Bond, S. 2014: Rationale and study design of the Adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D): a non-randomised, open label, adaptive dose finding trial. Bmj Open 4(6): E005559
Kuiper, J.L.; Heideman, D.A.M.; Würdinger, T.; Grünberg, K.; Groen, H.J.M.; Smit, E.F. 2015: Rationale and study design of the IRENE-trial (NVALT-16): a phase Ii trial to evaluate iressa rechallenge in advanced NSCLC patients with an activating EGFR mutation who responded to an EGFR-TKi used as first-line or previous treatment. Clinical Lung Cancer 16(1): 60-66
Kawamoto, T.; Nitta, H.; Murata, K.; Toda, E.; Tsukamoto, N.; Hasegawa, M.; Yamagata, Z.; Kayama, F.; Kishi, R.; Ohya, Y.; Saito, H.; Sago, H.; Okuyama, M.; Ogata, T.; Yokoya, S.; Koresawa, Y.; Shibata, Y.; Nakayama, S.; Michikawa, T.; Takeuchi, A.; Satoh, H. 2014: Rationale and study design of the Japan environment and children's study (JECS). Bmc Public Health 14: 25
De Ferrari, G.M.; Tuinenburg, A.E.; Ruble, S.; Brugada, J.; Klein, H.; Butter, C.; Wright, D.J.; Schubert, B.; Solomon, S.; Meyer, S.; Stein, K.; Ramuzat, A.; Zannad, F. 2014: Rationale and study design of the NEuroCardiac TherApy foR Heart Failure Study: NECTAR-HF. European Journal of Heart Failure 16(6): 692-699
Iaccarino, D.; Politi, L.; Rossi, R.; Sgura, F.; Monopoli, D.; Modena, M.Grazia.; Sangiorgi, G.M. 2010: Rationale and study design of the OISTER trial: optical coherence tomography evaluation of stent struts re-endothelialization in patients with non-ST-elevation acute coronary syndromes--a comparison of the intr Epide tRapidil eluting stent vs. taxus drug-eluting stent implantation. Journal of Cardiovascular Medicine 11(7): 536-543
Williams, B.; Cockcroft, J.R.; Kario, K.; Zappe, D.H.; Cardenas, P.; Hester, A.; Brunel, P.; Zhang, J. 2014: Rationale and study design of the Prospective comparison of Angiotensin Receptor neprilysin inhibitor with Angiotensin receptor blocker MEasuring arterial sTiffness in the eld ERly (PARAMETER) study. Bmj Open 4(2): E004254
Morgan, J.M.; Dimitrov, B.D.; Gill, J.; Kitt, S.; Ng, G.A.; McComb, J.M.; Raftery, J.; Roderick, P.; Seed, A.; Williams, S.G.; Witte, K.K.; Wright, D.J.; Yao, G.L.; Cowie, M.R. 2014: Rationale and study design of the REM-HF study: remote management of heart failure using implanted devices and formalized follow-up procedures. European Journal of Heart Failure 16(9): 1039-1045
Romaguera, R.; Brugaletta, S.; Gomez-Lara, J.; Pinar, E.; Jiménez-Quevedo, P.; Gracida, M.; Roura, G.; Ferreiro, J.L.; Teruel, L.; Gómez-Hospital, J.A.; Montanya, E.; Alfonso, F.; Valgimigli, M.; Sabate, M.; Cequier, A. 2015: Rationale and study design of the RESERVOIR trial: a randomized trial comparing reservoir-based polymer-free amphilimus-eluting stents versus everolimus-eluting stents with durable polymer in patients with diabetes mellitus. Catheterization and Cardiovascular Interventions: Official Journal of the Society for Cardiac Angiography and Interventions 85(4): E116-E122
Smith, J.J.; Morgan, P.J.; Plotnikoff, R.C.; Dally, K.A.; Salmon, J.; Okely, A.D.; Finn, T.L.; Babic, M.J.; Skinner, G.; Lubans, D.R. 2014: Rationale and study protocol for the 'active teen leaders avoiding screen-time' (ATLAS) group randomized controlled trial: an obesity prevention intervention for adolescent boys from schools in low-income communities. Contemporary Clinical Trials 37(1): 106-119
Lubans, D.R.; Morgan, P.J.; Weaver, K.; Callister, R.; Dewar, D.L.; Costigan, S.A.; Finn, T.L.; Smith, J.; Upton, L.; Plotnikoff, R.C. 2012: Rationale and study protocol for the supporting children's outcomes using rewards, exercise and skills (SCORES) group randomized controlled trial: a physical activity and fundamental movement skills intervention for primary schools in low-income communities. Bmc Public Health 12: 427
Riley, N.; Lubans, D.R.; Holmes, K.; Morgan, P.J. 2014: Rationale and study protocol of the EASY Minds (Encouraging Activity to Stimulate Young Minds) program: cluster randomized controlled trial of a primary school-based physical activity integration program for mathematics. Bmc Public Health 14: 816
Lee, B.Hui.; Yun, S-Su.; Kim, M.Ki.; Jung, H-Kyung.; Lee, D-Shik.; Kim, H-Jin. 2014: Rationale and surgical technique of laparoscopic left lateral sectionectomy using endoscopic staples. Annals of Surgical Treatment and Research 87(2): 66-71
Schuppan, D.; Popov, Y. 2009: Rationale and targets for antifibrotic therapies. Gastroenterologie Clinique et Biologique 33(10-11): 949-957
Kimmel, S.S. 2009: Rationale and technique for achieving occlusal harmony. New York State Dental Journal 75(1): 39-43
West, J. 2007: Rationale and technique for vertical compaction of warm gutta-percha: the heat wave approach. Dentistry Today 26(9): 80; 82 84 Passim
Macrì, A.; Fortugno, A.; Saladino, E. 2011: Rationale and techniques of cytoreductive surgery and peritoneal chemohyperthermia. World Journal of Gastrointestinal Oncology 3(12): 169-174
McKie, P.M.; Burnett, J.C. 2015: Rationale and therapeutic opportunities for natriuretic peptide system augmentation in heart failure. Current Heart Failure Reports 12(1): 7-14
Wanderer, A.A. 2010: Rationale and timeliness for IL-1beta-targeted therapy to reduce allogeneic organ injury at procurement and to diminish risk of rejection after transplantation. Clinical Transplantation 24(3): 307-311
Lin, Y.-K.; Kaag, M.; Raman, J.D. 2014: Rationale and timing of perioperative chemotherapy for upper-tract urothelial carcinoma. Expert Review of Anticancer Therapy 14(5): 543-551
de Zeeuw, D.; Akizawa, T.; Agarwal, R.; Audhya, P.; Bakris, G.L.; Chin, M.; Krauth, M.; Lambers Heerspink, H.J.; Meyer, C.J.; McMurray, J.J.; Parving, H-Henrik.; Pergola, P.E.; Remuzzi, G.; Toto, R.D.; Vaziri, N.D.; Wanner, C.; Warnock, D.G.; Wittes, J.; Chertow, G.M. 2013: Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON). American Journal of Nephrology 37(3): 212-222
Roncella, A.; Giornetti, A.; Cianfrocca, C.; Pasceri, V.; Pelliccia, F.; Denollet, J.; Pedersen, S.S.; Speciale, G.; Richichi, G.; Pristipino, C. 2009: Rationale and trial design of a randomized, controlled study on short-term psychotherapy after acute myocardial infarction: the STEP-IN-AMi trial (Short Term Psychotherapy in Acute Myocardial Infarction). Journal of Cardiovascular Medicine 10(12): 947
Cuisset, T.; Mudra, H.; Muller, O.; Vogt, P.; Angelillo-Scherrer, A.; Huber, K. 2008: Rationale and use of antiplatelet and antithrombotic drugs during cardiovascular interventions. Eurointervention: Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 4(2): 183-186
Cuisset, T.; Valgimigli, M.; Mudra, H.; Muller, O.; Wijns, W.; Huber, K. 2010: Rationale and use of antiplatelet and antithrombotic drugs during cardiovascular interventions: May 2010 update. EuroIntervention: journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 6(1): 39-45
Calder, P.C. 2010: Rationale and use of n-3 fatty acids in artificial nutrition. Proceedings of the Nutrition Society 69(4): 565-573
Waxman, S.; Ishibashi, F.; Caplan, J.D. 2007: Rationale and use of near-infrared spectroscopy for detection of lipid-rich and vulnerable plaques. Journal of Nuclear Cardiology: Official Publication of the American Society of Nuclear Cardiology 14(5): 719-728
Shann, K.G.; Giacomuzzi, C.R.; Jacobs, J.P.; Myers, G.J.; Paugh, T.A.; Mellas, N.; Puis, L.; Ojito, J.W.; Gomez, D.; Olshove, V.; Fitzgerald, D.C.; Itoh, H.; Brabant, C.; Thuys, C.A.; Charette, K.; Calaritis, C.; Parpard, M.; Chancy, T.; Baker, R.A.; Pourmoghadam, K.K.; Likosky, D.S. 2010: Rationale and use of perfusion variables in the 2010 update of the society of thoracic surgeons congenital heart surgery database. World Journal for Pediatric and Congenital Heart Surgery 1(1): 34-43
Strasberg, S.M.; Brunt, L.M. 2010: Rationale and use of the critical view of safety in laparoscopic cholecystectomy. Journal of the American College of Surgeons 211(1): 132-138
Marioni, G. 2013: Rationale behind survivin inhibition as a potential therapeutic strategy in head and neck carcinoma too. Current Oncology Reports 15(1): 1-2
Lenke, L.G.; Kuklo, T.R.; Ondra, S.; Polly, D.W. 2008: Rationale behind the current state-of-the-art treatment of scoliosis (in the pedicle screw era). Spine 33(10): 1051-1054
Kanehira, M.; Finger, W.J.; Ishihata, H.; Hoffmann, M.; Manabe, A.; Shimauchi, H.; Komatsu, M. 2009: Rationale behind the design and comparative evaluation of an all-in-one self-etch model adhesive. Journal of Dentistry 37(6): 432-439
Barder, T.E.; Buchwald, S.L. 2007: Rationale behind the resistance of dialkylbiaryl phosphines toward oxidation by molecular oxygen. Journal of the American Chemical Society 129(16): 5096-5101
Barton, V.; Ward, S.A.; Chadwick, J.; Hill, A.; O'Neill, P.M. 2010: Rationale design of biotinylated antimalarial endoperoxide carbon centered radical prodrugs for applications in proteomics. Journal of Medicinal Chemistry 53(11): 4555-4559
Elsheikh, M.A.; Elnaggar, Y.S.R.; Abdallah, O.Y. 2014: Rationale employment of cell culture versus conventional techniques in pharmaceutical appraisal of nanocarriers. Journal of controlled release: official journal of the Controlled Release Society 194: 92-102
Sanz, I.ña. 2014: Rationale for B cell targeting in SLE. Seminars in Immunopathology 36(3): 365-375
Hancock, W.W. 2011: Rationale for HDAC inhibitor therapy in autoimmunity and transplantation. Handbook of Experimental Pharmacology 206: 103-123
Wanderer, A.A. 2009: Rationale for IL-1beta targeted therapy for ischemia-reperfusion induced pulmonary and other complications in sickle cell disease. Journal of Pediatric Hematology/Oncology 31(8): 537-538
Nonas, C.; Silver, L.D.; Kettel Khan, L.; Leviton, L. 2014: Rationale for new York City's regulations on nutrition, physical activity, and screen time in early child care centers. Preventing Chronic Disease 11: E182
Duffy, P.L.; Naidu, S.S.; Kurian, K.C.; Marshall, J.Jeffrey. 2013: Rationale for ST-elevation myocardial infarction call compensation by healthcare systems. Catheterization and Cardiovascular Interventions: Official Journal of the Society for Cardiac Angiography and Interventions 81(6): 909-911
Alonso-Ramirez, R.; Loisel, S.év.; Buors, C.; Pers, J.-O.; Montero, E.; Youinou, P.; Renaudineau, Y. 2010: Rationale for Targeting CD6 as a Treatment for Autoimmune Diseases. Arthritis 2010: 130646
Greer, T.L.; Ring, K.M.; Warden, D.; Grannemann, B.D.; Church, T.S.; Somoza, E.; Blair, S.N.; Szapocznik, J.; Stoutenberg, M.; Rethorst, C.; Walker, R.; Morris, D.W.; Kosinski, A.S.; Kyle, T.; Marcus, B.; Crowell, B.; Oden, N.; Nunes, E.; Trivedi, M.H. 2012: Rationale for Using Exercise in the Treatment of Stimulant use Disorders. Journal of Global Drug Policy and Practice 6(1)
Park, K.; Harris, M.; Khavari, N.; Khosla, C. 2014: Rationale for Using Social Media to Collect Patient-Reported Outcomes in Patients with Celiac Disease. Journal of Gastrointestinal and Digestive System 4(1)
Cacciatore, M.; Hill, D.A. 2011: Rationale for a 39-week elective delivery policy. American Family Physician 84(12): 1335-1336
Davydenko, L.A. 2010: Rationale for a differential approach to molding a healthy lifestyle in schoolchildren. Gigiena i Sanitariia 1: 80-82
Leclercq, P.; Dohan, D.M. 2007: Rationale for a fixed implant-supported transitional prosthesis in full-arch implant restorations. Revue de Stomatologie et de Chirurgie Maxillo-Faciale 108(6): 530-535
Schachter, M.E.; Bargman, J.M.; Copland, M.; Hladunewich, M.; Tennankore, K.K.; Levin, A.; Oliver, M.; Pauly, R.P.; Perl, J.; Zimmerman, D.; Chan, C.T. 2014: Rationale for a home dialysis virtual ward: design and implementation. Bmc Nephrology 15: 33
Pacagnella, R.C.; Cecatti, J.G.; Camargo, R.P.; Silveira, C.; Zanardi, D.T.; Souza, J.P.; Parpinelli, M.A.; Haddad, S.M. 2010: Rationale for a long-term evaluation of the consequences of potentially life-threatening maternal conditions and maternal "near-miss" incidents using a multidimensional approach. Journal of Obstetrics and Gynaecology Canada: Jogc 32(8): 730-738
Lanza, G.M.; Marsh, J.N.; Hu, G.; Scott, M.J.; Schmieder, A.H.; Caruthers, S.D.; Pan, D.; Wickline, S.A. 2010: Rationale for a nanomedicine approach to thrombolytic therapy. Stroke 41(10 Suppl): S42-S44
Rizzari, C.; Putti, M.C.; Colombini, A.; Casagranda, S.; Ferrari, G.M.; Papayannidis, C.; Iacobucci, I.; Abbenante, M.C.; Sartor, C.; Martinelli, G. 2014: Rationale for a pediatric-inspired approach in the adolescent and young adult population with acute lymphoblastic leukemia, with a focus on asparaginase treatment. Hematology Reports 6(3): 5554
Johnson, B.E.; Jackman, D.; Jänne, P.A. 2007: Rationale for a phase i trial of erlotinib and the mammalian target of rapamycin inhibitor everolimus (RAD001) for patients with relapsed non small cell lung cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 13(15 Part 2): S4628-S4631
Ragni, M.V. 2011: Rationale for a randomized controlled trial comparing two prophylaxis regimens in adults with severe hemophilia A: the Hemophilia Adult Prophylaxis Trial. Expert Review of Hematology 4(5): 495-507
Arques, S. 2009: Rationale for a widespread use of the spectral tissue Doppler-derived E/E' despite its failure to closely predict invasively measured left ventricular diastolic pressures. International Journal of Cardiology 135(1): 139-140
Onik, G. 2008: Rationale for a "male lumpectomy," a prostate cancer targeted approach using cryoablation: results in 21 patients with at least 2 years of follow-up. Cardiovascular and interventional radiology 31(1): 98-106
Hindman, H.B.; Patel, S.B.; Jun, A.S. 2009: Rationale for adjunctive topical corticosteroids in bacterial keratitis. Archives of Ophthalmology 127(1): 97-102
Cohen, J.D. 2011: Rationale for aggressive lipid lowering in high-risk patients. Journal of the American Osteopathic Association 111(4 Suppl 3: Es7
Soeters, P.B. 2009: Rationale for albumin infusions. Current Opinion in Clinical Nutrition and Metabolic Care 12(3): 258-264
Beygui, F.; Vicaut, E.; Ecollan, P.; Machecourt, J.; Van Belle, E.; Zannad, F.; Montalescot, G. 2010: Rationale for an early aldosterone blockade in acute myocardial infarction and design of the ALBATROSS trial. American Heart Journal 160(4): 642-648
Khochikar, M.V. 2011: Rationale for an early detection program for bladder cancer. Indian Journal of Urology: Iju: Journal of the Urological Society of India 27(2): 218-225
Baumgartner, W.A.; Baumgartner, A.M. 2013: Rationale for an experimental treatment of retinitis pigmentosa: 140-month test of hypothesis with one patient. Medical Hypotheses 81(4): 720-728
Allan, L.D. 2012: Rationale for and current status of prenatal cardiac intervention. Early Human Development 88(5): 287-290
Holman, R.R.; Bethel, M.A.; Chan, J.C.N.; Chiasson, J.-L.; Doran, Z.ë; Ge, J.; Gerstein, H.; Huo, Y.; McMurray, J.J.; Ryden, L.; Liyanage, W.; Schröder, S.; Tendera, M.; Theodorakis, M.J.; Tuomilehto, J.; Yang, W.; Hu, D.; Pan, C.; Holman, R.R.; Pan, C.Y.; Hu, D. Y.; Chan, J.; Chiasson, J.-L.; Doran, Z.; Ge, J.; Gerstein, H.; Huo, Y.; Lang, Z.; McMurray, J.; Ryden, L.; Schröder, S.; Tendera, M.; Tuomilehto, J.; Yang, W.; Rouleau, J.; Collier, J.; Pocock, S.; Standl, E.; Swedberg, K.; Weng, J.; Zhao, D.; Wang, D.; Petrie, M.; Connelly, E.; Jhund, P.; MacDonald, M.; Myles, R.; Sattar, N.; Fisher, M.; Petrie, J.; Sun, Y.; Wei, Y.; Xu, W.; Groves, N.; Liyanage, W.; Tang, J.; Theodorakis, M.J.; Bi, J.; Feng, H.; Hu, R.; Liu, P.; Wei, M.; Wei, 2014: Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial. American Heart Journal 168(1): 23-9.E2
Goette, A.; D'Alessandro, A.; Bukowska, A.; Kropf, S.; Mewis, C.; Stellbrink, C.; Tebbenjohanns, J.ür.; Weiss, C.; Lendeckel, U. 2008: Rationale for and design of the CREATIVE-AF trial: randomized, double-blind, placebo-controlled, crossover study of the effect of irbesartan on oxidative stress and adhesion molecules in patients with persistent atrial fibrillation. Clinical Drug Investigation 28(9): 565-572
Irwin, A.L.; Mertz, H.J. 2010: Rationale for and dimensions of impact surfaces for biofidelity tests of different sizes of frontal and side impact dummies. Stapp Car Crash Journal 54: 19-35
Vavken, P. 2011: Rationale for and methods of superiority, noninferiority, or equivalence designs in orthopaedic, controlled trials. Clinical Orthopaedics and Related Research 469(9): 2645-2653
Li, J.; Dabaja, B.; Reed, V.; Allen, P.K.; Cai, H.; Amin, M.V.; Garcia, J.A.; Cox, J.D. 2011: Rationale for and preliminary results of proton beam therapy for mediastinal lymphoma. International Journal of Radiation Oncology Biology Physics 81(1): 167-174
Laupland, K.B.; Schønheyder, H.C.; Kennedy, K.J.; Lyytikäinen, O.; Valiquette, L.; Galbraith, J.; Collignon, P.; Church, D.L.; Gregson, D.B.; Kibsey, P. 2009: Rationale for and protocol of a multi-national population-based bacteremia surveillance collaborative. Bmc Research Notes 2: 146
McKay, R.R.; Choueiri, T.K.; Taplin, M.-E. 2013: Rationale for and review of neoadjuvant therapy prior to radical prostatectomy for patients with high-risk prostate cancer. Drugs 73(13): 1417-1430
Lambers Heerspink, H.J.; Fowler, M.J.; Volgi, J.; Reutens, A.T.; Klein, I.; Herskovits, T.A.; Packham, D.K.; Fraser, I.R.; Schwartz, S.L.; Abaterusso, C.; Lewis, J. 2007: Rationale for and study design of the sulodexide trials in Type 2 diabetic, hypertensive patients with microalbuminuria or overt nephropathy. Diabetic Medicine: a Journal of the British Diabetic Association 24(11): 1290-1295
Dexter, F.; Marco, A.P. 2011: Rationale for anesthesia groups to run additional flexible operating rooms for multiple surgeons who have scheduled more than 8 hours of cases. Anesthesia and Analgesia 113(6): 1295-1297
Kretz-Rommel, A.; Bowdish, K.S. 2008: Rationale for anti-CD200 immunotherapy in B-CLL and other hematologic malignancies: new concepts in blocking immune suppression. Expert Opinion on Biological Therapy 8(1): 5-15
De Paiva, C.S.; Pflugfelder, S.C. 2008: Rationale for anti-inflammatory therapy in dry eye syndrome. Arquivos Brasileiros de Oftalmologia 71(6 Suppl): 89-95
Bogatkevich, G.S.; Nietert, P.J.; Silver, R.M.; Highland, K.B. 2014: Rationale for anticoagulant therapy of pulmonary fibrosis. American Journal of Respiratory and Critical Care Medicine 189(3): 362-363
Rantala, A.; Lumio, J. 2012: Rationale for antimicrobial prophylaxis in surgery and its implementation in Finnish patient care. Duodecim; Laaketieteellinen Aikakauskirja 128(11): 1151-1158
Morena, M.; Martin-Mateo, M.; Cristol, J.P.; Canaud, B. 2001: Rationale for antioxidant supplementation in hemodialysis patients. Saudi Journal of Kidney Diseases and Transplantation: An Official Publication of the Saudi Center for Organ Transplantation Saudi Arabia 12(3): 312-324
Cerullo, F.; Gambassi, G.; Cesari, M. 2012: Rationale for antioxidant supplementation in sarcopenia. Journal of Aging Research 2012: 316943
Jabłoński, M.ła.; Gorzelak, M.ła.; Turzańska, K. 2006: Rationale for bisphosphonate use in patients with endoprosthesis. Ortopedia Traumatologia Rehabilitacja 8(2): 226-231
Goodnough, L.T. 2005: Rationale for blood conservation. Surgical Infections 6(Suppl 1): S3-S8
Richter, J.G.; Gossen, P.; Germing, U.; Blum, S.; Hildebrandt, B.; Braunstein, S.; Huscher, D.ör.; Schneider, M. 2009: Rationale for bone marrow examination in patients with inflammatory rheumatic diseases. Wiener Klinische Wochenschrift 121(21-22): 690-699
Platt, A.B.; Gurubhagavatula, I. 2014: Rationale for broader testing of drivers for obstructive sleep apnea: a response to Hartenbaum and colleagues. Journal of Occupational and Environmental Medicine 56(2): 121-122
Campbell, F.C.; Maxwell, R.J. 2009: Rationale for cancer prevention strategies in high-risk ulcerative colitis. Surgeon: Journal of the Royal Colleges of Surgeons of Edinburgh and Ireland 7(2): 96-100
Maucort-Boulch, D.; Baron, M.-H.; Pommier, P.; Weber, D.C.; Mizoe, J.-E.; Rochat, J.; Boissel, J.-P.; Balosso, J.; Tsujii, H.; Amsallem, E. 2010: Rationale for carbon ion therapy in high-grade glioma based on a review and a meta-analysis of neutron beam trials. Cancer Radiotherapie: Journal de la Societe Francaise de Radiotherapie Oncologique 14(1): 34-41
Iorio, A.; Magrì, D.; Paolillo, S.; Salvioni, E.; Di Lenarda, A.; Sinagra, G.; Agostoni, P.; Sciomer, S. 2013: Rationale for cardiopulmonary exercise test in the assessment of surgical risk. Journal of Cardiovascular Medicine 14(4): 254-261
Nissen, S.E. 2008: Rationale for cardiovascular medicine to separate from internal medicine and become an independent specialty. Current Cardiology Reports 10(6): 431-432
Ordás, I.; Salas, A.; Benítez, D.; Ricart, E.; Panés, J.án. 2010: Rationale for cell therapy in the treatment of inflammatory bowel disease. Gastroenterologia y Hepatologia 33(10): 716-720
O'Brien, C.P. 2012: Rationale for changes in DSM-5. Journal of Studies on Alcohol and Drugs 73(4): 705
Spigel, D.R.; Socinski, M.A. 2013: Rationale for chemotherapy, immunotherapy, and checkpoint blockade in SCLC: beyond traditional treatment approaches. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 8(5): 587-598
Hewing, B.; Fisher, E.A. 2012: Rationale for cholesteryl ester transfer protein inhibition. Current Opinion in Lipidology 23(4): 372-376
Agius, M.; Butler, S. 2012: Rationale for clinical interventions in prodromal psychosis. Are such interventions safe?. Psychiatria Danubina 24(Suppl 1): S28-S35
Spaide, R.F. 2009: Rationale for combination therapy in age-related macular degeneration. Retina 29(6 Suppl): S5-S7
Mascarenhas, J. 2014: Rationale for combination therapy in myelofibrosis. Best Practice and Research. Clinical Haematology 27(2): 197-208
Coleman, R.L.; Kohn, E.C. 2008: Rationale for combination use of targeted agents in ovarian cancer: do we have one?. Cancer 113(4): 665-667
Thom, J.M.; Clare, L. 2011: Rationale for combined exercise and cognition-focused interventions to improve functional independence in people with dementia. Gerontology 57(3): 265-275
Siragy, H.M. 2011: Rationale for combining a direct renin inhibitor with other renin- angiotensin system blockers. Focus on aliskiren and combinations. Cardiovascular Drugs and Therapy 25(1): 87-97
Cohen, D.J.; Hochster, H.S. 2008: Rationale for combining biotherapy in the treatment of advanced colon cancer. Gastrointestinal Cancer Research: Gcr 2(3): 145-151
Azizi, M.; Wuerzner, G.ég. 2007: Rationale for combining blockers of the renin-angiotensin system. Seminars in Nephrology 27(5): 544-554
Francis, P.T.; Parsons, C.G.; Jones, R.W. 2012: Rationale for combining glutamatergic and cholinergic approaches in the symptomatic treatment of Alzheimer's disease. Expert Review of Neurotherapeutics 12(11): 1351-1365
Moore, K. 2010: Rationale for complementary and alternative medicine in nursing school curriculum. Journal of Alternative and Complementary Medicine 16(6): 611-612
Ollila, D.W.; Gleisner, A.L.; Hsueh, E.C. 2011: Rationale for complete metastasectomy in patients with stage IV metastatic melanoma. Journal of Surgical Oncology 104(4): 420-424
Murry, T. 2009: Rationale for compounding commercially available products. American Journal of Veterinary Research 70(11): 1307; Author Reply 1307-8
Loomba, R. 2014: Rationale for conducting a randomized trial to examine the efficacy of metformin in improving survival in cirrhosis: pleiotropic effects hypothesis. Hepatology 60(6): 1818-1822
Morschhauser, F.; Dreyling, M.; Rohatiner, A.; Hagemeister, F.; Bischof Delaloye, A. 2009: Rationale for consolidation to improve progression-free survival in patients with non-Hodgkin's lymphoma: a review of the evidence. Oncologist 14(Suppl 2): 17-29
Ramaraj, R.; Ewy, G.A. 2009: Rationale for continuous chest compression cardiopulmonary resuscitation. Heart 95(24): 1978-1982
Lewis, W.M.; Wurtsbaugh, W.A.; Paerl, H.W. 2011: Rationale for control of anthropogenic nitrogen and phosphorus to reduce eutrophication of inland waters. Environmental Science and Technology 45(24): 10300-10305
Yan, S.-M.; Wu, G. 2009: Rationale for cross-species infection and cross-subtype mutation in hemagglutinins from influenza a virus. Interdisciplinary Sciences Computational Life Sciences 1(4): 303-307
Simpson, B.S.; Coles, A.J. 2007: Rationale for cytotoxic monoclonal antibodies in MS. International Ms Journal 14(2): 48-56
Schapira, A.H.V.; Albrecht, S.; Barone, P.; Comella, C.L.; McDermott, M.P.; Mizuno, Y.; Poewe, W.; Rascol, O.; Marek, K. 2010: Rationale for delayed-start study of pramipexole in Parkinson's disease: the PROUD study. Movement Disorders: Official Journal of the Movement Disorder Society 25(11): 1627-1632
Ramanna, H.; Ding, X.S.; Nelson, R.S. 2013: Rationale for developing new virus vectors to analyze gene function in grasses through virus-induced gene silencing. Methods in Molecular Biology 975: 15-32
Pinigin, M.A.; Popov, B.A.; Sabirova, Z.F.; Budarina, O.V.; Ul'ianova, A.V. 2013: Rationale for differentiated sanitary protection zones for battery recycling enterprises in modern conditions. Gigiena i Sanitariia 6: 90-92
Brovkina, A.F.; Iatsenko, O.I. 2013: Rationale for distinguishing the lipogenic form of thyroid orbitopathy. Vestnik Oftalmologii 129(2): 30-34
Maltais, Fçois.; Dennis, N.; Chan, C.K.N. 2013: Rationale for earlier treatment in COPD: a systematic review of published literature in mild-to-moderate COPD. Copd 10(1): 79-103
Grantham, J.J. 2015: Rationale for early treatment of polycystic kidney disease. Pediatric Nephrology 30(7): 1053-1062
Israel, H.A.; Behrman, D.A.; Friedman, J.M.; Silberstein, J. 2010: Rationale for early versus late intervention with arthroscopy for treatment of inflammatory/degenerative temporomandibular joint disorders. Journal of Oral and Maxillofacial Surgery: Official Journal of the American Association of Oral and Maxillofacial Surgeons 68(11): 2661-2667
Dien Bard, J.; Hindler, J.A.; Gold, H.S.; Limbago, B. 2014: Rationale for eliminating Staphylococcus breakpoints for β-lactam agents other than penicillin, oxacillin or cefoxitin, and ceftaroline. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 58(9): 1287-1296
Richmond, J.C. 1982: Rationale for emittance and reflectivity. Applied Optics 21(1)
Ahmed, M.; Osser, D.N.; Boisvert, C.M.; Albert, L.G.; Aslam, M. 2007: Rationale for emphasis on management over treatment of schizophrenia in clinical practice. Annals of PharmacoTherapy 41(4): 693-695
Trimpou, G.; Weigl, P.; Krebs, M.; Parvini, P.; Nentwig, G.-H. 2010: Rationale for esthetic tissue preservation of a fresh extraction socket by an implant treatment concept simulating a tooth replantation. Dental Traumatology: Official Publication of International Association for Dental Traumatology 26(1): 105-111
Au, W.Y.; Lie, A.K.W.; Liang, R. 2009: Rationale for ethnic-based haematopoietic stem cell transplantation cooperative groups. Hong Kong Medical Journal 15(3 Suppl 3: 7-8
Srinivas, N.R. 2009: Rationale for faster oral delivery to overcome the pathophysiology associated with dental pain--biopharmaceutic and pharmacokinetic challenges. European Journal of Drug Metabolism and Pharmacokinetics 34(1): 7-10
Basile, J.N. 2008: Rationale for fixed-dose combination therapy to reach lower blood pressure goals. Southern Medical Journal 101(9): 918-924
Makari, D.; Checchia, P.A.; Devincenzo, J. 2014: Rationale for full-season dosing for passive antibody prophylaxis of respiratory syncytial virus. Human Vaccines and Immunotherapeutics 10(3): 607-614
Schiffman, S.S. 2012: Rationale for further medical and health research on high-potency sweeteners. Chemical Senses 37(8): 671-679
Díaz de Liaño, A.; Yarnoz, C.ón.; Aguilar, R.én.; Artieda, C.; Ortiz, H.éc. 2008: Rationale for gastrectomy with D2 lymphadenectomy in the treatment of gastric cancer. Gastric Cancer: Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 11(2): 96-102
Piché, N.; Leblond, F.ço.A.; Sidéris, L.; Pichette, V.; Drolet, P.; Fortier, L.-P.; Mitchell, A.; Dubé, P. 2011: Rationale for heating oxaliplatin for the intraperitoneal treatment of peritoneal carcinomatosis: a study of the effect of heat on intraperitoneal oxaliplatin using a murine model. Annals of Surgery 254(1): 138-144
Capodaglio, P.; Lafortuna, C.; Petroni, M.L.; Salvadori, A.; Gondoni, L.; Castelnuovo, G.; Brunani, A. 2013: Rationale for hospital-based rehabilitation in obesity with comorbidities. European Journal of Physical and Rehabilitation Medicine 49(3): 399-417
Rakitskiĭ, V.N.; Sinitskaia, T.A.; Batishchev, I.S. 2011: Rationale for hygienic regulations for the use of a new mixed herbicide antidote. Gigiena i Sanitariia 4: 73-77
Torres, N.; Chabardès, S.; Benabid, A.L. 2011: Rationale for hypothalamus-deep brain stimulation in food intake disorders and obesity. Advances and Technical Standards in Neurosurgery 36: 17-30
Shuman, M.D.; Mcgrane, I.R. 2014: Rationale for iloperidone in the treatment of posttraumatic stress disorder. Innovations in Clinical Neuroscience 11(5-6): 23-25
Stoiukhina, A.S. 2011: Rationale for implant insertion after enucleation of eyes with uveal melanoma. Vestnik Oftalmologii 127(1): 29-32
Nykula, T.D.; Furleta, V.V. 2013: Rationale for improved treatment of ulcerative disease complicated by chronic pyelonephritis. Likars'ka Sprava 4: 71-76
Sørensen, B.; Auerswald, G.ün.; Benson, G.; Elezović, I.; Felder, M.; Lambert, T.; Morfini, M.; Remor, E.; Salaj, P.; Santagostino, E.; Šalek, S.Z.; Ljung, R. 2015: Rationale for individualizing haemophilia care. Blood Coagulation and Fibrinolysis: An International Journal in Haemostasis and Thrombosis 26(8): 849-857
Dimou, A.; Syrigos, K.; Saif, M.W. 2011: Rationale for inhibition of the hedgehog pathway paracrine loop in pancreatic adenocarcinoma. Jop: Journal of the Pancreas 12(1): 1-5
Alekseev, M.V.; Shelygin, I.A.; Revel'skiĭ, I.A.; Rybakov, E.G. 2011: Rationale for intraoperative intrapelvic chemotherapy in combination with hyperthermia in the treatment of rectal cancer. Voprosy Onkologii 57(2): 173-178
Oral, E.A.; Chan, J.L. 2010: Rationale for leptin-replacement therapy for severe lipodystrophy. Endocrine Practice: Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 16(2): 324-333
Heller, A. 2010: Rationale for low-modulus endodontic posts. Dentistry Today 29(4): 66; 68-75
Banica, B.; Ene, P.; Dabu, A.; Ene, R.; Cirstoiu, C. 2013: Rationale for management of frontal sinus fractures. Maedica 8(4): 398-403
Allen, D.J.; Beaulé, P.E. 2008: Rationale for metal-on-metal total hip replacement. Journal of Surgical Orthopaedic Advances 17(1): 6-11
Edgerton, Z.J.; Edgerton, J.R. 2008: Rationale for minimally invasive pulmonary vein isolation and partial autonomic denervation for surgical treatment of atrial fibrillation. Innovations 3(3): 121-124
Givi, B.; Andersen, P.E. 2008: Rationale for modifying neck dissection. Journal of Surgical Oncology 97(8): 674-682
Furlan, V.; Lykavieris, P.; Maubert, M.A.; Habes, D.; Debray, D. 2009: Rationale for monitoring cyclosporine concentration at 2 hours after administration in infants posttransplantation. Transplantation Proceedings 41(8): 3333-3334
Ozer, N.; Schiffer, C.A.; Haliloglu, T. 2010: Rationale for more diverse inhibitors in competition with substrates in HIV-1 protease. Biophysical Journal 99(5): 1650-1659
Erhardt, L.R. 2007: Rationale for multiple risk intervention: the need to move from theory to practice. Vascular Health and Risk Management 3(6): 985-997
Granberg, C.F.; Gettman, M.T. 2010: Rationale for natural orifice transluminal endoscopic surgery and current limitations. Bju International 106(6 Part B): 908-912
Winkler, H. 2009: Rationale for one stage exchange of infected hip replacement using uncemented implants and antibiotic impregnated bone graft. International Journal of Medical Sciences 6(5): 247-252
Ghochikyan, A. 2009: Rationale for peptide and DNA based epitope vaccines for Alzheimer's disease immunotherapy. Cns and Neurological Disorders Drug Targets 8(2): 128-143
Yokogawa, H.; Kobayashi, A.; Saito, Y.; Yamazaki, N.; Masaki, T.; Sugiyama, K. 2012: Rationale for performing penetrating keratoplasty rather than DSAEK in patients with bullous keratopathy in Japan. Ophthalmic Surgery Lasers and Imaging: the Official Journal of the International Society for Imaging in the Eye 43(6): 446-451
Coates, R.J.; Yoon, P.W.; Zaza, S.; Ogden, L.; Thacker, S.B. 2012: Rationale for periodic reporting on the use of adult clinical preventive services of public health priority--United States. Mmwr Supplements 61(2): 3-10
Yeung, L.F.; Shapira, S.K.; Coates, R.J.; Shaw, F.E.; Moore, C.A.; Boyle, C.A.; Thacker, S.B. 2014: Rationale for periodic reporting on the use of selected clinical preventive services to improve the health of infants, children, and adolescents--United States. Mmwr Supplements 63(2): 3-13
Barrasa, A.; Van de Speeten, K.; Anthony Stuart, O.; Hendrick Sugarbaker, P.; Zappa, L. 2009: Rationale for perioperative chemotherapy treatment in peritoneal carcinomatosis. Cirugia Espanola 85(1): 3-13
Bogart, J.A. 2008: Rationale for phase IIi trials of thoracic radiation therapy doses in limited-stage small-cell lung cancer. Clinical Lung Cancer 9(4): 202-205
Nydegger, U.E. 2012: Rationale for plasma exchange turns to innate immunity. Transfusion and Apheresis Science: Official Journal of the World Apheresis Association: Official Journal of the European Society for Haemapheresis 46(1): 79-80
Murai, J.; Zhang, Y.; Morris, J.; Ji, J.; Takeda, S.; Doroshow, J.H.; Pommier, Y. 2014: Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition. Journal of Pharmacology and Experimental Therapeutics 349(3): 408-416
Ouaïssi, M.; Giger, U.; Sielezneff, I.; Pirrò, N.; Sastre, B.; Ouaissi, A. 2011: Rationale for possible targeting of histone deacetylase signaling in cancer diseases with a special reference to pancreatic cancer. Journal of Biomedicine and Biotechnology 2011: 315939
Schultz, M.; Lindström, A.L. 2008: Rationale for probiotic treatment strategies in inflammatory bowel disease. Expert Review of Gastroenterology and Hepatology 2(3): 337-355
Loprinzi, P.D.; Lee, H. 2014: Rationale for promoting physical activity among cancer survivors: literature review and epidemiologic examination. Oncology Nursing Forum 41(2): 117-125
Krzych, L.J.; Szurlej, D.; Bochenek, A. 2009: Rationale for propofol use in cardiac surgery. Journal of Cardiothoracic and Vascular Anesthesia 23(6): 878-885
Jäger, M.; Tillmann, F.P.; Thornhill, T.S.; Mahmoudi, M.; Blondin, D.; Hetzel, G.R.üd.; Zilkens, C.; Krauspe, R.üd. 2008: Rationale for prostaglandin I2 in bone marrow oedema--from theory to application. Arthritis Research and Therapy 10(5): R120
Gauthier, R. 2008: Rationale for providing some AFP content online only. American Family Physician 78(9): 1020; Author Reply 1020
Perry, J.D.; Feldon, S.E. 2009: Rationale for radiotherapy in thyroid eye disease. American Journal of Ophthalmology 148(6): 818-819
Vamvakas, E.C. 2008: Rationale for randomized controlled trials and for intention-to-treat analysis in transfusion medicine: are they one and the same?. Vox Sanguinis 95(3): 165-173
Sullivan, D.R.; Thomas, D.W.; Tognarini, D.P. 2007: Rationale for recommendations for lipid testing and reporting by Australian pathology laboratories. Clinical Biochemist. Reviews 28(2): 46-49
White, N.J.; Qiao, L.G.; Qi, G.; Luzzatto, L. 2012: Rationale for recommending a lower dose of primaquine as a Plasmodium falciparum gametocytocide in populations where G6PD deficiency is common. Malaria Journal 11: 418
Low, S.; Chin, M.C.; Ma, S.; Heng, D.; Deurenberg-Yap, M. 2009: Rationale for redefining obesity in Asians. Annals of the Academy of Medicine Singapore 38(1): 66-69
Leddy, L.R. 2010: Rationale for reduced pressure reaming when stabilizing actual or impending pathological femoral fractures: a review of the literature. Injury 41 Suppl. 2: S48-S50
Alexander, K.; Daley, A.M.; Dempsey, A.F. 2012: Rationale for reducing the spread of human papillomavirus in adolescents: strategies to improve outcomes (CME multimedia activity). Journal of Adolescent Health: Official Publication of the Society for Adolescent Medicine 50(5): Ibc
Miguel, J.é A.M.; Cunha, D.L.; Calheiros, A.d.A.; Koo, D. 2005: Rationale for referring class Ii patients for early orthodontic treatment. Journal of Applied Oral Science: Revista Fob 13(3): 312-317
Truman, B.I.; Smith, K.C.; Roy, K.; Chen, Z.; Moonesinghe, R.; Zhu, J.; Crawford, C.Gotway.; Zaza, S. 2011: Rationale for regular reporting on health disparities and inequalities - United States. Mmwr Supplements 60(1): 3-10
Filsoufi, F.; Chikwe, J.; Carpentier, A. 2015: Rationale for remodelling annuloplasty to address functional tricuspid regurgitation during left-sided valve surgery. European Journal of Cardio-Thoracic Surgery: Official Journal of the European Association for Cardio-Thoracic Surgery 47(1): 1-3
Brolin, R.E.; Asad, M. 2009: Rationale for reversal of failed bariatric operations. Surgery for Obesity and Related Diseases: Official Journal of the American Society for Bariatric Surgery 5(6): 673-676
Weinstein, M.P.; Klugman, K.P.; Jones, R.N. 2009: Rationale for revised penicillin susceptibility breakpoints versus Streptococcus pneumoniae: coping with antimicrobial susceptibility in an era of resistance. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 48(11): 1596-1600
Hutt, M.L.; Shor, J. 1946: Rationale for routine Rorschach testing the limits. Rorschach Research Exchange and Journal of Projective Techniques 10: 70-76
Wigginton, J.G.; Pepe, P.E.; Idris, A.H. 2010: Rationale for routine and immediate administration of intravenous estrogen for all critically ill and injured patients. Critical Care Medicine 38(10 Suppl): S620-S629
Rapoport, Aão.; Ortellado, D.K.; Dedivitis, Rério.A. 2009: Rationale for selective neck dissection in N+ oral cancer. International Surgery 94(4): 339-343
Hamilton, R.J.; Freedland, S.J. 2008: Rationale for statins in the chemoprevention of prostate cancer. Current Urology Reports 9(3): 189-196
Bhattasali, O.; Chen, L.N.; Tong, M.; Lei, S.; Collins, B.T.; Krishnan, P.; Kalhorn, C.; Lynch, J.H.; Suy, S.; Dritschilo, A.; Dawson, N.A.; Collins, S.P. 2013: Rationale for stereotactic body radiation therapy in treating patients with oligometastatic hormone-naïve prostate cancer. Frontiers in Oncology 3: 293
Hariprasad, G. 2008: Rationale for student exposure to pre- and paramedical sciences as part of internship. Medical education 42(6): 645
Morse, R.L.D. 1951: Rationale for studies of consumer food preferences. Advances in Food Research 3: 385-427
Forestier, S. 2008: Rationale for sunscreen development. Journal of the American Academy of Dermatology 58(5 Suppl 2: S133-S138
Lazić, P.; Atodiresei, N.; Caciuc, V.; Brako, R.; Gumhalter, B.; Blügel, S. 2012: Rationale for switching to nonlocal functionals in density functional theory. Journal of Physics. Condensed Matter: An Institute of Physics Journal 24(42): 424215
Clark, P.E. 2010: Rationale for targeted therapies and potential role of pazopanib in advanced renal cell carcinoma. Biologics: Targets and Therapy 4: 187-197
Ballas, M.S.; Chachoua, A. 2011: Rationale for targeting VEGF, FGF, and PDGF for the treatment of NSCLC. Oncotargets and Therapy 4: 43-58
Johnston, N.; Wells, C.W.; Samuels, T.L.; Blumin, J.H. 2010: Rationale for targeting pepsin in the treatment of reflux disease. Annals of Otology Rhinology and Laryngology 119(8): 547-558
Bartalucci, N.ò; Guglielmelli, P.; Vannucchi, A.M. 2013: Rationale for targeting the PI3K/Akt/mTOR pathway in myeloproliferative neoplasms. Clinical Lymphoma Myeloma and Leukemia 13(Suppl 2): S307-S309
Giltnane, J.M.; Balko, J.M. 2014: Rationale for targeting the Ras/MAPK pathway in triple-negative breast cancer. Discovery Medicine 17(95): 275-283
Zielinski, C.; Knapp, S.; Mascaux, C.; Hirsch, F. 2013: Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer. Annals of Oncology: Official Journal of the European Society for Medical Oncology 24(5): 1170-1179
Kerkerian-Le Goff, L.; Jouve, L.; Melon, C.; Salin, P. 2009: Rationale for targeting the thalamic centre-median parafascicular complex in the surgical treatment of Parkinson's disease. Parkinsonism and Related Disorders 15(Suppl 3): S167-S170
Longair, J.A. 1992: Rationale for the CVMA's position on elastrators. Canadian Veterinary Journal 33(10): 628
Mechetina, T.A.; Bystrovskaia, E.V.; Il'chenko, A.A. 2011: Rationale for the allocation of clinical variants of the postcholecystectomical syndrome associated with bacterial overgrowth in the small intestine. Eksperimental'naia i Klinicheskaia Gastroenterologiia 4: 37-43
Makras, P.; Salagianni, M.; Revelos, K.; Anastasilakis, A.D.; Schini, M.; Tsoli, M.; Kaltsas, G.; Andreakos, E. 2015: Rationale for the application of RANKL inhibition in the treatment of Langerhans cell histiocytosis. Journal of Clinical Endocrinology and Metabolism 100(2): E282-E286
Steinglass, J.E.; Sysko, R.; Glasofer, D.; Albano, A.Marie.; Simpson, H.Blair.; Walsh, B.Timothy. 2011: Rationale for the application of exposure and response prevention to the treatment of anorexia nervosa. International Journal of Eating Disorders 44(2): 134-141
Lisianskaia, A.S. 2014: Rationale for the approach to the choice of hormone therapy for ovarian cancer. Voprosy Onkologii 60(3): 274-279
van de Loosdrecht, A.A.; Ireland, R.; Kern, W.; Della Porta, M.G.; Alhan, C.; Balleisen, J.Sebastian.; Bettelheim, P.; Bowen, D.T.; Burbury, K.; Eidenschink, L.; Cazzola, M.; Chu, S.S.C.; Cullen, M.; Cutler, J.A.; Dräger, A.M.; Feuillard, J.; Fenaux, P.; Font, P.; Germing, U.; Haase, D.; Hellström-Lindberg, E.; Johansson, U.; Kordasti, S.; Loken, M.R.; Malcovati, L.; te Marvelde, J.G.; Matarraz, S.; Milne, T.; Moshaver, B.; Mufti, G.J.; Nikolova, V.; Ogata, K.; Oelschlaegel, U.; Orfao, A.; Ossenkoppele, G.J.; Porwit, A.; Platzbecker, U.; Preijers, F.; Psarra, K. 2013: Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group. Leukemia and Lymphoma 54(3): 472-475
Pregliasco, F.; Terracciano, L.; Marcassa, S.; Zava, D.; Anselmi, G. 2009: Rationale for the clinical use of a ribosome-component immune modulator. Allergy and Asthma Proceedings 30(Suppl 1): S5-12
Kobylinski, K.C.; Alout, H.; Foy, B.D.; Clements, A.; Adisakwattana, P.; Swierczewski, B.E.; Richardson, J.H. 2014: Rationale for the coadministration of albendazole and ivermectin to humans for malaria parasite transmission control. American Journal of Tropical Medicine and Hygiene 91(4): 655-662
Kränzlin, N.; Staniuk, M.; Heiligtag, F.J.; Luo, L.; Emerich, H.; van Beek, W.; Niederberger, M.; Koziej, D. 2014: Rationale for the crystallization of titania polymorphs in solution. Nanoscale 6(24): 14716-14723
Langhammer, S. 2013: Rationale for the design of an oncology trial using a generic targeted therapy multi‑drug regimen for NSCLC patients without treatment options (Review). Oncology Reports 30(4): 1535-1541
Kesten, S.; Anderson, J.C.; Tuck, S.A. 2012: Rationale for the development and the mechanism of action of endoscopic thermal vapor ablation (InterVapor) for the treatment of emphysema. Journal of Bronchology and Interventional Pulmonology 19(3): 237-245
Shah, G.D.; Loizos, N.; Youssoufian, H.; Schwartz, J.D.; Rowinsky, E.K. 2010: Rationale for the development of IMC-3G3, a fully human immunoglobulin G subclass 1 monoclonal antibody targeting the platelet-derived growth factor receptor alpha. Cancer 116(4 Suppl): 1018-1026
Aiello, L.P.; Beck, R.W.; Bressler, N.M.; Browning, D.J.; Chalam, K.V.; Davis, M.; Ferris, F.L.; Glassman, A.R.; Maturi, R.K.; Stockdale, C.R.; Topping, T.M. 2011: Rationale for the diabetic retinopathy clinical research network treatment protocol for center-involved diabetic macular edema. Ophthalmology 118(12): E5-14
Feldman, L.S.; Brunt, L.M.; Fuchshuber, P.; Jones, D.B.; Jones, S.B.; Mischna, J.; Munro, M.G.; Rozner, M.A.; Schwaitzberg, S.D.; Jones, D.B.; Feldman, L.S.; Fuchshuber, P.; Brunt, L. M.; Grundfest, W.; Ianitti, D.; Jones, S.B.; Mikami, D.; Munro, M.G.; Portenier, D.; Robinson, T.; Rozner, M.A.; Schwaitzberg, S.; Varela, E.; Voyles, C. R. 2013: Rationale for the fundamental use of surgical Energy™ (FUSE) curriculum assessment: focus on safety. Surgical Endoscopy 27(11): 4054-4059
Hong, S.; Rahman, T.S. 2013: Rationale for the higher reactivity of interfacial sites in methanol decomposition on Au13/TiO2(110). Journal of the American Chemical Society 135(20): 7629-7635
Gańczak, M.; Szych, Z. 2009: Rationale for the implementation of pre-operative testing for HCV in the light of anti-HCV and HBsAG tests results in surgical patients from a teaching hospital. Przeglad Epidemiologiczny 63(3): 387-392
White, R.J.; Hiremath, J. 2010: Rationale for the judicious use of placebos in PAH trials. Journal of Heart and Lung Transplantation: the Official Publication of the International Society for Heart Transplantation 29(7): 826-827
Ravaud, A.; Roca, S.; Quivy, A.; Gross-Goupil, M. 2011: Rationale for the local treatment of metastases. Journal de Radiologie 92(9): 821-824
Bueren-Calabuig, J.A.; Negri, A.; Morreale, A.; Gago, F. 2012: Rationale for the opposite stereochemistry of the major monoadducts and interstrand crosslinks formed by mitomycin C and its decarbamoylated analogue at CpG steps in DNA and the effect of cytosine modification on reactivity. Organic and Biomolecular Chemistry 10(8): 1543-1552
Ribeiro, C.C.C.; de Oliveira Lula, E.C.; da Costa, R.C.N.; Nunes, A.M.M. 2012: Rationale for the partial removal of carious tissue in primary teeth. Pediatric Dentistry 34(1): 39-41
Bourgeois, D.M.; Phantumvanit, P.; Llodra, J.Carlos.; Horn, V.; Carlile, M.; Eiselé, J-Luc. 2014: Rationale for the prevention of oral diseases in primary health care: an international collaborative study in oral health education. International Dental Journal 64 Suppl. 2: 1-11
Zhao, H.; Oczos, J.; Janowski, P.; Trembecka, D.; Dobrucki, J.; Darzynkiewicz, Z.; Wlodkowic, D. 2010: Rationale for the real-time and dynamic cell death assays using propidium iodide. CYTOMETRY. Part A: the Journal of the International Society for Analytical Cytology 77(4): 399-405
Livendahl, M.; Goehry, C.; Maseras, F.; Echavarren, A.M. 2014: Rationale for the sluggish oxidative addition of aryl halides to Au(I). Chemical Communications 50(13): 1533-1536
Coyne, K.S.; Sexton, C.C.; Kopp, Z.S.; Luks, S.; Gross, A.; Irwin, D.; Milsom, I. 2009: Rationale for the study methods and design of the epidemiology of lower urinary tract symptoms (EpiLUTS) study. Bju International 104(3): 348-351
Formby, C.; Scherer, R.; Sierra, B.; Haber-Perez, A.; Sullivan, M.; Packer, M.; Esquivel, C.; Eades, C.; Harper, C.; Simmons, K.; Burkhead, S.; Christensen, N.; Spencer, M.; Jylka, M.; Kantor, S.; Sorensen, M.; Teti, V.; Conley, G.; Downey, N.; Matthews, C.; Snowden, B.; DeChant, J.; Billari, S.; Farrar, A.; Kirby, C.; Ferrell-Pack, A.; Olsson, R.; Ellman, R.; Nicholson, J.; Travis, P.; Hoffer, M.; Goerge, P.; Mouck, P.; Vanides, E.; Skelton, S.; Gold, S.; Erdman, S.; Nix, C.; Tucker, M.; Jensinger, L.; Jones, J.; Lassiter, L.; Toepfner, M.; Broadnax, A.; Ahuja, A.; Hughes, G. 2013: Rationale for the tinnitus retraining therapy trial. Noise and Health 15(63): 134-142
Jovanovic, L. 2010: Rationale for the treatment of mild hyperglycemia during pregnancy. Journal of Diabetes 2(1): 7-8
Borghi, C.; Cicero, A.F.G. 2010: Rationale for the use of a fixed-dose combination in the management of hypertension: efficacy and tolerability of lercanidipine/enalapril. Clinical Drug Investigation 30(12): 843-854
Cetinel, B.ül.; Onal, B. 2013: Rationale for the use of anticholinergic agents in overactive bladder with regard to central nervous system and cardiovascular system side effects. Korean Journal of Urology 54(12): 806-815
Merlin, E.; Kanold, J.; Hannani, D.; Terral, D.; D'Incan, M.; Deméocq, F. 2010: Rationale for the use of extracorporeal photochemotherapy in children. Archives de Pediatrie: Organe Officiel de la Societe Francaise de Pediatrie 17(9): 1327-1337
Gray, S.G.; Dangond, F. 2006: Rationale for the use of histone deacetylase inhibitors as a dual therapeutic modality in multiple sclerosis. Epigenetics 1(2): 67-75
Boiardi, A. 2007: Rationale for the use of liposomal cytarabine in meningeal carcinomatosis. Tumori 93(3): Suppl: 1-3
Dobretsov, K.G.; Afon'kin, V.I.; Sipkin, A.V.; Kolenchukova, O.A. 2009: Rationale for the use of local antibacterial therapy in the postoperative period following rhinosurgical interventions. Vestnik Otorinolaringologii 4: 60-62
Misdrahi, D.; Delgado, A.; Bouju, S.; Comet, D.; Chiariny, J.-F. 2013: Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists. L'Encephale 39(Suppl 1): S8-14
Rahnama'i, M.S.; Van Koeveringe, G.A.; Van Kerrebroeck, P.E. 2013: Rationale for the use of prostaglandins and phosphodiesterase inhibitors in the treatment of functional bladder disorders. Nephro-Urology Monthly 5(5): 949-954
Poo, J.L.; Cervera, E.; de Hoyos, A.; Gil, S.; Cadena, M.; Uribe, M. 1990: Rationale for the use of sodium benzoate in clinical hepatology. Revista de Investigacion Clinica; Organo del Hospital de Enfermedades de la Nutricion 42 Suppl: 101-105
Ho, M.W.; Cassidy, C.; Brown, J.S.; Shaw, R.J.; Bekiroglu, F.; Rogers, S.N. 2014: Rationale for the use of the implantable Doppler probe based on 7 years' experience. British Journal of Oral and Maxillofacial Surgery 52(6): 530-534
Antzelevitch, C.; Yan, G.-X.; Viskin, S. 2011: Rationale for the use of the terms J-wave syndromes and early repolarization. Journal of the American College of Cardiology 57(15): 1587-1590
Tallet, A.V.; Azria, D.; Le Rhun, E.; Barlesi, F.; Carpentier, A.F.; Gonçalves, A.; Taillibert, S.; Dhermain, F.éd.ér.; Spano, J.-P.; Metellus, P. 2014: Rationale for the use of upfront whole brain irradiation in patients with brain metastases from breast cancer. International Journal of Molecular Sciences 15(5): 8138-8152
McMahon, C. 1981: Rationale for the use of vibration in management of tactile defensive patients. Australian Journal of PhysioTherapy 27(3): 75-79
Maraganore, D.M. 2011: Rationale for therapeutic silencing of alpha-synuclein in Parkinson's disease. Journal of Movement Disorders 4(1): 1-7
Colwell, C.W. 2007: Rationale for thromboprophylaxis in lower joint arthroplasty. American Journal of Orthopedics 36(9 Suppl): 11-13
DE Vico, G.; Bonino, M.; Spinelli, D.; Schiavetti, R.; Sannino, G.; Pozzi, A.; Ottria, L. 2011: Rationale for tilted implants: FEA considerations and clinical reports. Oral and Implantology 4(3-4): 23-33
Lehmann-Horn, F.; Weber, M.-A.é; Nagel, A.M.; Meinck, H.-M.; Breitenbach, S.; Scharrer, J.; Jurkat-Rott, K. 2012: Rationale for treating oedema in Duchenne muscular dystrophy with eplerenone. Acta Myologica: Myopathies and Cardiomyopathies: Official Journal of the Mediterranean Society of Myology 31(1): 31-39
Le Dantec, C.; Alonso, R.; Fali, T.; Montero, E.; Devauchelle, V.ér.; Saraux, A.; Pers, J.-O.; Renaudineau, Y. 2013: Rationale for treating primary Sjögren's syndrome patients with an anti-CD6 monoclonal antibody (Itolizumab). Immunologic Research 56(2-3): 341-347
Lawson, M.F.; Neal, D.W.; Mocco, J.; Hoh, B.L. 2013: Rationale for treating unruptured intracranial aneurysms: actuarial analysis of natural history risk versus treatment risk for coiling or clipping based on 14,050 patients in the Nationwide Inpatient Sample database. World Neurosurgery 79(3-4): 472-478
Farina, G.; Longo, F.; Martelli, O.; Pavese, I.; Mancuso, A.; Moscetti, L.; Labianca, R.; Bertolini, A.; Cortesi, E.; Farris, A.; Fagnani, D.; Locatelli, M.C.; Valmadre, G.; Ardizzoia, A.; Tomirotti, M.; Rulli, E.; Garassino, M.C.; Scanni, A. 2011: Rationale for treatment and study design of tailor: a randomized phase IIi trial of second-line erlotinib versus docetaxel in the treatment of patients affected by advanced non-small-cell lung cancer with the absence of epidermal growth factor receptor mutations. Clinical Lung Cancer 12(2): 138-141
Stewart, P.M.; Petersenn, S. 2009: Rationale for treatment and therapeutic options in Cushing's disease. Best Practice and Research. Clinical Endocrinology and Metabolism 23(Suppl 1): S15-S22
Pearson, S.-A.; Chin, M.; Faedo, M.; Ward, R. 2010: Rationale for treatment durations of targeted cancer agents. LANCET. Oncology 11(12): 1113-1115
Göke, F.; Franzen, A.; Menon, R.; Goltz, D.; Kirsten, R.; Boehm, D.; Vogel, W.; Göke, A.; Scheble, V.; Ellinger, J.; Gerigk, U.; Fend, F.; Wagner, P.; Schroeck, A.; Perner, S. 2012: Rationale for treatment of metastatic squamous cell carcinoma of the lung using fibroblast growth factor receptor inhibitors. Chest 142(4): 1020-1026
Volpe, M.; Tocci, G. 2012: Rationale for triple fixed-dose combination therapy with an angiotensin Ii receptor blocker, a calcium channel blocker, and a thiazide diuretic. Vascular Health and Risk Management 8: 371-380
Gradman, A.H. 2010: Rationale for triple-combination therapy for management of high blood pressure. Journal of Clinical Hypertension 12(11): 869-878
Dibao-Dina, C.; Caille, Aès.; Sautenet, Bénédicte.; Chazelle, E.; Giraudeau, B. 2014: Rationale for unequal randomization in clinical trials is rarely reported: a systematic review. Journal of Clinical Epidemiology 67(10): 1070-1075
Hee, H.T.; Kundnani, V. 2010: Rationale for use of polyetheretherketone polymer interbody cage device in cervical spine surgery. Spine Journal: Official Journal of the North American Spine Society 10(1): 66-69
Ilic, D. 2010: Rationale for using OSCEs to assess student competency in evidence-based medicine. Education for Health 23(2): 434
Wéclawiak, H.; Kamar, N.; Ould-Mohamed, A.; Cardeau-Desangles, I.; Rostaing, L. 2010: Rationale for using belatacept in combination with sirolimus. Transplantation Proceedings 42(9 Suppl): S29-S31
Hoare, B. 2014: Rationale for using botulinum toxin a as an adjunct to upper limb rehabilitation in children with cerebral palsy. Journal of Child Neurology 29(8): 1066-1076
Kurilovich, S.A.; Kruchinina, M.V.; Gromov, A.A.; Generalov, V.M.; Bakirov, T.S.; Rikhter, T.C.; Semenov, D.V. 2010: Rationale for using essential phospholipids in chronic diseases of the liver: the dynamics of electric and viscoelastic parameters of erythrocytes. Eksperimental'naia i Klinicheskaia Gastroenterologiia 11: 46-52
Cembrowski, G.S.; Smith, B.; Tung, D. 2010: Rationale for using insensitive quality control rules for today's hematology analyzers. International Journal of Laboratory Hematology 32(6 Part 2): 606-615
Yuen, A.W.C.; Sander, J.W. 2014: Rationale for using intermittent calorie restriction as a dietary treatment for drug resistant epilepsy. Epilepsy and Behavior: E&b 33: 110-114
Wimalawansa, S.J. 2007: Rationale for using nitric oxide donor therapy for prevention of bone loss and treatment of osteoporosis in humans. Annals of the new York Academy of Sciences 1117: 283-297
Udagawa, H.; Ueno, M.; Kinoshita, Y. 2009: Rationale for video-assisted radical esophagectomy. General Thoracic and Cardiovascular Surgery 57(3): 127-131
Harjo, L.D.; Burhansstipanov, L.; Lindstrom, D. 2014: Rationale for "cultural" native patient navigators in Indian country. Journal of Cancer Education: the Official Journal of the American Association for Cancer Education 29(3): 414-419
Jenkins, M.A.; Southey, M.C.; Giles, G.G.; Hopper, J.L. 2007: Rationale for, and approach to, studying modifiers of risk in persons with a genetic predisposition to colorectal cancer. Current Oncology Reports 9(3): 202-207
Agréus, L.; Kuipers, E.J.; Kupcinskas, L.; Malfertheiner, P.; Di Mario, F.; Leja, M.; Mahachai, V.; Yaron, N.; van Oijen, M.; Perez Perez, G.; Rugge, M.; Ronkainen, J.; Salaspuro, M.; Sipponen, P.; Sugano, K.; Sung, J. 2012: Rationale in diagnosis and screening of atrophic gastritis with stomach-specific plasma biomarkers. Scandinavian Journal of Gastroenterology 47(2): 136-147
Heidbreder, C. 2013: Rationale in support of the use of selective dopamine D₃ receptor antagonists for the pharmacotherapeutic management of substance use disorders. Naunyn-Schmiedeberg's Archives of Pharmacology 386(2): 167-176
Vidyadhara, S. 2014: Rationale in the management of 4-level lumbar spondylolyses with or without instability and/or spondylolisthesis. Spine 39(12): E734-E738
De Vries, J.P.P.M.; Van De Pavoordt, H.D.W.M.; Jordan, W.D. 2014: Rationale of EndoAnchors in abdominal aortic aneurysms with short or angulated necks. Journal of Cardiovascular Surgery 55(1): 103-107
Shimizu, K. 2012: Rationale of Miyamoto's technique for reconstruction of tracheal carina. General Thoracic and Cardiovascular Surgery 60(2): 71-72
Martin, W.B.; Laufman, H.; Tuell, S.W. 1949: Rationale of Therapy in Acute Vascular Occlusions Based upon Micrometric Observations. Annals of Surgery 129(4): 476-493
Pircher, A.; Ploner, F.; Popper, H.; Hilbe, W. 2010: Rationale of a relaunch of gefitinib in Caucasian non-small cell lung cancer patients. Lung Cancer 69(3): 265-271
Rai, S.; Jain, S.; Prasad, K.N.; Ghoshal, U.; Dhole, T.N. 2012: Rationale of azithromycin prescribing practices for enteric fever in India. Indian Journal of Medical Microbiology 30(1): 30-33
Huang, Z.; Moseley, H.; Bown, S. 2010: Rationale of combined PDT and SDT modalities for treating cancer patients in terminal stage: the proper use of photosensitizer. Integrative Cancer Therapies 9(4): 317-319; Discussion: 320-321
Tusman, G.; Sipmann, F.S.; Bohm, S.H. 2012: Rationale of dead space measurement by volumetric capnography. Anesthesia and Analgesia 114(4): 866-874
Eberle, W.R. 1946: Rationale of denture retention. Dental Digest 52: 315-322
Andacoglu, O.; Kanbour-Shakir, A.; Teh, Y-Ching.; Bonaventura, M.; Ozbek, U.; Anello, M.; Ganott, M.; Kelley, J.; Dirican, A.; Soran, A. 2013: Rationale of excisional biopsy after the diagnosis of benign radial scar on core biopsy: a single institutional outcome analysis. American Journal of Clinical Oncology 36(1): 7-11
Ronco, C.; Piccinni, P.; Kellum, J. 2010: Rationale of extracorporeal removal of endotoxin in sepsis: theory, timing and technique. Contributions to Nephrology 167: 25-34
De Wilde, R.L.; Brosens, I. 2012: Rationale of first-line endoscopy-based fertility exploration using transvaginal hydrolaparoscopy and minihysteroscopy. Human Reproduction 27(8): 2247-2253
Warheit, D.B.; Donner, E.Maria. 2010: Rationale of genotoxicity testing of nanomaterials: regulatory requirements and appropriateness of available OECD test guidelines. Nanotoxicology 4: 409-413
Loewe, L. 1947: Rationale of heparin in the treatment of thromboembolic disease. Interne 13(12): 543-546
Fleig, S.V.; Humphreys, B.D. 2014: Rationale of mesenchymal stem cell therapy in kidney injury. NEPHRON. Clinical Practice 127(1-4): 75-80
Wang, P.-H.; Chao, H.-T.; Lee, W.-L. 2007: Rationale of myomectomy for perimenopausal women. Maturitas 58(4): 406-407
Masaki, T.; Ohkura, Y.; Matsuoka, H.; Kobayashi, T.; Miyano, S.; Abe, N.; Sugiyama, M.; Atomi, Y. 2010: Rationale of pelvic autonomic nerve preservation in rectal cancer surgery based on immunohistochemical study. International Journal of Clinical Oncology 15(5): 462-467
Di Benedetto, P.; Coidessa, A.; Floris, S. 2008: Rationale of pelvic floor muscles training in women with urinary incontinence. Minerva Ginecologica 60(6): 529-541
Chen, K.; Man, K.; Metselaar, H.J.; Janssen, H.L.A.; Peppelenbosch, M.P.; Pan, Q. 2014: Rationale of personalized immunosuppressive medication for hepatocellular carcinoma patients after liver transplantation. Liver Transplantation: Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 20(3): 261-269
Tourtier, J.-P.; Galinou, N.ém.; Rivet, C.; Lefort, H.; Domanski, L. 2014: Rationale of plasma-to-RBC ratios. Critical Care Medicine 42(3): E245
Piechota, M.; Barylski, M.; Hannam, S.; Piechota-Urbańska, M.; Banach, M. 2013: Rationale of statin therapy in septic patients. Current Vascular Pharmacology 11(5): 795-800
Van den Berg, S.W.; Gielissen, M.F.M.; Ottevanger, P.B.; Prins, J.B. 2012: Rationale of the BREAst cancer e-healTH [BREATH] multicentre randomised controlled trial: an internet-based self-management intervention to foster adjustment after curative breast cancer by decreasing distress and increasing empowerment. Bmc Cancer 12: 394
Battaglia, E.; Fulgenzi, A.; Ferrero, M.Elena. 2009: Rationale of the combined use of inspiratory and expiratory devices in improving maximal inspiratory pressure and maximal expiratory pressure of patients with chronic obstructive pulmonary disease. Archives of Physical Medicine and Rehabilitation 90(6): 913-918
Kahn, A.J. 1947: Rationale of the medical treatment of essential hypertension. Journal. Bowman Gray School of Medicine 5(2): 37-44
Ristagno, G.; Gullo, A. 2008: Rationale of the use of vasopressor agents for cardiopulmonary resuscitation. Is epinephrine the correct first choice? Maybe not. American journal of emergency medicine 26(3): 368-70; author reply 370
Laufman, H.; Martin, W.B.; Tuell, S.W. 1949: Rationale of therapy in acute vascular occlusions based on micrometric observations. American Journal of Medicine 6(5): 670
Maxwell, M.M.; Schork, C.J.; Heidt, E. 1946: Rationale of treatment in maxillofacial injuries with report of four cases. Journal of Oral Surgery 4: 269-303
Hasa, D.; Perissutti, B.; Dall'Acqua, S.; Chierotti, M.R.; Gobetto, R.; Grabnar, I.; Cepek, C.; Voinovich, D. 2013: Rationale of using Vinca minor Linne dry extract phytocomplex as a vincamine's oral bioavailability enhancer. European Journal of Pharmaceutics and Biopharmaceutics: Official Journal of Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik E.V 84(1): 138-144
Geyer, M.; Müller-Ladner, U. 2010: Rationale of using different biological therapies in rheumatoid arthritis. Arthritis Research and Therapy 12(4): 214
Goldhaber, S.Z. 2013: Rationale supporting an "opt-out" policy for pharmacological venous thromboembolism prophylaxis in hospitalized medical patients. Journal of Thrombosis and Thrombolysis 35(3): 371-374
Scheen, A.J.; Paquot, N. 2013: Rationale supporting basal insulin-incretin combined therapies in type 2 diabetes. Revue Medicale de Liege 68(11): 562-568
Appel, W. 1949: Rationale therapy of allergic disease. Journal - Michigan State Medical Society 48(8): 1029-1031
Unger, J. 2013: Rationale use of GLP-1 receptor agonists in patients with type 1 diabetes. Current Diabetes Reports 13(5): 663-668
Oono, H. 2011: Rationale use of oral antibiotics for elderly patients. Nihon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics 48(5): 451-456
Nadeem, M.; Ather, M.H.; Jamshaid, A.; Zaigham, S.; Mirza, R.; Salam, B. 2012: Rationale use of unenhanced multi-detector CT (CT KUB) in evaluation of suspected renal colic. International Journal of Surgery 10(10): 634-637
Sulaiman, K.J.; Panduranga, P.; Al-Zakwani, I.; Alsheikh-Ali, A.; Al-Habib, K.; Al-Suwaidi, J.; Al-Mahmeed, W.; Al-Faleh, H.; El-Asfar, A.; Al-Motarreb, A.; Ridha, M.; Bulbanat, B.; Al-Jarallah, M.; Bazargani, N.; Asaad, N.; Amin, H. 2014: Rationale, Design, Methodology and Hospital Characteristics of the first Gulf Acute Heart Failure Registry (Gulf CARE). Heart Views: the Official Journal of the Gulf Heart Association 15(1): 6-12
Ong, M.Eng.Hock.; Shin, S.Do.; Tanaka, H.; Ma, M.Huei-Ming.; Nishiuchi, T.; Lee, E.Jung.; Ko, P.Chow-In.; Edwin Doctor, N.; Khruekarnchana, P.; Naroo, G.Yasin.; Wong, K.Darin.; Nakagawa, T.; Ryoo, H.Wook.; Lin, C-Hao.; Goh, E-Shaun.; Khunkhlai, N.; Alsakaf, O.Ahmed.; Hisamuddin, N.A.B.Rahman.Nik.; Bobrow, B.J.; McNally, B.; Assam, P.Nkouibert.; Chan, E.S.Y. 2015: Rationale, Methodology, and Implementation of a Dispatcher-assisted Cardiopulmonary Resuscitation Trial in the Asia-Pacific (Pan-Asian Resuscitation Outcomes Study Phase 2). Prehospital Emergency Care: Official Journal of the National Association of Ems Physicians and the National Association of State Ems Directors 19(1): 87-95
Eick, S.; Loudermilk, B.; Walberg, E.; Wente, M.N. 2013: Rationale, bench testing and in vivo evaluation of a novel 5 mm laparoscopic vessel sealing device with homogeneous pressure distribution in long instrument jaws. Annals of Surgical Innovation and Research 7(1): 15
Reddy, K.R.; Belle, S.H.; Fried, M.W.; Afdhal, N.; Navarro, V.J.; Hawke, R.L.; Wahed, A.S.; Doo, E.; Meyers, C.M.; Afdhal, N.; Colagreco, J.; Thomas, N.P.; Gupta, D.; Miller, C.; Navarro, V.; Verma, M.; Borg, E.; Davis, P.; Fried, M.; Hawke, R.; Howell, M.; Soule, T.; Kaplan, D.E.; Kennedy, C.; Micheli, A.; Reddy, K. R.; Wirjosemito, A.; Belle, S.; Bowen, J.; Kurs-Lasky, M.; Lawlor, S.; Wahed, A.; Zadorozny, E.; Duffy, L.; Meyers, C.; Doo, E.; Hoofnagle, J.; Seeff, L.; D'Amato, M.; Rovati, L. 2012: Rationale, challenges, and participants in a Phase Ii trial of a botanical product for chronic hepatitis C. Clinical Trials 9(1): 102-112
Ritter, M. 2008: Rationale, conduct, and outcome using hypofractionated radiotherapy in prostate cancer. Seminars in Radiation Oncology 18(4): 249-256
Shanker, J.; Maitra, A.; Rao, V.S.; Mundkur, L.; Dhanalakshmi, B.; Hebbagodi, S.; Kakkar, V.V. 2010: Rationale, design and preliminary findings of the Indian Atherosclerosis Research Study. Indian Heart Journal 62(4): 286-295
Ridderstråle, M.; Svaerd, R.; Zeller, C.; Kim, G.; Woerle, H.J.; Broedl, U.C. 2013: Rationale, design and baseline characteristics of a 4-year (208-week) phase IIi trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control. Cardiovascular Diabetology 12: 129
Sakamoto, T.; Ogawa, H.; Nakao, K.; Koide, S.; Yamamoto, N.; Shimomura, H.; Matsumura, T.; Oshima, S.; Kikuta, K.; Oka, H.; Kimura, K.; Matsui, K.; Ogawa, H.; Sakamoto, T.; Kojima, S.; Sumiyoshi, T.; Daida, H.; Miyazaki, S-ichi.; Murohara, T.; Yoshimura, M.; Fujita, M.; Yoshiyama, M.; Holmes, D.R.; Matsui, K.; Sakamoto, T. 2013: Rationale, design and baseline characteristics of a study to evaluate effects of candesartan on cardiovascular events after drug-eluting stent implantation in patients with ischemic heart disease. Journal of Atherosclerosis and Thrombosis 20(5): 472-480
Ansley, D.M.; Raedschelders, K.; Chen, D.D.Y.; Choi, P.T. 2009: Rationale, design and baseline characteristics of the PRO-TECT Ii study: PROpofol CardioproTECTion for Type Ii diabetics: a randomized, controlled trial of high-dose propofol versus isoflurane preconditioning in patients undergoing on-pump coronary artery bypass graft surgery. Contemporary Clinical Trials 30(4): 380-385
Yates, T.; Davies, M.; Gorely, T.; Bull, F.; Khunti, K. 2008: Rationale, design and baseline data from the Pre-diabetes Risk Education and Physical Activity Recommendation and Encouragement (PREPARE) programme study: a randomized controlled trial. Patient Education and Counseling 73(2): 264-271
Hilderson, D.; Westhovens, R.; Wouters, C.; Van der Elst, K.; Goossens, E.; Moons, P. 2013: Rationale, design and baseline data of a mixed methods study examining the clinical impact of a brief transition programme for young people with juvenile idiopathic arthritis: the DON'T RETARD project. Bmj Open 3(12): E003591
Kostapanos, M.S.; Tsimihodimos, V.; Elisaf, M.S.; Tzouvelekis, E.; Nikas, N. 2014: Rationale, design and baseline patient characteristics of the optimal type 2 diabetes management including benchmarking and standard treatment study in Greece. World Journal of Diabetes 5(1): 76-83
Lv, Y.; Zou, Y.; Liu, J.; Chen, K.; Huang, D.; Shen, Y.; Zhong, Y.; Liu, Z.; Jiang, B.; Li, Q.; Qing, L.; Zhang, W.; Chen, L.; Wang, F.; Xia, B.; Yang, L.; Yang, X. 2014: Rationale, design and baseline results of the Guangxi manganese-exposed workers healthy cohort (GXMEWHC) study. Bmj Open 4(7): E005070
Loguidice, V.; Bini, W.; Shabat, S.; Miller, L.E.; Block, J.E. 2011: Rationale, design and clinical performance of the Superion® Interspinous Spacer: a minimally invasive implant for treatment of lumbar spinal stenosis. Expert Review of Medical Devices 8(4): 419-426
Miller, L.E.; Ramp, W.K.; Steele, C.R.; Nickols-Richardson, S.M.; Herbert, W.G. 2013: Rationale, design and clinical performance of the mechanical response tissue analyser: a non-invasive technology for measurement of long bone bending stiffness. Journal of Medical Engineering and Technology 37(2): 144-149
Peters-Klimm, F.; Müller-Tasch, T.; Schellberg, D.; Gensichen, J.; Muth, C.; Herzog, W.; Szecsenyi, J. 2007: Rationale, design and conduct of a randomised controlled trial evaluating a primary care-based complex intervention to improve the quality of life of heart failure patients: HICMan (Heidelberg Integrated Case Management). Bmc Cardiovascular Disorders 7: 25
Young, T. 2009: Rationale, design and findings from the Wisconsin Sleep Cohort Study: Toward understanding the total societal burden of sleep disordered breathing. Sleep Medicine Clinics 4(1): 37-46
Uva, M.S.; Matias, F.; Cavaco, S.; Magalhães, M.P. 2008: Rationale, design and methodology for a Prospective Randomized Study of graft patency in Off-pump and On-pump MultI-vessel coronary artery bypasS Surgery (PROMISS) using multidetector computed tomography. Trials 9: 44
Hansen, B.Hedegaard.; Hanash, J.Abed.; Rasmussen, A.; Hansen, Jørgen.Fischer.; Birket-Smith, M. 2009: Rationale, design and methodology of a double-blind, randomized, placebo-controlled study of escitalopram in prevention of Depression in Acute Coronary Syndrome (DECARD). Trials 10: 20
James, A.; Hunter, M.; Straker, L.; Beilby, J.; Bucks, R.; Davis, T.; Eikelboom, R.H.; Hillman, D.; Hui, J.; Hung, J.; Knuiman, M.; Mackey, D.A.; Newton, R.U.; Palmer, L.J.; Musk, A.B. 2013: Rationale, design and methods for a community-based study of clustering and cumulative effects of chronic disease processes and their effects on ageing: the Busselton healthy ageing study. Bmc Public Health 13: 936
Piek, J.P.; Straker, L.M.; Jensen, L.; Dender, A.; Barrett, N.C.; McLaren, S.; Roberts, C.; Reid, C.; Rooney, R.; Packer, T.; Bradbury, G.; Elsley, S. 2010: Rationale, design and methods for a randomised and controlled trial to evaluate "Animal Fun"--a program designed to enhance physical and mental health in young children. Bmc Pediatrics 10: 78
Straker, L.M.; Abbott, R.A.; Piek, J.P.; Pollock, C.M.; Davies, P.S.; Smith, A.J. 2009: Rationale, design and methods for a randomised and controlled trial to investigate whether home access to electronic games decreases children's physical activity. Bmc Public Health 9: 212
Straker, L.M.; Smith, K.L.; Fenner, A.A.; Kerr, D.A.; McManus, A.; Davis, M.C.; Fielding, A.M.; Olds, T.S.; Hagger, M.S.; Smith, A.J.; Abbott, R.A. 2012: Rationale, design and methods for a staggered-entry, waitlist controlled clinical trial of the impact of a community-based, family-centred, multidisciplinary program focussed on activity, food and attitude habits (Curtin University's Activity, Food and Attitudes Program--CAFAP) among overweight adolescents. Bmc Public Health 12: 471
Behre, H.M.; Heinemann, L.; Morales, A.; Pexman-Fieth, C. 2008: Rationale, design and methods of the ESPRIT study: Energy, Sexual desire and body PropoRtions wIth AndroGel, Testosterone 1% gel therapy, in hypogonadal men. Aging Male: the Official Journal of the International Society for the Study of the Aging Male 11(2): 101-106
Bishop, A.; Wynne-Jones, G.; Lawton, S.A.; van der Windt, D.; Main, C.; Sowden, G.; Burton, A.K.; Lewis, M.; Jowett, S.; Sanders, T.; Hay, E.M.; Foster, N.E. 2014: Rationale, design and methods of the Study of Work and Pain (SWAP): a cluster randomised controlled trial testing the addition of a vocational advice service to best current primary care for patients with musculoskeletal pain (ISRCTN 52269669). Bmc Musculoskeletal Disorders 15: 232
de la Poza Abad, M.; Mas Dalmau, G.; Moreno Bakedano, M.; González González, A.Isabel.; Canellas Criado, Y.; Hernández Anadón, S.; Rotaeche del Campo, R.; Torán Monserrat, P.; Negrete Palma, A.; Pera, G.; Borrell Thió, Eàlia.; Llor, C.; Little, P.; Alonso Coello, P.; Alonso-Coello, P.; Zapata, Jé.Martínez.; Urrutia Cuchí, G.; Villamar, L.Martínez.; Gich, I.; Dalmau, G.Mas.; De la Poza Abad, M.; Navarro, M.Liroz.; Thió, Eàlia.Borrell.; Aguilera, Núria.Barrera.; Perona, M.Coll.; Libre Saló, A.; Gómez, M.Cañibano.; Pujante, S.Sierra.; Castellà, M.Besa.; Baquero, M.Miguel.; Casalduero, M.Alsina.; Ri 2013: Rationale, design and organization of the delayed antibiotic prescription (DAP) trial: a randomized controlled trial of the efficacy and safety of delayed antibiotic prescribing strategies in the non-complicated acute respiratory tract infections in general practice. Bmc Family Practice 14: 63
Hennerici, M.G.; Bots, M.L.; Ford, I.; Laurent, Séphane.; Touboul, P.Jean. 2010: Rationale, design and population baseline characteristics of the PERFORM vascular project: an ancillary study of the Prevention of cerebrovascular and cardiovascular Events of ischemic origin with te Rutroban in patients with a history oF ischemic str Oke or tRansient ische Mic attack (PERFORM) trial. Cardiovascular Drugs and Therapy 24(2): 175-180
Whellan, D.J.; O'Connor, C.M.; Ousdigian, K.T.; Lung, T-Hsin.; Whellan, D.J.; Kloosterman, E.Martin.; O'Connor, C.M.; Donahue, M.; Greenspon, A.J.; Smith, A.L.; Ahmad, S.; Teegala, S.; Al-Khatib, S.; West, V.; Alsheikh, T.; Lane, B.; Arshad, A.; Sayles, K.; Atiga, W.; Overbeck, D.; Banish, D.; Nicely, V.; Bissett, J.; Shuler, S.; Blaber, R.; Enochs, K.; Breuer, G.; Terry, P.; Brownstein, S.; Hausfeld, A.; Buetikofer, J.; Chase, M.; Burkett, S.; Powell, C.; Castle, L.; Kovach, C.; Chandler, A.Bleakley.; Easler, P.; Chandra, R.; Murphy, T.; Chaskes, M.;, 2008: Rationale, design, and baseline characteristics of a Program to Assess and Review Trending INformation and Evaluate CorRelation to Symptoms in Patients with Heart Failure (PARTNERS HF). American Heart Journal 156(5): 833-9 839.E2
Mita, T.; Katakami, N.; Shiraiwa, T.; Yoshii, H.; Onuma, T.; Kuribayashi, N.; Osonoi, T.; Kaneto, H.; Kosugi, K.; Umayahara, Y.; Yamamoto, T.; Matsumoto, K.; Yokoyama, H.; Tsugawa, M.; Gosho, M.; Shimomura, I.; Watada, H. 2014: Rationale, design, and baseline characteristics of a clinical trial for prevention of atherosclerosis in patients with insulin-treated type 2 diabetes mellitus using DPP-4 inhibitor: the Sitagliptin Preventive study of Intima-media thickness Evaluation (SPIKE). Diabetology and Metabolic Syndrome 6(1): 35
Ackermann, R.T.; Finch, E.A.; Schmidt, K.K.; Hoen, H.M.; Hays, L.M.; Marrero, D.G.; Saha, C. 2014: Rationale, design, and baseline characteristics of a community-based comparative effectiveness trial to prevent type 2 diabetes in economically disadvantaged adults: the RAPID Study. Contemporary Clinical Trials 37(1): 1-9
Zinman, B.; Inzucchi, S.E.; Lachin, J.M.; Wanner, C.; Ferrari, R.; Fitchett, D.; Bluhmki, E.; Hantel, S.; Kempthorne-Rawson, J.; Newman, J.; Johansen, O.E.; Woerle, H.-J.; Broedl, U.C. 2014: Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™). Cardiovascular Diabetology 13: 102
Katakami, N.; Mita, T.; Yoshii, H.; Onuma, T.; Kaneto, H.; Osonoi, T.; Shiraiwa, T.; Kosugi, K.; Umayahara, Y.; Yamamoto, T.; Yokoyama, H.; Kuribayashi, N.; Jinnouchi, H.; Gosho, M.; Watada, H.; Shimomura, I.; Jinnouchi, H.; Yokoyama, H.; Abe, S.; Ishida, K.; Onuma, T.; Yamashiro, K.; Yoshii, H.; Abe, H.; Fujitani, Y.; Goto, H.; Hirose, T.; Ikeda, F.; Kanazawa, A.; Kawaguchi, M.; Komiya, K.; Mita, T.; Ogihara, T.; Ohmura, C.; Sakurai, Y.; Sato, F.; Shimizu, T.; Tamaki, M.; Hayashi, I.; Yamamoto, T.; Yamamoto, Y.; Kuribayashi, N.; Osonoi, T.; Saito, M.; Tamazawa, A.; Hatazaki, M.; Kataoka, R.; Umayahara, Y.; Kosugi, K.; Sakamoto, K.; Yoshiuchi, K 2013: Rationale, design, and baseline characteristics of a trial for the prevention of diabetic atherosclerosis using a DPP-4 inhibitor: the Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A). Journal of Atherosclerosis and Thrombosis 20(12): 893-902
Costa, E.; Reis, Hélder.; de Assis, G.M.C.C.; Cardoso, G.L.; Barbosa, Márcio.M.; de Aguiar Filho, F.A.A.; Gama, C.A.V.; Silva, M.Góes.A.; Aguiar, B.M.; Ferreira, M.G.; Feitosa, G.S.; Victor Filho, E.; Rocha, E.B.D.; Paiva, M.S.M.O.; Czochra, E.R.; Oliveira, L.A.R.R.; de Oliveira, I.R.; Pinheiro, Fávia.; Dourado, G.O.; Luna Filho, Aônio.L.; Pacheco, A.; Nunes, P.M.S.; de Sá Filho, A.P.; Martins, H.C.; Lopes, M.A.C.; Barros, M.A.V.; Mattos, Cáudia.; Neves, M.A.; Medeiros, C.Rocha.; Mattos, Cáudia.; Duarte, L.; Mattos, Cáudia.; Cramer, H.; Santos, Báulio.; Tura, B.R.; Rodrigues,; 2009: Rationale, design, and baseline characteristics of the Acetylcystein for Contrast-Induced nephropa Thy (ACT) Trial: a pragmatic randomized controlled trial to evaluate the efficacy of acetylcysteine for the prevention of contrast-induced nephropathy. Trials 10: 38
Neal, B.; Perkovic, V.; de Zeeuw, D.; Mahaffey, K.W.; Fulcher, G.; Stein, P.; Desai, M.; Shaw, W.; Jiang, J.; Vercruysse, F.; Meininger, G.; Matthews, D. 2013: Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial. American Heart Journal 166(2): 217-223.E11
Fox, K.; Ford, I.; Steg, P.G.; Tardif, J.-C.; Tendera, M.; Ferrari, R. 2013: Rationale, design, and baseline characteristics of the Study assessInG the morbidity-mortality be Nefits of the if inhibitor ivabradine in patients with coronarY artery disease (SIGNIFY trial): a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease without clinical heart failure. American Heart Journal 166(4): 654-661.E6
Teramoto, T.; Shimada, K.; Uchiyama, S.; Sugawara, M.; Goto, Y.; Yamada, N.; Oikawa, S.; Ando, K.; Ishizuka, N.; Yamazaki, T.; Yokoyama, K.; Murata, M.; Ikeda, Y. 2010: Rationale, design, and baseline data of the Japanese Primary Prevention Project (JPPP)-a randomized, open-label, controlled trial of aspirin versus no aspirin in patients with multiple risk factors for vascular events. American Heart Journal 159(3): 361-369.E4
Swinnen, S.G.H.A.; Snoek, F.J.; Dain, M-Paule.; DeVries, J.Hans.; Hoekstra, J.B.L.; Holleman, F. 2009: Rationale, design, and baseline data of the insulin glargine (Lantus) versus insulin detemir (Levemir) Treat-To-Target (L2T3) study: A multinational, randomized noninferiority trial of basal insulin initiation in type 2 diabetes. Diabetes Technology and Therapeutics 11(11): 739-743
Nagai, Y.; Kohriyama, T.; Origasa, H.; Minematsu, K.; Yokota, C.; Uchiyama, S.; Ibayashi, S.; Terayama, Y.; Takagi, M.; Kitagawa, K.; Nomura, E.; Hosomi, N.; Ohtsuki, T.; Yamawaki, T.; Matsubara, Y.; Nakamura, M.; Yamasaki, Y.; Mori, E.; Fukushima, M.; Kobayashi, S.; Shinohara, Y.; Yamaguchi, T.; Matsumoto, M. 2014: Rationale, design, and baseline features of a randomized controlled trial to assess the effects of statin for the secondary prevention of stroke: the Japan Statin Treatment Against Recurrent Stroke (J-STARS). International Journal of Stroke: Official Journal of the International Stroke Society 9(2): 232-239
Dobscha, S.K.; Corson, K.; Leibowitz, R.Q.; Sullivan, M.D.; Gerrity, M.S. 2008: Rationale, design, and baseline findings from a randomized trial of collaborative care for chronic musculoskeletal pain in primary care. Pain Medicine 9(8): 1050-1064
Azmat, S.K.; Hameed, W.; Lendvay, A.; Shaikh, B.T.; Mustafa, G.; Siddiqui, M.A.; Brohi, S.; Karim, A.; Ishaque, M.; Hussain, W.; Bilgrami, M.; Feldblum, P.J. 2014: Rationale, design, and cohort enrolment of a prospective observational study of the clinical performance of the new contraceptive implant (Femplant) in Pakistan. International Journal of Women's Health 6: 573-583
Gao, T.Y.; Zhang, P.; Li, L.; Lin, Z.; Jhanji, V.; Peng, Y.; Li, Z.W.; Sun, L.P.; Han, W.; Wang, N.L.; Liang, Y.B. 2014: Rationale, design, and demographic characteristics of the Handan Offspring Myopia Study. Ophthalmic Epidemiology 21(2): 124-132
Chinnaiyan, K.M.; Depetris, A.M.; Al-Mallah, M.; Abidov, A.; Ananthasubramaniam, K.; Gallagher, M.J.; Girard, S.; Goraya, T.Y.; Kazerooni, E.A.; Patel, S.; Peyser, P.; Poopat, C.; Raff, G.L.; Saba, S.; Song, T.; Share, D. 2012: Rationale, design, and goals of the Advanced Cardiovascular Imaging Consortium (ACIC): a Blue Cross Blue Shield of Michigan collaborative quality improvement project. American Heart Journal 163(3): 346-353
Becker, M.C.; Wang, T.H.; Wisniewski, L.; Wolski, K.; Libby, P.; Lüscher, T.F.; Borer, J.S.; Mascette, A.M.; Husni, M.E.; Solomon, D.H.; Graham, D.Y.; Yeomans, N.D.; Krum, H.; Ruschitzka, F.; Lincoff, A.M.; Nissen, S.E. 2009: Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis. American Heart Journal 157(4): 606-612
Zgibor, J.C.; Kuo, S.; Emerson, S.; Gittinger, P.; Solano, F.X.; Tilves, D.; Maloney, M.; Davidson, M.B. 2014: Rationale, design, and implementation of a cluster randomized trial using certified diabetes educators to intensify treatment for glycemia, blood pressure and lipid control: REMEDIES 4D. Contemporary Clinical Trials 39(1): 124-131
Turan, T.N.; Lynn, M.J.; Nizam, A.; Lane, B.; Egan, B.M.; Le, N-Anh.; Lopes-Virella, M.F.; Hermayer, K.L.; Benavente, O.; White, C.L.; Brown, W.Virgil.; Caskey, M.F.; Steiner, M.R.; Vilardo, N.; Stufflebean, A.; Derdeyn, C.P.; Fiorella, D.; Janis, S.; Chimowitz, M.I. 2012: Rationale, design, and implementation of aggressive risk factor management in the Stenting and Aggressive Medical Management for Prevention of Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) trial. Circulation. Cardiovascular Quality and Outcomes 5(5): E51-E60
Mann, D.M.; Kannry, J.L.; Edonyabo, D.; Li, A.C.; Arciniega, J.; Stulman, J.; Romero, L.; Wisnivesky, J.; Adler, R.; McGinn, T.G. 2011: Rationale, design, and implementation protocol of an electronic health record integrated clinical prediction rule (iCPR) randomized trial in primary care. Implementation Science: Is 6: 109
te Boveldt, N.; Engels, Y.; Besse, K.; Vissers, K.; Vernooij-Dassen, M. 2011: Rationale, design, and implementation protocol of the Dutch clinical practice guideline pain in patients with cancer: a cluster randomised controlled trial with Short Message Service (SMS) and Interactive Voice Response (IVR). Implementation Science: Is 6: 126
Zhang, C.; Hu, F.B.; Olsen, S.F.; Vaag, A.; Gore-Langton, R.; Chavarro, J.E.; Bao, W.; Yeung, E.; Bowers, K.; Grunnet, L.G.; Sherman, S.; Kiely, M.; Strøm, M.; Hansen, S.; Liu, A.; Mills, J.; Fan, R. 2014: Rationale, design, and method of the Diabetes and Women's Health study--a study of long-term health implications of glucose intolerance in pregnancy and their determinants. Acta Obstetricia et Gynecologica Scandinavica 93(11): 1123-1130
Berry, D.C.; Neal, M.; Hall, E.G.; Schwartz, T.A.; Verbiest, S.; Bonuck, K.; Goodnight, W.; Brody, S.; Dorman, K.F.; Menard, M.K.; Stuebe, A.M. 2013: Rationale, design, and methodology for the optimizing outcomes in women with gestational diabetes mellitus and their infants study. Bmc Pregnancy and Childbirth 13: 184
Ridker, P.M.; Chasman, D.I.; Zee, R.Y.L.; Parker, A.; Rose, L.; Cook, N.R.; Buring, J.E. 2008: Rationale, design, and methodology of the Women's Genome Health Study: a genome-wide association study of more than 25,000 initially healthy american women. Clinical Chemistry 54(2): 249-255
Greenberg, B.; Czerska, B.; Abraham, W.T.; Neaton, J.D.; Delgado, R.M.; Mather, P.; Bourge, R.; Parker, I.C.; Konstam, M.A. 2007: Rationale, design, and methods for a pivotal randomized clinical trial of continuous aortic flow augmentation in patients with exacerbation of heart failure: the MOMENTUM trial. Journal of Cardiac Failure 13(9): 715-721
Mehra, M.R.; McCluskey, T.; Barr, M.; Bourge, R.C.; Jessup, M.L.; Mancini, D.; Radovancevic, B.; Rayburn, B.; Taylor, D.O.; Lilly-Hersley, J.; Linde, P. 2007: Rationale, design, and methods for the Transplant-Eligible MAnagement of Congestive Heart Failure (TMAC) trial: a multicenter clinical outcomes trial using nesiritide for TMAC. American Heart Journal 153(6): 932-940
San Román, J.é A.; López, J.; Revilla, A.; Vilacosta, I.; Tornos, P.; Almirante, B.; Mota, P.; Villacorta, E.; Sevilla, T.; Gómez, I.; Del Carmen Manzano, M.ía.; Fulquet, E.; Rodríguez, E.; Igual, A. 2008: Rationale, design, and methods for the early surgery in infective endocarditis study (ENDOVAL 1): a multicenter, prospective, randomized trial comparing the state-of-the-art therapeutic strategy versus early surgery strategy in infective endocarditis. American Heart Journal 156(3): 431-436
Green, J.B.; Bethel, M.A.; Paul, S.K.; Ring, A.; Kaufman, K.D.; Shapiro, D.R.; Califf, R.M.; Holman, R.R. 2013: Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease. American Heart Journal 166(6): 983-989.E7
Kitamura, T.; Kawamura, T.; Tamakoshi, A.; Wakai, K.; Ando, M.; Ohno, Y. 2009: Rationale, design, and profiles of the new Integrated Suburban Seniority Investigation (NISSIN) Project: a study of an age-specific, community-based cohort of Japanese elderly. Journal of Epidemiology 19(5): 237-243
George, S.Z.; Childs, J.D.; Teyhen, D.S.; Wu, S.S.; Wright, A.C.; Dugan, J.L.; Robinson, M.E. 2007: Rationale, design, and protocol for the prevention of low back pain in the military (POLM) trial (NCT00373009). Bmc Musculoskeletal Disorders 8: 92
Pang, P.S.; Mehra, M.; Maggioni, A.P.; Filippatos, G.; Middlebrooks, J.; Turlapaty, P.; Kazei, D.; Gheorghiade, M.; Gheorghiade, M.; Filippatos, G.; Maggioni, A.; Mehra, M.; Pang, P.S.; Thygesen, K.; DeGroote, P.; Arnold, M.; Martinez, F.; Broncel, M.; Macarie, C.; Arutyunov, G.; Sefarovic, P.; Parkhomenko, A.; Alvarez, C.; Cartasegna, L.; Fernandez, A.; Fuselli, J.Jose.; Giacomi, G.; Guzman, L.; Hasbani, E.; Navarro, J.Luis.; Patocchi, C.; Schygiel, P.Omar.; Nguyen, V.; Rajda, M.; Nunez Peirano, L.; Araneda, G.; Cobos, J.; Escobar, J.; Larico, M 2011: Rationale, design, and results from RENO-DEFEND 1: a randomized, dose-finding study of the selective A1 adenosine antagonist SLV320 in patients hospitalized with acute heart failure. American Heart Journal 161(6): 1012-23.E3
van Bergen, J.E.A.M.; Fennema, J.S.A.; van den Broek, I.V.F.; Brouwers, E.E.H.G.; de Feijter, E.M.; Hoebe, C.J.P.A.; Koekenbier, R.H.; de Coul, E.L.M.Op.; van Ravesteijn, S.M.; Götz, H.M. 2010: Rationale, design, and results of the first screening round of a comprehensive, register-based, Chlamydia screening implementation programme in the Netherlands. Bmc Infectious Diseases 10: 293
Samuel-Hodge, C.D.; Garcia, B.A.; Johnston, L.F.; Kraschnewski, J.L.; Gustafson, A.A.; Norwood, A.F.; Glasgow, R.E.; Gold, A.D.; Graham, J.W.; Evenson, K.R.; Stearns, S.C.; Gizlice, Z.; Keyserling, T.C. 2012: Rationale, design, and sample characteristics of a practical randomized trial to assess a weight loss intervention for low-income women: the Weight-Wise II Program. Contemporary Clinical Trials 33(1): 93-103
Berg, K.M.; Mouriz, J.; Li, X.; Duggan, E.; Goldberg, U.; Arnsten, J.H. 2009: Rationale, design, and sample characteristics of a randomized controlled trial of directly observed antiretroviral therapy delivered in methadone clinics. Contemporary Clinical Trials 30(5): 481-489
Liang, Y.Bo.; Friedman, D.S.; Wong, T.Yin.; Wang, F.Hua.; Duan, X.Rong.; Yang, X.Hui.; Zhou, Q.; Tao, Q.; Zhan, S.Yan.; Sun, L.Ping.; Wang, N.Li.; Wang, N.; Friedman, D.S.; Wong, T.Yin.; Zhan, S.; Sun, L.; Liang, Y.; Wang, J.Jin.; Wang, F.; Duan, X.; Yang, X.; Zhou, Q.; Tao, Q.; Huang, W.; Wen, J.; Yang, J.; Liang, Y.; Wang, F.; Duan, X.; Yang, X.; Zhou, Q.; Tao, Q.; Zhao, J.; He, M.; Wang, G.; Xu, L.; Jiang, Y. 2009: Rationale, design, methodology, and baseline data of a population-based study in rural China: the Handan Eye Study. Ophthalmic Epidemiology 16(2): 115-127
Rietzschel, E.-R.; De Buyzere, M.L.; Bekaert, S.; Segers, P.; De Bacquer, D.; Cooman, L.; Van Damme, P.; Cassiman, P.; Langlois, M.; van Oostveldt, P.; Verdonck, P.; De Backer, G.; Gillebert, T.C. 2007: Rationale, design, methods and baseline characteristics of the Asklepios Study. European Journal of Cardiovascular Prevention and Rehabilitation: Official Journal of the European Society of Cardiology Working Groups on Epidemiology and Prevention and Cardiac Rehabilitation and Exercise Physiology 14(2): 179-191
Morrison, L.J.; Nichol, G.; Rea, T.D.; Christenson, J.; Callaway, C.W.; Stephens, S.; Pirrallo, R.G.; Atkins, D.L.; Davis, D.P.; Idris, A.H.; Newgard, C. 2008: Rationale, development and implementation of the Resuscitation Outcomes Consortium Epistry-Cardiac Arrest. Resuscitation 78(2): 161-169
Marcantuono, R.; Gutsche, J.; Burke-Julien, M.; Anwaruddin, S.; Augoustides, J.G.; Jones, D.; Mangino-Blanchard, L.; Hoke, N.; Houseman, S.; Li, R.; Patel, P.; Stetson, R.; Walsh, E.; Szeto, W.Y.; Herrmann, H.C. 2015: Rationale, development, implementation, and initial results of a fast track protocol for transfemoral transcatheter aortic valve replacement (TAVR). Catheterization and Cardiovascular Interventions: Official Journal of the Society for Cardiac Angiography and Interventions 85(4): 648-654
Uderzo, C. 2007: Rationale, indications and results of stem cell transplantation in childhood. Lijecnicki Vjesnik 129(Suppl 3): 9-10
Pollo, C.; Villemure, J.G. 2007: Rationale, mechanisms of efficacy, anatomical targets and future prospects of electrical deep brain stimulation for epilepsy. Acta Neurochirurgica. Suppl 97(Part 2): 311-320
Hubert, Hé.; Tazarourte, K.; Wiel, E.; Zitouni, D.; Vilhelm, C.; Escutnaire, Jéphine.; Cassan, P.; Gueugniaud, P-Yves. 2014: Rationale, methodology, implementation, and first results of the French out-of-hospital cardiac arrest registry. Prehospital Emergency Care: Official Journal of the National Association of Ems Physicians and the National Association of State Ems Directors 18(4): 511-519
Thapa, S.S.; Rana, P.P.; Twayana, S.N.; Shrestha, M.K.; Paudel, I.; Paudyal, G.; Gurung, R.; Ruit, S.; Hewitt, A.W.; Craig, J.E.; van Rens, G. 2011: Rationale, methods and baseline demographics of the Bhaktapur Glaucoma Study. Clinical and Experimental Ophthalmology 39(2): 126-134
Motlagh, M.E.; Kelishadi, R.; Ardalan, G.; Gheiratmand, R.; Majdzadeh, R.; Heidarzadeh, A. 2009: Rationale, methods and first results of the Iranian national programme for prevention of chronic diseases from childhood: CASPIAN Study. Eastern Mediterranean Health Journal 15(2): 302-314
Rollema, H.; Coe, J.W.; Chambers, L.K.; Hurst, R.S.; Stahl, S.M.; Williams, K.E. 2007: Rationale, pharmacology and clinical efficacy of partial agonists of alpha4beta2 nACh receptors for smoking cessation. Trends in Pharmacological Sciences 28(7): 316-325
Dubensky, T.W.; Kanne, D.B.; Leong, M.L. 2013: Rationale, progress and development of vaccines utilizing STING-activating cyclic dinucleotide adjuvants. Therapeutic Advances in Vaccines 1(4): 131-143
Cirillo, M. 2009: Rationale, pros and cons of GFR estimation: the Cockcroft-Gault and MDRD equations. Giornale Italiano di Nefrologia: Organo Ufficiale Della Societa Italiana di Nefrologia 26(3): 310-317
Kario, K.; Hoshide, S. 2014: Rationale, study design, and implementation of the ACS1 study: effect of azilsartan on circadian and sleep blood pressure as compared with amlodipine. Blood Pressure Monitoring 19(3): 123-128
Moler, F.W.; Silverstein, F.S.; Meert, K.L.; Clark, A.E.; Holubkov, R.; Browning, B.; Slomine, B.S.; Christensen, J.R.; Dean, J.M. 2013: Rationale, timeline, study design, and protocol overview of the therapeutic hypothermia after pediatric cardiac arrest trials. Pediatric Critical Care Medicine: a Journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies 14(7): E304-E315
Hecht, R.; Li, Y.-S.; Sun, J.; Belouski, E.; Hall, M.; Hager, T.; Yie, J.; Wang, W.; Winters, D.; Smith, S.; Spahr, C.; Tam, L.-T.; Shen, Z.; Stanislaus, S.; Chinookoswong, N.; Lau, Y.; Sickmier, A.; Michaels, M.L.; Boone, T.; Véniant, M.M.; Xu, J. 2012: Rationale-Based Engineering of a Potent Long-Acting FGF21 Analog for the Treatment of Type 2 Diabetes. Plos one 7(11): E49345
Pathak, S.; Chauhan, V.S. 2011: Rationale-based, de novo design of dehydrophenylalanine-containing antibiotic peptides and systematic modification in sequence for enhanced potency. Antimicrobial Agents and ChemoTherapy 55(5): 2178-2188
Veyel, D.; Erban, A.; Fehrle, I.; Kopka, J.; Schroda, M. 2014: Rationales and approaches for studying metabolism in eukaryotic microalgae. Metabolites 4(2): 184-217
Jacobsen, R.; Møldrup, C.; Christrup, L. 2010: Rationales behind the choice of administration form with fentanyl: Delphi survey among Danish general practitioners. Journal of Opioid Management 6(4): 259-268
Gaylord, S.A.; Mann, J.Douglas. 2007: Rationales for CAM Education in Health Professions Training Programs. Academic medicine: journal of the Association of American Medical Colleges 82(10): 927-933
Smithers, J. 2007: Rationales for developing a perioperative web-based resource: informatics in action. AORN Journal 86(2): 239-248
Wang, H.-L.; Bai, H.; Li, Y.; Sun, J.; Wang, X.-Q. 2007: Rationales for expression and altered expression of apoptotic protease activating factor-1 gene in gastric cancer. World Journal of Gastroenterology 13(38): 5060-5064
Lee, J.J.; Pinker, S. 2010: Rationales for indirect speech: the theory of the strategic speaker. Psychological Review 117(3): 785-807
Tayebi, Z.; Borimnejad, L.; Dehghan-Nayeri, N.; Kohan, M. 2014: Rationales of restricted visiting hour in Iranian intensive care units: a qualitative study. Nursing in Critical Care 19(3): 117-125
Vandentorren, S.ép.; Bois, C.; Pirus, C.; Sarter, H.él.èn.; Salines, G.; Leridon, H.; Arduin, P.; Dufourg, M.N.; Lanoe, J.L.; Baltzinger, N.; Oleko, A.; Popa, R.; Cheminat, M.; Som, S.; Gonzales, C.; Boivin, M. 2009: Rationales, design and recruitment for the Elfe longitudinal study. Bmc Pediatrics 9: 58
Wang, X.; Lu, M.; Qian, J.; Yang, Y.; Li, S.; Lu, D.; Yu, S.; Meng, W.; Ye, W.; Jin, L. 2009: Rationales, design and recruitment of the Taizhou Longitudinal Study. Bmc Public Health 9: 223
Jonker, D.; Rolander, B.; Balogh, I.; Sandsjö, L.; Ekberg, K.; Winkel, J. 2013: Rationalisation in public dental care--impact on clinical work tasks and mechanical exposure for dentists--a prospective study. Ergonomics 56(2): 303-313
Makhuvha, T.R.; Davhana-Maselesele, M.; Netshandama, V.O. 2007: Rationalisation of nursing education in Limpopo province : nurse educators' perspectives. Curationis 30(4): 61-72
Autore, F.; Bergeron, J.R.C.; Malim, M.H.; Fraternali, F.; Huthoff, H. 2010: Rationalisation of the differences between APOBEC3G structures from crystallography and NMR studies by molecular dynamics simulations. Plos one 5(7): E11515
Nagel, E.; Alber, K.; Bayerl, B. 2010: Rationalisation, prioritisation and rationing: approaches to future health care delivery. Zeitschrift für Evidenz Fortbildung und Qualitat Im Gesundheitswesen 104(5): 355-359
Bourne, T.; Condous, G. 2009: Rationalising acute gynaecology services: is it time to move away from 'stand-alone' early pregnancy units?. Best Practice and Research. Clinical Obstetrics and Gynaecology 23(5): 575-576
Bamford, R.F.; Hall, A.; Loftus, I.M.; Thompson, M.M.; Black, S.A. 2014: Rationalising cross-match requests in vascular surgery is safe and cost effective. Journal of Perioperative Practice 24(9): 206-209
Anonymous 2010: Rationalising estates. Changing rooms. Health service journal Suppl: 7
Klatt, T.; Cavner, D.; Egan, V. 2014: Rationalising predictors of child sexual exploitation and sex-trading. Child Abuse and Neglect 38(2): 252-260
Ryan, M.; Watson, V.; Entwistle, V. 2009: Rationalising the 'irrational': a think aloud study of discrete choice experiment responses. Health Economics 18(3): 321-336
Jacobs, M.L.; Anderson, R.H. 2012: Rationalising the nomenclature of common arterial trunk. Cardiology in the Young 22(6): 639-646
Likosky, D.S.; Surgenor, S.D.; Dacey, L.J.; DeFoe, G.R.; Maislen, E.L.; Clark, J.A.; Aubuchon, J.P.; Higgins, J.H.; Beaulieu, P.A.; O'Connor, G.T.; Ross, C.S. 2010: Rationalising the treatment of anaemia in cardiac surgery: short and mid-term results from a local quality improvement initiative. Quality and Safety in Health Care 19(5): 392-398
McNamara, R.; Molloy, E.J. 2008: Rationalising the use of "growing bloods" in stable preterm infants. Archives of Disease in Childhood. Fetal and Neonatal Edition 93(2): F171-F172
Benoit, D.M. 2009: Rationalising the vibrational spectra of biomolecules using atomistic simulations. Frontiers in Bioscience 14(11): 4229-4241
Nikkhah, D.; Rodrigues, J.; Mahajan, A.L. 2012: Rationalising treatment of Raynaud's syndrome. Journal of Plastic Reconstructive and Aesthetic Surgery: Jpras 65(7): 986; Author Reply 986-7
Cooke, W.R. 1949: Rationalism in regard to gynecologic operations. Journal. Kansas City Southwest Clinical Society 25(3): 5-8
Paul, N.W. 2009: Rationalities of knowledge production: on transformations of objects, technologies and information in biomedicine and the life sciences. Berichte Zur Wissenschaftsgeschichte 32(3): 230-245
Anonymous 1915: Rationality in the Control of Measles. American Journal of Public Health 5(12): 1230-1231
Lin, Y. 2010: Rationality analysis on current validity period of preparations in medical institutions. Zhongguo Zhong Yao Za Zhi 35(15): 2038-2040
Kirman, A.; Livet, P.; Teschl, M. 2010: Rationality and emotions. Philosophical Transactions of the Royal Society of London. Series B Biological Sciences 365(1538): 215-219
Maratka, Z. 2008: Rationality and irrationality in the medicine and in the life. Casopis Lekaru Ceskych 147(11): 584-587
Mattos, L.Alberto.Piva.E. 2011: Rationality and methods of ACCEPT registry - Brazilian registry of clinical practice in acute coronary syndromes of the Brazilian Society of Cardiology. Arquivos brasileiros de cardiologia 97(2): 94-99
Mattos, L.A.P.E. 2011: Rationality and methods: registry of clinical practice in high-risk cardiovascular patients. Arquivos Brasileiros de Cardiologia 97(1): 3-7
Myskja, B.ør.K. 2009: Rationality and religion in the public debate on embryo stem cell research and prenatal diagnostics. Medicine Health Care and Philosophy 12(2): 213-224
Turner, S.P. 1989: Rationality and risk: classical probability in the enlightenment. Science 243(4888): 242-243
Fuller, J. 2013: Rationality and the generalization of randomized controlled trial evidence. Journal of Evaluation in Clinical Practice 19(4): 644-647
Hayry, M. 2011: Rationality and the genetic challenge revisited. Cambridge Quarterly of Healthcare Ethics: Cq: the International Journal of Healthcare Ethics Committees 20(3): 468-483
Evans, J.S.B.T. 2014: Rationality and the illusion of choice. Frontiers in Psychology 5: 104
Wei, Y.-j.; Wang, M.; Xu, Q.-f.; He, Q.; Jia, X.-b. 2011: Rationality for dynamic detection of shikonin of Arnerbia euchroma in industrial process. Zhong Yao Cai 34(7): 1129-1133
Edwards, S.C.; Pratt, S.C. 2009: Rationality in collective decision-making by ant colonies. Proceedings. Biological Sciences 276(1673): 3655-3661
Bost, P.R.; Prunier, S.G. 2013: Rationality in conspiracy beliefs: the role of perceived motive. Psychological Reports 113(1): 1130-1140
Miettinen, O.S. 2009: Rationality in medicine. Journal of Evaluation in Clinical Practice 15(6): 960-963
Onodera, Y.; Nakano, T.; Takeyama, D.; Maruyama, S.; Taniyama, Y.; Sakurai, T.; Heishi, T.; Sato, C.; Kumagai, T.; Kamei, T. 2017: Combined thoracoscopic and endoscopic surgery for a large esophageal schwannoma. World Journal of Gastroenterology 23(46): 8256-8260
Janušonis, T.; Mačiulaitis, R.; Sveikata, A.; Milašius, A.; Kregždytė, R. 2011: Rationality of administered gentamicin dose in cerebral coma patients treated in an intensive care unit. Medicina 47(2): 79-84
Wang, J.; Zhang, X.; Xiao, X.; Chu, X.; Zhou, C.; Jin, C.; Yan, D. 2010: Rationality of commercial specification of rhubarb based on chemical analysis. Zhongguo Zhong Yao Za Zhi 35(4): 470-476
Wen, R.-Q.; Li, D.-H.; Zhao, X.; Wang, J.-B.; Zhao, Y.-L.; Zhang, P.; Sun, Z.-Y.; Yan, D.; Xiao, X.-H.; Ren, Y.-Z.; Li, F.; Du, J.; Zhou, H.-Y. 2013: Rationality of the processing methods of aconiti lateralis radix (Fuzi) based on chemical analysis. Yao Xue Xue Bao 48(2): 286-290
McCaughey, D.; Bruning, N.S. 2010: Rationality versus reality: the challenges of evidence-based decision making for health policy makers. Implementation Science: Is 5: 39
Radicchi, F.; Baronchelli, A.; Amaral, L.ís.A.N. 2012: Rationality, irrationality and escalating behavior in lowest unique bid auctions. Plos one 7(1): E29910
McMahon-Parkes, K. 2013: Rationality, religion and refusal of treatment in an ambulance revisited. Journal of Medical Ethics 39(9): 587-590
Buller, T. 2010: Rationality, responsibility, and brain function. Cambridge Quarterly of Healthcare Ethics: Cq: the International Journal of Healthcare Ethics Committees 19(2): 196-204
Rogers, A.; Bury, M.; Kennedy, A. 2009: Rationality, rhetoric, and religiosity in health care: the case of England's Expert Patients Programme. International Journal of Health Services: Planning Administration Evaluation 39(4): 725-747
Wenmackers, S.; Vanpoucke, D.E.P.; Douven, I. 2014: Rationality: a social-epistemology perspective. Frontiers in Psychology 5: 581
Dayan, P. 2014: Rationalizable irrationalities of choice. Topics in Cognitive Science 6(2): 204-228
Yu, C-Ming.; Peng, H-Pin.; Chen, I-Chien.; Lee, Y-Ching.; Chen, J-Bo.; Tsai, K-Chang.; Chen, C-Tai.; Chang, J-Yih.; Yang, E-Wen.; Hsu, P-Chiang.; Jian, J-Wei.; Hsu, H-Ju.; Chang, H-Ju.; Hsu, W-Lian.; Huang, K-Fa.; Ma, A.Che.; Yang, A-Suei. 2012: Rationalization and design of the complementarity determining region sequences in an antibody-antigen recognition interface. Plos one 7(3): E33340
Cottyn, B.; Kollmann, A.; Waffo-Teguo, P.; Ducrot, P.-H. 2011: Rationalization and in vitro modeling of the chemical mechanisms of the enzymatic oxidation of phenolic compounds in planta: from flavonols and stilbenoids to lignins. Chemistry 17(26): 7282-7287
Lutz, J.D.; Fujioka, Y.; Isoherranen, N. 2010: Rationalization and prediction of in vivo metabolite exposures: the role of metabolite kinetics, clearance predictions and in vitro parameters. Expert Opinion on Drug Metabolism and Toxicology 6(9): 1095-1109
Parisien, M.; Yi, C.; Pan, T. 2012: Rationalization and prediction of selective decoding of pseudouridine-modified nonsense and sense codons. Rna 18(3): 355-367
Strech, D. 2014: Rationalization and rationing at the bedside. a normative and empirical status quo analysis. Medizinische Klinik Intensivmedizin und Notfallmedizin 109(1): 27-33
Babica, J.; Rusek, Václav. 2014: Rationalization in 20th-century Czechoslovak pharmacy practice - commission for rationalization and standardization in medicine, veterinary medicine and pharmacy - part 1. Ceska a Slovenska Farmacie: Casopis Ceske Farmaceuticke Spolecnosti a Slovenske Farmaceuticke Spolecnosti 63(3): 141-146
Babica, J.; Rusek, Václav. 2014: Rationalization in 20th-century czechoslovak pharmacy practice - commission for rationalization and standardization in medicine, veterinary medicine and pharmacy - part 2*. Ceska a Slovenska Farmacie: Casopis Ceske Farmaceuticke Spolecnosti a Slovenske Farmaceuticke Spolecnosti 63(4): 178-183
Arvidsson, I.; Balogh, I.; Hansson, G.-Åk.; Ohlsson, K.; Akesson, I.; Nordander, C. 2012: Rationalization in meat cutting - consequences on physical workload. Applied Ergonomics 43(6): 1026-1032
Arneson, A.N. 1948: Rationalization in the treatment of cancer of the uterine cervix. Bulletin. Chicago Medical Society 51(24): 413-416
Morell, C.; Ayers, P.W.; Grand, A.é; Gutiérrez-Oliva, S.; Toro-Labbé, A. 2008: Rationalization of Diels-Alder reactions through the use of the dual reactivity descriptor Deltaf(r). Physical Chemistry Chemical Physics: Pccp 10(48): 7239-7246
Kreutzer, S. 2012: Rationalization of Protestant nursing. A comparison of Deaconess Motherhouses in West Germany and the United States, 1945-1970. Medizinhistorisches Journal 47(2-3): 221-243
Rabinovich, E.A.; Pechersky, M.M. 1945: Rationalization of a device for lavage (Janet's. Vestnik Venerologii i Dermatologii 3: 24
Medina-Franco, J.é L.; Méndez-Lucio, O.; Yoo, J. 2014: Rationalization of activity cliffs of a sulfonamide inhibitor of DNA methyltransferases with induced-fit docking. International Journal of Molecular Sciences 15(2): 3253-3261
Zareian, S.; Khajeh, K.; Pazhang, M.; Ranjbar, B. 2012: Rationalization of allosteric pathway in Thermus sp. GH5 methylglyoxal synthase. Bmb Reports 45(12): 748-753
Burés, J.; Dingwall, P.; Armstrong, A.; Blackmond, D.G. 2014: Rationalization of an unusual solvent-induced inversion of enantiomeric excess in organocatalytic selenylation of aldehydes. Angewandte Chemie 53(33): 8700-8704
Gianotti, V.; Favaro, G.; Bonandini, L.; Palin, L.; Croce, G.; Boccaleri, E.; Artuso, E.; van Beek, W.; Barolo, C.; Milanesio, M. 2014: Rationalization of dye uptake on titania slides for dye-sensitized solar cells by a combined chemometric and structural approach. Chemsuschem 7(11): 3039-3052
Mavundla, T.R.; Netswera, F.G.; Bottoman, B.; Toth, F. 2009: Rationalization of indigenous male circumcision as a sacred religious custom: health beliefs of Xhosa men in South Africa. Journal of Transcultural Nursing: Official Journal of the Transcultural Nursing Society 20(4): 395-404
Acerbi, N.; Tsang, S.C.E.; Jones, G.; Golunski, S.; Collier, P. 2013: Rationalization of interactions in precious metal/ceria catalysts using the d-band center model. Angewandte Chemie 52(30): 7737-7741
Agarwal, M.Mohan.; Patil, S.; Roy, K.; Bandawar, M.; Choudhury, S.; Mavuduru, R.; Sharma, S.K.; Mandal, A.K.; Singh, S.K. 2014: Rationalization of interpretation of uroflowmetry for a non-caucasian (Indian) population: conceptual development and validation of volume-normalized flow rate index. Neurourology and Urodynamics 33(1): 135-141
Fink, H. 1966: Rationalization of literature coverage in special documentation. Methods of Information in Medicine 5(2): 75-80
Miliavskaia, P.F. 1945: Rationalization of methods of air bacteriology. Gigiena i Sanitariia 10(6): 30-32
Spera, G.; La Torre, A.; Gianferro, M.; Bugliosi, R. 2007: Rationalization of pesticide treatments against powdery mildew of grape. Communications in Agricultural and Applied Biological Sciences 72(2): 315-319
Manivannan, E.; Prasanna, S.; Chaturvedi, S.C. 2004: Rationalization of physico-chemical properties of 5, 6-diarylthiazolo [3,2-b]-1, 2, 4-triazoles towards cyclooxygenase-2 (COX-2) inhibition: a QSAR approach. Indian Journal of Biochemistry and Biophysics 41(4): 179-183
Nayeem, S.M.; Deep, S. 2010: Rationalization of poor solubility of TGF-β3 using MD simulation. Biochemical and Biophysical Research Communications 401(4): 544-547
Paloncýová, M.ét.; DeVane, R.H.; Murch, B.P.; Berka, K.; Otyepka, M. 2014: Rationalization of reduced penetration of drugs through ceramide gel phase membrane. Langmuir: the Acs Journal of Surfaces and Colloids 30(46): 13942-13948
Katsyuba, S.A.; Zvereva, E.E.; Yan, N.; Yuan, X.; Kou, Y.; Dyson, P.J. 2012: Rationalization of solvation and stabilization of palladium nanoparticles in imidazolium-based ionic liquids by DFT and vibrational spectroscopy. Chemphyschem: a European Journal of Chemical Physics and Physical Chemistry 13(7): 1781-1790
Nagy, G.; Oostenbrink, C. 2012: Rationalization of stereospecific binding of propranolol to cytochrome P450 2D6 by free energy calculations. European Biophysics Journal: Ebj 41(12): 1065-1076
Lu, D.; Liu, P. 2014: Rationalization of the Hubbard U parameter in CeO(x) from first principles: unveiling the role of local structure in screening. Journal of Chemical Physics 140(8): 084101
Kumar, D.; Latifi, R.; Kumar, S.; Rybak-Akimova, E.V.; Sainna, M.A.; de Visser, S.P. 2013: Rationalization of the barrier height for p-Z-styrene epoxidation by iron(IV)-oxo porphyrin cation radicals with variable axial ligands. Inorganic Chemistry 52(14): 7968-7979
Tabookht, Z.; López, X.; de Graaf, C.; Guihéry, N.; Suaud, N.; Benamor, N. 2012: Rationalization of the behavior of M2(CH3CS2)4i (M = Ni, Pt) chains at room temperature from periodic density functional theory and ab initio cluster calculations. Journal of Computational Chemistry 33(21): 1748-1761
Leroy, F.éd.ér.; Müller-Plathe, F. 2011: Rationalization of the behavior of solid-liquid surface free energy of water in Cassie and Wenzel wetting states on rugged solid surfaces at the nanometer scale. Langmuir: the Acs Journal of Surfaces and Colloids 27(2): 637-645
Parker, L.L.; Chung, Y.-H.; Margulis, C.J.; Jensen, J.H. 2008: Rationalization of the difference in lifetime of two covalent sialosyl-enzyme intermediates of Trypanosoma rangeli sialidase. Journal of Physical Chemistry. B 112(45): 14093-14095
Casini, A.; Edafe, F.; Erlandsson, M.; Gonsalvi, L.; Ciancetta, A.; Re, N.; Ienco, A.; Messori, L.; Peruzzini, M.; Dyson, P.J. 2010: Rationalization of the inhibition activity of structurally related organometallic compounds against the drug target cathepsin B by DFT. Dalton Transactions 39(23): 5556-5563
Tanase, S.; Ferbinteanu, M.; Cimpoesu, F. 2011: Rationalization of the lanthanide-ion-driven magnetic properties in a series of 4f-5d cyano-bridged chains. Inorganic Chemistry 50(19): 9678-9687
Ugur, I.; Marion, A.; Parant, S.ép.; Jensen, J.H.; Monard, G. 2014: Rationalization of the pKa values of alcohols and thiols using atomic charge descriptors and its application to the prediction of amino acid pKa's. Journal of Chemical Information and Modeling 54(8): 2200-2213
Tan, L.; Batista, J.é; Bajorath, J.ür. 2010: Rationalization of the performance and target dependence of similarity searching incorporating protein-ligand interaction information. Journal of Chemical Information and Modeling 50(6): 1042-1052
Ayed, T.; Réal, F.; Montavon, G.; Galland, N. 2013: Rationalization of the solvation effects on the AtO+ ground-state change. Journal of Physical Chemistry. B 117(36): 10589-10595
Viglianti, B.L.; Dewhirst, M.W.; Abraham, J.P.; Gorman, J.M.; Sparrow, E.M. 2014: Rationalization of thermal injury quantification methods: application to skin burns. Burns: Journal of the International Society for Burn Injuries 40(5): 896-902
Winkler, E. 2011: Rationalization, rationing, prioritization: terminology and ethical approaches to the allocation of limited resources in hematology/oncology. Onkologie 34(Suppl 1): 2-5
Rakicevic, L.B.; Kusic-Tisma, J.S.; Kovac, M.K.; Backovic, D.T.; Radojkovic, D.P. 2013: Rationalized DNA sequencing-based protocol for genotyping patients receiving coumarin therapy. Scandinavian Journal of Clinical and Laboratory Investigation 73(6): 523-527
Melzak, K.A.; Moreno-Flores, S.; Yu, K.; Kizhakkedathu, J.; Toca-Herrera, J.é L. 2010: Rationalized approach to the determination of contact point in force-distance curves: application to polymer brushes in salt solutions and in water. Microscopy Research and Technique 73(10): 959-964
Rodie, M.E.; Harry, C.; Taylor, R.; Barclay, A.R.; Cochran, D.; Simpson, J.H. 2012: Rationalized assessment of prolonged jaundice is safe and cost-effective. Scottish Medical Journal 57(3): 144-147
Das, S.K.; Bhattacharya, S.; Kundu, A. 2013: Rationalized design, synthesis and pharmacological screening of amino acid linked spiro pyrrolidino oxyindole analogs through environment friendly reaction. Journal of Advanced Pharmaceutical Technology and Research 4(4): 198-205
Pang, X.; Qin, S.; Zhou, H.-X. 2011: Rationalizing 5000-fold differences in receptor-binding rate constants of four cytokines. Biophysical Journal 101(5): 1175-1183
Sezer, D. 2014: Rationalizing Overhauser DNP of nitroxide radicals in water through MD simulations. Physical Chemistry Chemical Physics: Pccp 16(3): 1022-1032
Zdetsis, A.D. 2009: Rationalizing and functionalizing stannaspherene: very stable stannaspherene "alloys". Journal of Chemical Physics 131(22): 224310
Ganguly, N.K.; Arora, N.K.; Chandy, S.J.; Fairoze, M.N.; Gill, J.P.S.; Gupta, U.; Hossain, S.; Joglekar, S.; Joshi, P.C.; Kakkar, M.; Kotwani, A.; Rattan, A.; Sudarshan, H.; Thomas, K.; Wattal, C.; Easton, A.; Laxminarayan, R. 2011: Rationalizing antibiotic use to limit antibiotic resistance in India. Indian Journal of Medical Research 134: 281-294
Kulej, M.ła.; Wall, A.; Dragan, S.; Krawczyk, A.; Koprowski, P.; Orzechowski, W. 2005: Rationalizing blood management in orthopedics and traumatology. Ortopedia Traumatologia Rehabilitacja 7(3): 322-330
Slight, R.D.; O'Donohoe, P.; Fung, A.K.Y.; Alonzi, C.; McClelland, D.B.L.; Mankad, P.S. 2008: Rationalizing blood transfusion in cardiac surgery: the impact of a red cell volume-based guideline on blood usage and clinical outcome. Vox Sanguinis 95(3): 205-210
Sella, B. 1999: Rationalizing charity in fifteenth-century Milan: the "Scuola delle quattro Marie" (1447-1451). Nuova rivista storica 83(2): 73-96
Poater, A.; Bahri-Laleh, N.; Cavallo, L. 2011: Rationalizing current strategies to protect N-heterocyclic carbene-based ruthenium catalysts active in olefin metathesis from C-H (de)activation. Chemical Communications 47(23): 6674-6676
Manoharan, P.; Vijayan, R.S.K.; Ghoshal, N. 2010: Rationalizing fragment based drug discovery for BACE1: insights from FB-QSAR, FB-QSSR, multi objective (MO-QSPR) and MIF studies. Journal of Computer-Aided Molecular Design 24(10): 843-864
Saper, C.B. 2014: Rationalizing funding of graduate medical education. Annals of Neurology 76(4): 467-468
Liu, K.-L.; Kubarev, A.V.; Van Loon, J.; Uji-i, H.; De Vos, D.E.; Hofkens, J.; Roeffaers, M.B.J. 2014: Rationalizing inter- and intracrystal heterogeneities in dealuminated acid mordenite zeolites by stimulated Raman scattering microscopy correlated with super-resolution fluorescence microscopy. Acs Nano 8(12): 12650-12659
Raymond, J.W.; Watson, I.A.; Mahoui, A. 2009: Rationalizing lead optimization by associating quantitative relevance with molecular structure modification. Journal of Chemical Information and Modeling 49(8): 1952-1962
Manoharan, P.; Ghoshal, N. 2012: Rationalizing lead optimization by consensus 2D- CoMFA CoMSIA GRIND (3D) QSAR guided fragment hopping in search of γ-secretase inhibitors. Molecular Diversity 16(3): 563-577
McEwan, E.D. 1982: Rationalizing medicare. Canadian Medical Association Journal 127(1): 13-16
Chang, H.-H. 2008: Rationalizing medicine and the social ambitions of physicians in classical Greece. Journal of the History of Medicine and Allied Sciences 63(2): 217-244
Baalousha, M.; Lead, J.R. 2012: Rationalizing nanomaterial sizes measured by atomic force microscopy, flow field-flow fractionation, and dynamic light scattering: sample preparation, polydispersity, and particle structure. Environmental Science and Technology 46(11): 6134-6142
Briand, G.G.; Decken, A.; Hamilton, N.S. 2010: Rationalizing oligomerization in dimethylindium(III) chalcogenolates (Me2InER') (E = O, S, Se): a structural and computational study. Dalton Transactions 39(16): 3833-3841
Jamin, C.; Madelenat, P. 2008: Rationalizing progestin-only contraception (except IUS with levonorgestrel). Gynecologie Obstetrique and Fertilite 36(5): 557-562
Ajmani, S.; Karanam, S.; Kulkarni, S.A. 2009: Rationalizing protein-ligand interactions for PTP1B inhibitors using computational methods. Chemical Biology and Drug Design 74(6): 582-595
Gatt, P.; Petrie, S.; Stranger, R.; Pace, R.J. 2012: Rationalizing the 1.9 Å crystal structure of photosystem II--A remarkable Jahn-Teller balancing act induced by a single proton transfer. Angewandte Chemie 51(48): 12025-12028
Xia, Y.; Viel, Séphane.; Wang, Y.; Ziarelli, F.; Laurini, E.; Posocco, P.; Fermeglia, M.; Qu, F.; Pricl, S.; Peng, L. 2012: Rationalizing the F···S interaction discovered within a tetrafluorophenylazido-containing bola-phospholipid. Chemical Communications 48(36): 4284-4286
Ammann, R.A.; Tissing, W.J.E.; Phillips, B. 2012: Rationalizing the approach to children with fever in neutropenia. Current Opinion in Infectious Diseases 25(3): 258-265
Sperandio, O.; Reynès, C.H.; Camproux, A.-C.; Villoutreix, B.O. 2010: Rationalizing the chemical space of protein-protein interaction inhibitors. Drug Discovery Today 15(5-6): 220-229
Pinkerton, P.H.; Callum, J.L. 2010: Rationalizing the clinical use of frozen plasma. Cmaj: Canadian Medical Association Journal 182(10): 1019-1020
Christian, G.; Stranger, R.; Yates, B.F.; Cummins, C.C. 2007: Rationalizing the different products in the reaction of N2 with three-coordinate MoL3 complexes. Dalton Transactions 19: 1939-1947
Ruivo, D.; Pereiro, A.B.; Esperança, J.é M.S.S.; Canongia Lopes, J.é N.; Rebelo, L.P.N. 2010: Rationalizing the diverse solid-liquid equilibria of binary mixtures of benzene and its fluorinated derivatives. Journal of Physical Chemistry. B 114(39): 12589-12596
Lo Presti, L.; Ellern, A.; Destro, R.; Soave, R.; Lunelli, B. 2011: Rationalizing the effect of halogenation on the molecular structure of simple cyclobutene derivatives by topological real-space analysis of their electron density. Journal of Physical Chemistry. a 115(45): 12695-12707
Römling, U. 2009: Rationalizing the evolution of EAL domain-based cyclic di-GMP-specific phosphodiesterases. Journal of Bacteriology 191(15): 4697-4700
Van Calster, B.; Abdallah, Y.; Guha, S.; Kirk, E.; Van Hoorde, K.; Condous, G.; Preisler, J.; Hoo, W.; Stalder, C.; Bottomley, C.; Timmerman, D.; Bourne, T. 2013: Rationalizing the management of pregnancies of unknown location: temporal and external validation of a risk prediction model on 1962 pregnancies. Human Reproduction 28(3): 609-616
Low, K.S.; Cole, J.M.; Zhou, X.; Yufa, N. 2012: Rationalizing the molecular origins of Ru- and Fe-based dyes for dye-sensitized solar cells. Acta Crystallographica. Section B Structural Science 68(Part 2): 137-149
Boulenger, J.-P.; Attal, J.ér.ôm. 2008: Rationalizing the prescription of antidepressants. La Revue du Praticien 58(4): 395-402
Rokob, T.A.ás.; Hamza, A.; Pápai, I. 2009: Rationalizing the reactivity of frustrated Lewis pairs: thermodynamics of H(2) activation and the role of acid-base properties. Journal of the American Chemical Society 131(30): 10701-10710
Ripphausen, P.; Nisius, B.; Wawer, M.; Bajorath, J.ür. 2011: Rationalizing the role of SAR tolerance for ligand-based virtual screening. Journal of Chemical Information and Modeling 51(4): 837-842
Fonseca Guerra, C.él.; Sanz Miguel, P.J.; Cebollada, A.; Bickelhaupt, F.M.; Lippert, B. 2014: Rationalizing the structural variability of the exocyclic amino groups in nucleobases and their metal complexes: cytosine and adenine. Chemistry 20(31): 9494-9499
Glassford, N.J.; Eastwood, G.M.; Young, H.; Peck, L.; Schneider, A.G.; Bellomo, R. 2011: Rationalizing the use of NGAL in the intensive care unit. American Journal of Respiratory and Critical Care Medicine 184(1): 142; Author Reply 143
Ponce, J.; Esplugues, J.V. 2013: Rationalizing the use of PPIs: an unresolved matter. Revista espanola de enfermedades digestivas: organo oficial de la Sociedad Espanola de Patologia Digestiva 105(3): 121-124
Peltason, L.; Iyer, P.; Bajorath, Jürgen. 2010: Rationalizing three-dimensional activity landscapes and the influence of molecular representations on landscape topology and the formation of activity cliffs. Journal of Chemical Information and Modeling 50(6): 1021-1033
Kuhn, B.; Fuchs, J.E.; Reutlinger, M.; Stahl, M.; Taylor, N.R. 2011: Rationalizing tight ligand binding through cooperative interaction networks. Journal of Chemical Information and Modeling 51(12): 3180-3198
Trusina, A.; Papa, F.R.; Tang, C. 2008: Rationalizing translation attenuation in the network architecture of the unfolded protein response. Proceedings of the National Academy of Sciences of the United States of America 105(51): 20280-20285
Farina, K. 2012: Rationalizing treatment and coverage decisions with predictive biomarkers. American Journal of Managed Care 18(4 Spec No.): Sp157-Sp158
Galetin, A. 2014: Rationalizing underprediction of drug clearance from enzyme and transporter kinetic data: from in vitro tools to mechanistic modeling. Methods in Molecular Biology 1113: 255-288
Chang, K.-C.; Dheda, K. 2013: Rationalizing use of fluoroquinolones and pyrazinamide in the battle against multidrug-resistant tuberculosis. American Journal of Respiratory and Critical Care Medicine 188(1): 10-11
Mello, M.M. 2008: Rationalizing vaccine injury compensation. Bioethics 22(1): 32-42
Planas Vilà, M. 2014: Rationalizing versus rationing in the practice of clinical nutrition; fourth Jesús Culebras lecture. Nutricion Hospitalaria 29(1): 3-9
Gao, M.; London, N.; Cheng, K.; Tamura, R.; Jin, J.; Schueler-Furman, O.; Yin, H. 2014: Rationally Designed Macrocyclic Peptides as Synergistic Agonists of LPS-Induced Inflammatory Response. Tetrahedron 70(42): 7664-7668
Pedneault, A.; Beauregard, E.; Harris, D.A.; Knight, R.A. 2015: Rationally Irrational: the Case of Sexual Burglary. Sexual Abuse: a Journal of Research and Treatment 27(4): 376-397
Yagai, S.; Gushiken, M.; Karatsu, T.; Kitamura, A.; Kikkawa, Y. 2011: Rationally controlled helical organization of a multiple-hydrogen-bonding oligothiophene: guest-induced transition of helical-to-twisted ribbons. Chemical Communications 47(1): 454-456
Rocks, L.; Faulds, K.; Graham, D. 2011: Rationally designed SERS active silica coated silver nanoparticles. Chemical Communications 47(15): 4415-4417
Retnakumari, A.P.; Hanumanthu, P.L.; Malarvizhi, G.L.; Prabhu, R.; Sidharthan, N.; Thampi, M.V.; Menon, D.; Mony, U.; Menon, K.; Keechilat, P.; Nair, S.; Koyakutty, M. 2012: Rationally designed aberrant kinase-targeted endogenous protein nanomedicine against oncogene mutated/amplified refractory chronic myeloid leukemia. Molecular Pharmaceutics 9(11): 3062-3078
Tan, B.; Hernández-Torres, G.; Barbas, C.F. 2012: Rationally designed amide donors for organocatalytic asymmetric Michael reactions. Angewandte Chemie 51(22): 5381-5385
Lin, Q.; Zhu, X.; Fu, Y.-P.; Zhang, Y.-M.; Fang, R.; Yang, L.-Z.; Wei, T.-B. 2014: Rationally designed anion-responsive-organogels: sensing F⁻ via reversible color changes in gel-gel states with specific selectivity. Soft Matter 10(31): 5715-5723
Qi, Z.; Shi, W.; Xue, N.; Pan, C.; Jing, W.; Liu, K.; Jiang, S. 2008: Rationally designed anti-HIV peptides containing multifunctional domains as molecule probes for studying the mechanisms of action of the first and second generation HIV fusion inhibitors. Journal of Biological Chemistry 283(44): 30376-30384
Perrier, S.; Ravelet, C.; Guieu, V.ér.; Fize, J.; Roy, B.éa.; Perigaud, C.; Peyrin, E. 2010: Rationally designed aptamer-based fluorescence polarization sensor dedicated to the small target analysis. Biosensors and Bioelectronics 25(7): 1652-1657
Li, Y.; Wang, M.; Wang, H.; Urbas, A.; Li, Q. 2014: Rationally designed axially chiral diarylethene switches with high helical twisting power. Chemistry 20(49): 16286-16292
Yang, S.; Sleight, S.C.; Sauro, H.M. 2013: Rationally designed bidirectional promoter improves the evolutionary stability of synthetic genetic circuits. Nucleic Acids Research 41(1): E33
Düker, M.H.; Schäfer, H.; Zeller, M.; Azov, V.A. 2013: Rationally designed calix[4]arene-pyrrolotetrathiafulvalene receptors for electron-deficient neutral guests. Journal of Organic Chemistry 78(10): 4905-4912
Vats, I.D.; Chaudhary, S.; Sharma, A.; Nath, M.; Pasha, S. 2010: Rationally designed chimeric peptide of met-enkephalin and FMRFa-[D-Ala2,p-Cl-Phe4]YFa induce multiple opioid receptors mediated antinociception and up-regulate their expression. European Journal of Pharmacology 638(1-3): 54-60
Feng, S.; Zhu, M.; Lu, L.; Du, L.; Zhang, Y.; Wang, T. 2009: Rationally designed chiral Ni5L6 clusters with the in situ generated tridentate ligand. Hydrothermal synthesis, crystal structures, morphology and magnetic properties. Dalton Transactions 32: 6385-6395
Gowetski, D.B.; Kodis, E.J.; Kahn, J.D. 2013: Rationally designed coiled-coil DNA looping peptides control DNA topology. Nucleic Acids Research 41(17): 8253-8265
Laimou, D.; Katsila, T.; Matsoukas, J.; Schally, A.; Gkountelias, K.; Liapakis, G.; Tamvakopoulos, C.; Tselios, T. 2012: Rationally designed cyclic analogues of luteinizing hormone-releasing hormone: enhanced enzymatic stability and biological properties. European Journal of Medicinal Chemistry 58: 237-247
Rangachari, V.; Davey, Z.S.; Healy, B.; Moore, B.D.; Sonoda, L.K.; Cusack, B.; Maharvi, G.M.; Fauq, A.H.; Rosenberry, T.L. 2009: Rationally designed dehydroalanine (DeltaAla)-containing peptides inhibit amyloid-beta (Abeta) peptide aggregation. Biopolymers 91(6): 456-465
Ko, K.C.; Wu, J.-S.; Kim, H.J.; Kwon, P.S.; Kim, J.W.; Bartsch, R.A.; Lee, J.Y.; Kim, J.S. 2011: Rationally designed fluorescence 'turn-on' sensor for Cu2+. Chemical Communications 47(11): 3165-3167
Jung, H.S.; Ko, K.C.; Lee, J.H.; Kim, S.H.; Bhuniya, S.; Lee, J.Y.; Kim, Y.; Kim, S.J.; Kim, J.S. 2010: Rationally designed fluorescence turn-on sensors: a new design strategy based on orbital control. Inorganic Chemistry 49(18): 8552-8557
Singh, P.; Shaveta; Sharma, S.; Bhatti, R. 2014: Rationally designed hybrid molecules with appreciable COX-2 inhibitory and anti-nociceptive activities. Bioorganic and Medicinal Chemistry Letters 24(1): 77-82
Zervoudi, E.; Saridakis, E.; Birtley, J.R.; Seregin, S.S.; Reeves, E.; Kokkala, P.; Aldhamen, Y.A.; Amalfitano, A.; Mavridis, I.M.; James, E.; Georgiadis, D.; Stratikos, E. 2013: Rationally designed inhibitor targeting antigen-trimming aminopeptidases enhances antigen presentation and cytotoxic T-cell responses. Proceedings of the National Academy of Sciences of the United States of America 110(49): 19890-19895
Luo, B.-H.; Karanicolas, J.; Harmacek, L.D.; Baker, D.; Springer, T.A. 2009: Rationally designed integrin beta3 mutants stabilized in the high affinity conformation. Journal of Biological Chemistry 284(6): 3917-3924
Bocanegra, R.; Nevot, M.ía.; Doménech, R.; López, I.; Abián, O.; Rodríguez-Huete, A.; Cavasotto, C.N.; Velázquez-Campoy, A.án.; Gómez, J.; Martínez, M.Án.; Neira, J.é L.; Mateu, M.G. 2011: Rationally designed interfacial peptides are efficient in vitro inhibitors of HIV-1 capsid assembly with antiviral activity. Plos one 6(9): E23877
Alexiou, P.; Papakyriakou, A.; Ntougkos, E.; Papaneophytou, C.P.; Liepouri, F.; Mettou, A.; Katsoulis, I.; Maranti, A.; Tsiliouka, K.; Strongilos, A.; Chaitidou, S.; Douni, E.; Kontopidis, G.; Kollias, G.; Couladouros, E.; Eliopoulos, E. 2014: Rationally designed less toxic SPD-304 analogs and preliminary evaluation of their TNF inhibitory effects. Archiv der Pharmazie 347(11): 798-805
Zhang, S.; Leem, G.; Srisombat, L-Ongnuan.; Lee, T.Randall. 2008: Rationally designed ligands that inhibit the aggregation of large gold nanoparticles in solution. Journal of the American Chemical Society 130(1): 113-120
Gholivand, M.B.; Khodadadian, M. 2011: Rationally designed molecularly imprinted polymers for selective extraction of methocarbamol from human plasma. Talanta 85(3): 1680-1688
Xie, W.; Schlücker, S. 2014: Rationally designed multifunctional plasmonic nanostructures for surface-enhanced Raman spectroscopy: a review. Reports on Progress in Physics. Physical Society 77(11): 116502
Gu, Y.; Wang, Y.; Yu, T.-Y.; Liang, Y.-M.; Xu, P.-F. 2014: Rationally designed multifunctional supramolecular iminium catalysis: direct vinylogous Michael addition of unmodified linear dienol substrates. Angewandte Chemie 53(51): 14128-14131
Zhan, P.; Liu, X. 2013: Rationally designed multitarget anti-HIV agents. Current Medicinal Chemistry 20(13): 1743-1758
Chen, Z.; Han, L.; Xu, M.; Xu, Y.; Qian, X. 2013: Rationally designed multitarget anticancer agents. Current Medicinal Chemistry 20(13): 1694-1714
Banholzer, M.J.; Millstone, J.E.; Qin, L.; Mirkin, C.A. 2008: Rationally designed nanostructures for surface-enhanced Raman spectroscopy. Chemical Society Reviews 37(5): 885-897
Livney, Y.D.; Assaraf, Y.G. 2013: Rationally designed nanovehicles to overcome cancer chemoresistance. Advanced Drug Delivery Reviews 65(13-14): 1716-1730
Wang, F.; Liu, B.; Huang, P-Jung.Jimmy.; Liu, J. 2013: Rationally designed nucleobase and nucleotide coordinated nanoparticles for selective DNA adsorption and detection. Analytical Chemistry 85(24): 12144-12151
Paraskar, A.; Soni, S.; Roy, B.; Papa, A-Laure.; Sengupta, S. 2012: Rationally designed oxaliplatin-nanoparticle for enhanced antitumor efficacy. Nanotechnology 23(7): 075103
Turner, J.P.; Lutz-Rechtin, T.; Moore, K.A.; Rogers, L.; Bhave, O.; Moss, M.A.; Servoss, S.L. 2014: Rationally designed peptoids modulate aggregation of amyloid-beta 40. Acs Chemical Neuroscience 5(7): 552-558
Grunda, J.M.; Fiveash, J.; Palmer, C.A.; Cantor, A.; Fathallah-Shaykh, H.M.; Nabors, L.B.; Johnson, M.R. 2010: Rationally designed pharmacogenomic treatment using concurrent capecitabine and radiotherapy for glioblastoma; gene expression profiles associated with outcome. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 16(10): 2890-2898
Kobayashi, N.; Furuyama, T.; Satoh, K. 2011: Rationally designed phthalocyanines having their main absorption band beyond 1000 nm. Journal of the American Chemical Society 133(49): 19642-19645
Bolliger, J.L.; Blacque, O.; Frech, C.M. 2008: Rationally designed pincer-type heck catalysts bearing aminophosphine substituents: Pd IV intermediates and palladium nanoparticles. Chemistry 14(26): 7969-7977
Ma, R.; Baldwin, A.F.; Wang, C.; Offenbach, I.; Cakmak, M.; Ramprasad, R.; Sotzing, G.A. 2014: Rationally designed polyimides for high-energy density capacitor applications. Acs Applied Materials and Interfaces 6(13): 10445-10451
Stuparu, M.C. 2013: Rationally designed polymer hosts of fullerene. Angewandte Chemie 52(30): 7786-7790
Liu, F.; Vijayakrishnan, B.; Faridmoayer, A.; Taylor, T.A.; Parsons, T.B.; Bernardes, G.ça.J.L.; Kowarik, M.; Davis, B.G. 2014: Rationally designed short polyisoprenol-linked PglB substrates for engineered polypeptide and protein N-glycosylation. Journal of the American Chemical Society 136(2): 566-569
Car, D.; Wang, J.; Verheijen, M.A.; Bakkers, E.P.A.M.; Plissard, S.éb.R. 2014: Rationally designed single-crystalline nanowire networks. Advanced Materials 26(28): 4875-4879
Childs-Disney, J.L.; Hoskins, J.; Rzuczek, S.G.; Thornton, C.A.; Disney, M.D. 2012: Rationally designed small molecules targeting the RNA that causes myotonic dystrophy type 1 are potently bioactive. Acs Chemical Biology 7(5): 856-862
Niewiadomski, S.; Beebeejaun, Z.; Denton, H.; Smith, T.K.; Morris, R.J.; Wagner, G.K. 2010: Rationally designed squaryldiamides - a novel class of sugar-nucleotide mimics?. Organic and Biomolecular Chemistry 8(15): 3488-3499
Choy, C.J.; Fulton, M.D.; Davis, A.L.; Hopkins, M.; Choi, J.K.; Anderson, M.O.; Berkman, C.E. 2013: Rationally designed sulfamides as glutamate carboxypeptidase Ii inhibitors. Chemical Biology and Drug Design 82(5): 612-619
Zhang, L.; Zhang, Z.; He, C.; Dai, L.; Liu, J.; Wang, L. 2014: Rationally designed surfactants for few-layered graphene exfoliation: ionic groups attached to electron-deficient π-conjugated unit through alkyl spacers. Acs Nano 8(7): 6663-6670
Maurya, I.K.; Thota, C.K.; Verma, S.D.; Sharma, J.; Rawal, M.K.; Ravikumar, B.; Sen, S.; Chauhan, N.; Lynn, A.M.; Chauhan, V.S.; Prasad, R. 2013: Rationally designed transmembrane peptide mimics of the multidrug transporter protein Cdr1 act as antagonists to selectively block drug efflux and chemosensitize azole-resistant clinical isolates of Candida albicans. Journal of Biological Chemistry 288(23): 16775-16787
Spiliopoulou, P.; Arkenau, H.-T. 2014: Rationally designed treatment for metastatic colorectal cancer: current drug development strategies. World Journal of Gastroenterology 20(30): 10288-10295
Mann, B.J.; Ark, N.M. 2009: Rationally designed tularemia vaccines. Expert Review of Vaccines 8(7): 877-885
Karagiannis, E.D.; Alabi, C.A.; Anderson, D.G. 2012: Rationally designed tumor-penetrating nanocomplexes. Acs Nano 6(10): 8484-8487
Rajadas, J.; Liu, C.W.; Novick, P.; Kelley, N.W.; Inayathullah, M.; Lemieux, M.C.; Pande, V.S. 2011: Rationally designed turn promoting mutation in the amyloid-β peptide sequence stabilizes oligomers in solution. Plos one 6(7): E21776
Iyer, S.; Doktycz, M.J. 2012: Rationally designed vaccines. Nanomedicine 7(11): 1654
Wang, H.; Abedini, A.; Ruzsicska, B.; Raleigh, D.P. 2014: Rationally designed, nontoxic, nonamyloidogenic analogues of human islet amyloid polypeptide with improved solubility. Biochemistry 53(37): 5876-5884
Li, S.; Liao, C.; Li, W.; Chen, Y.; Hao, X. 2007: Rationally designing molecularly imprinted polymer towards predetermined high selectivity by using metal as assembled pivot. Macromolecular Bioscience 7(9-10): 1112-1120
Birch, A.M.; Groombridge, S.; Law, R.; Leach, A.G.; Mee, C.D.; Schramm, C. 2012: Rationally designing safer anilines: the challenging case of 4-aminobiphenyls. Journal of Medicinal Chemistry 55(8): 3923-3933
Mattozzi, M.d.l.P.ña.; Keasling, J.D. 2010: Rationally engineered biotransformation of p-nitrophenol. Biotechnology Progress 26(3): 616-621
Cambon, E.; Piamtongkam, R.; Bordes, F.; Duquesne, S.; André, I.; Marty, A. 2010: Rationally engineered double substituted variants of Yarrowia lipolytica lipase with enhanced activity coupled with highly inverted enantioselectivity towards 2-bromo phenyl acetic acid esters. Biotechnology and Bioengineering 106(6): 852-859
Paraskar, A.; Soni, S.; Basu, S.; Amarasiriwardena, C.J.; Lupoli, N.; Srivats, S.; Roy, R.Sinha.; Sengupta, S. 2011: Rationally engineered polymeric cisplatin nanoparticles for improved antitumor efficacy. Nanotechnology 22(26): 265101
Watanabe, K.; Hotta, K.; Praseuth, A.P.; Searcey, M.; Wang, C.C.C.; Oguri, H.; Oikawa, H. 2009: Rationally engineered total biosynthesis of a synthetic analogue of a natural quinomycin depsipeptide in Escherichia coli. Chembiochem: a European Journal of Chemical Biology 10(12): 1965-1968
Piccinini, A.M.; Knebl, K.; Rek, A.; Wildner, G.; Diedrichs-Möhring, M.; Kungl, A.J. 2010: Rationally evolving MCP-1/CCL2 into a decoy protein with potent anti-inflammatory activity in vivo. Journal of Biological Chemistry 285(12): 8782-8792
Ye, T.; Dong, Z.; Zhao, Y.; Yu, J.; Wang, F.; Zhang, L.; Zou, Y. 2011: Rationally fabricating hollow particles of complex oxides by a templateless hydrothermal route: the case of single-crystalline SrHfO3 hollow cuboidal nanoshells. Dalton Transactions 40(11): 2601-2606
Rauniyar, V.; Hall, D.G. 2009: Rationally improved chiral Brønsted acid for catalytic enantioselective allylboration of aldehydes with an expanded reagent scope. Journal of Organic Chemistry 74(11): 4236-4241
Bhattacharyya, D.; Nguyen, K.; Basu, S. 2014: Rationally induced RNA:DNA G-quadruplex structures elicit an anticancer effect by inhibiting endogenous eIF-4E expression. Biochemistry 53(33): 5461-5470
Han, C.; Zhu, L.; Li, J.; Zhao, F.; Xu, H.; Ma, D.; Yan, P. 2014: Rationally investigating the influence of T1 location on electroluminescence performance of aryl amine modified phosphine oxide materials. Chemistry 20(49): 16350-16359
Armstrong, R.E.; Strouse, G.F. 2014: Rationally manipulating aptamer binding affinities in a stem-loop molecular beacon. Bioconjugate Chemistry 25(10): 1769-1776
Kashuba, C.M.; Benson, J.D.; Critser, J.K. 2014: Rationally optimized cryopreservation of multiple mouse embryonic stem cell lines: I--Comparative fundamental cryobiology of multiple mouse embryonic stem cell lines and the implications for embryonic stem cell cryopreservation protocols. Cryobiology 68(2): 166-175
Kashuba, C.M.; Benson, J.D.; Critser, J.K. 2014: Rationally optimized cryopreservation of multiple mouse embryonic stem cell lines: II--Mathematical prediction and experimental validation of optimal cryopreservation protocols. Cryobiology 68(2): 176-184
Jiang, T.; Gao, C.; Dou, P.; Ma, C.; Kong, J.; Xu, P. 2012: Rationally re-designed mutation of NAD-independent L-lactate dehydrogenase: high optical resolution of racemic mandelic acid by the engineered Escherichia coli. Microbial Cell Factories 11: 151
Wu, T.; Zhang, J.; Xia, N. 2014: Rationally respond to post-vaccination adverse events. Science China. Life Sciences 57(5): 557-560
Rizvi, S.A.; Liu, S.; Chen, Z.; Skau, C.; Pytynia, M.; Kovar, D.R.; Chmura, S.J.; Kozmin, S.A. 2010: Rationally simplified bistramide analog reversibly targets actin polymerization and inhibits cancer progression in vitro and in vivo. Journal of the American Chemical Society 132(21): 7288-7290
Khi, N.Tien.; Baik, H.; Lee, H.; Yoon, J.; Sohn, J-Hun.; Lee, K. 2014: Rationally synthesized five-fold twinned core-shell Pt3Ni@Rh nanopentagons, nanostars and nanopaddlewheels for selective reduction of a phenyl ring of phthalimide. Nanoscale 6(19): 11007-11012
Liu, Q.; Chen, A.-H. 2007: Rationally use inhaled corticosteroids for better safety of children with asthma. Zhonghua Er Ke Za Zhi 45(10): 749-752
Budhathoki, P.; Bernal-Perez, L.F.; Annunziata, O.; Ryu, Y. 2012: Rationally-designed fluorescent lysine riboswitch probes. Organic and Biomolecular Chemistry 10(39): 7872-7874
Guichard, G.; Trouche, N.; Wieckowski, Sébastien.; Sun, W.; Chaloin, O.; Bianco, A.; Hoebeke, J.; Schneider, P.; Fournel, S. 2009: Rationally-designed multivalent architectures for mimicking homotrimers of CD40L, a member of the TNF superfamily. Advances in Experimental Medicine and Biology 611: 355-357
Hauguel, T.M.; Hackett, C.J. 2008: Rationally-designed vaccine adjuvants: separating efficacy from toxicity. Frontiers in Bioscience: a Journal and Virtual Library 13: 2806-2813
Stodart, K. 2012: Rationed care a reality in New Zealand hospitals. Nursing New Zealand 18(5): 11
Hansen, T.W.R. 2010: Rationed treatment of expensive premature infants?. Tidsskrift for den Norske Laegeforening: Tidsskrift for Praktisk Medicin Ny Raekke 130(15): 1447
Anonymous 1943: Rationing and Experimental Laboratories. Science 97(2529): 548
Kelly, A.Marie.; Cronin, P. 2011: Rationing and health care reform: not a question of if, but when. Journal of the American College of Radiology: Jacr 8(12): 830-837
Teixeira, J.é F. 2011: Rationing and rationalization in health care. Revista Portuguesa de Cirurgia Cardio-Toracica e Vascular: Orgao Oficial da Sociedade Portuguesa de Cirurgia Cardio-Toracica e Vascular 18(4): 197-198
Cassell, E.J. 2011: Rationing and reality. Hastings Center Report 41(6): 4; Author Reply 6
Friedman, A.W. 2011: Rationing and social value judgments. American Journal of Bioethics: Ajob 11(7): 28-29
Day, G. 1948: Rationing and tuberculosis. British Medical Journal 1(4546): 363
Ford, N.; Mills, E.; Calmy, A. 2009: Rationing antiretroviral therapy in Africa--treating too few, too late. New England Journal of Medicine 360(18): 1808-1810
Mathew, R.; McCombe, A. 2012: Rationing based on 'procedures of limited clinical effectiveness': what are the risks?. British Journal of Hospital Medicine 73(4): 184-185
Krause, S.W.; Schildmann, J.; Lotze, C.; Winkler, E.C. 2013: Rationing cancer care: a survey among the members of the german society of hematology and oncology. Journal of the National Comprehensive Cancer Network: JNCCN 11(6): 658-665
Callahan, D. 2011: Rationing cancer care: the emerging debate. Clinical Advances in Hematology and Oncology: H&o 9(4): 301-303
Misleh, J. 2011: Rationing care: stifling progress while increasing cost of cancer care. Gastrointestinal Cancer Research: Gcr 4(5-6): 199
Stanbrook, M.B. 2013: Rationing drink size to help rationalize our sugar intake. Cmaj: Canadian Medical Association Journal 185(1): 9
Donato, A.A. 2009: Rationing empathy. Academic Medicine: Journal of the Association of American Medical Colleges 84(2): 268
Schöne-Seifert, B.; Friedrich, D.R.; Diederich, A. 2012: Rationing health care by thresholds for clinical benefit and its acceptance by the German population. Zeitschrift für Evidenz Fortbildung und Qualitat Im Gesundheitswesen 106(6): 426-434
Pinho, M.M. 2008: Rationing health care services: an inherent issue. Cadernos de Saude Publica 24(3): 690-695